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2 ABSTRACT 
This thesis characterizes the extent of regulatory T cell–mediated immune suppression in 
breast cancer and explores the possibilities for its potential therapeutic modulation. 
Based on initial results obtained from a pilot clinical study of adoptive transfer of autologous 
bone marrow derived T cells in advanced metastatic breast cancer patients, we observed 
that T-cell unresponsiveness in 53% of study patients was associated with an existing 
immune suppression exerted by Treg. Further IFN-γ secretion assays with primary breast 
cancer samples revealed that T-cell activation, proliferation as well as CTL responses upon 
tumour antigen stimulation were hampered when Treg were present.  
Flow cytometric data displayed that in primary breast cancer patients the bone marrow (BM) 
contained significantly lower frequencies of Treg than the peripheral blood (PB) (p<0.001), 
which may at least partially explain the improved functional potential of BM-derived 
memory T cells. Different migratory capacities of Treg in the BM and the PB were observed 
regarding breast cancer profiled chemokine receptors CCR2, CCR4 and CCR5, which might be 
responsible for this scenario.  
By removing Treg through CD25 targeting, the pre-existing T-cell anti-tumour immunity was 
evoked remarkably in both BM and PB, especially in otherwise less responding PB, as 
determined by IFN-γ ELISpot assay with polyvalent tumour antigens (MCF7 and KS24.22) as 
well as with defined tumour associated antigens (polypeptides).  
This rescuing effect in the PB provides an opportunity of utilizing PB instead of limited BM as 
a source for adoptive T cell transfer immunotherapy. As a pioneer exploitation, a large-scale 
Treg-depletion in a leukapheresis sample obtained from a metastatic breast cancer patient 
was operated with CliniMACS system under clinical-grade conditions (GMP). A sufficient 
depletion of Treg, a high viability of isolated cells and a satisfying recovery of total cells were 
documented. 
To exploit immunotherapy regarding eliminating Treg, an oral metronomic 
cyclophosphamide (CTX) treatment (50 mg/day) was performed to selectively deplete Treg 
in vivo. This pilot clinical trial was applied on 13 advanced metastatic breast cancer patients 
for 3 months. Clinical responses was observed in 64% of study patients accompanied by a 
rapid and effective reduction of Treg on Day14 (p=0.005) and by an augmentation of 
spontaneous anti-tumour T-cell immunity on Day70.  
Last but not least, in this thesis we found that Treg existing in breast cancer patients exhibit 
breast tumour antigen specificity, which was evidenced indirectly and directly. MCF7- or 
KS24.22-specific IFN-γ secretion was abrogated when Treg were added back in ELISpot assay. 
The production of immunosuppressive cytokine IL-10 was increased only when Treg 
encountered breast tumour antigens measured by ELISA and intracellular staining 
experiments. By applying a novelly designed Treg Specificity Assay, we detected a broad 
spectrum of tumour antigens recognized by Treg in at least 47% of tested breast cancer 
patients with Mammaglobin A as the most frequent one (85%). 
ZUSAMMENFASSUNG 
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3 ZUSAMMENFASSUNG 
Die vorliegende Arbeit charakterisiert das Ausmaß der über regulatorische T Zellen (Treg) 
vermittelten Immunsuppression im Mammakarzinom und erforscht potentielle 
Möglichkeiten zur therapeutischen Modulation. 
Nach ersten Erkenntnissen einer klinischen Pilotstudie des adoptiven Transfers von 
autologen T Zellen aus dem Knochenmark in Patientinnen mit metastasiertem Brustkrebs, 
wurde beobachtet, dass das Fehlen einer T-Zell-Reaktivität in 53% der Studienpatientinnen  
mit einer existierenden Immunsuppression assoziiert war, die auf Treg zurückzuführen war. 
Weitere IFN-γ Sekretionstests mit klinischem Material vom primären Mammakarzinom 
zeigten, dass T-Zell-Aktivierung, Proliferation und zytotoxische Immunantwort nach 
Stimulation mit Tumorantigen unterdrückt wurden, wenn Treg präsent waren.  
Durchflusszytometrische Untersuchungen von primäroperierten Brustkrebspatientinnen 
demonstrierten, dass das Knochenmark (KM) signifikant niedrigere Treg-Frequenzen als das 
periphere Blut (PB) aufwies (p<0,001); dies kann zumindest teilweise die verbesserte 
Funktion der Gedächtnis-T-Zellen im KM erklären. In Treg aus KM und PB wurde 
unterschiedliches migratorisches Potential für die Mammakarzinom-relevanten 
Chemokinrezeptoren CCR2, CCR4 und CCR5 beobachtet, das möglicherweise für die 
obengenannte Beobachtung verantwortlich ist.  
Durch die Depletion von Treg über CD25-Targeting wurde die bereits existierende T-Zell 
Anti-Tumor Immunität in beiden Kompartimenten, KM und PB, bemerkenswert unterstützt; 
dies war im sonst nicht reaktiven PB besonders auffällig, wie IFN-γ ELISpot Tests mit 
polyvalenten Tumorantigenen (MCF7 und KS24.22) sowie mit definierten tumorassoziierten 
Antigenen (Polypeptide) demonstrierten.  
Diese Rettungsaktion im PB ermöglicht den Einsatz von PB anstelle von limitiertem KM als 
Quelle für die adoptive T-Zell-Immuntherapie. In einem Pionieransatz wurden aus einem 
Leukapherese-Produkt einer metastasierten Brustkrebspatientin die Treg mit Hilfe des 
CliniMACS Systems nach guter Herstellungspraxis (GMP) in großem Umfang depletiert. 
Ausreichende Treg-Depletion, hohe Vitalität der isolierten Zellen und zufriedenstellende 
Ausbeute an Gesamtzellen wurden dokumentiert.    
Auf diesen auf Treg-Depletion basierenden immuntherapeutischen Ansatz wurde näher 
eingegangen, indem Cyclophosphamid (CTX) metronomisch verabreicht wurde (50mg/Tag), 
um die Treg selektiv in vivo zu depletieren. An dieser klinischen Pilotstudie nahmen 13 
Patientinnen mit metastasiertem Mammakarzinom für drei Monate teil. Klinische Antworten 
wurden in 64% der Studienpatienten beobachtet, die von einer schnellen und effektiven 
Reduktion der Treg an Tag 14 (p=0,005) und von einer Steigerung der Anti-Tumor T-Zell-
Reaktivität an Tag 70 begleitet waren.  
Nicht zuletzt wurde in der vorliegenden Arbeit gezeigt, dass Treg, die in 
Brustkrebspatientinnen existieren, eine Spezifität für Brustkrebsantigen aufweisen; dies 
wurde indirekt und direkt nachgewiesen. Die MCF7 oder KS24.22 spezifische IFN-γ Sekretion 
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wurde inhibiert sobald Treg im ELISpot Test zurückaddiert wurden. Die Produktion vom 
immunsuppressiven Zytokin IL-10 war nur dann erhöht, wenn Treg auf Brustkrebsantigen 
trafen, wie ELISA Tests und intrazelluläre Färbungen belegen. In einem neu entwickelten 
Treg Spezifikationstest wurde ein breites Spektrum an Tumorantigenen detektiert, das von 
Treg von mindestens 47% der untersuchten Brustkrebspatientinnen erkannt wurde; 
Mammaglobin A war dabei das am häufigsten erkannte Antigen (85%). 
INTRODUCTION 
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4 INTRODUCTION 
4.1 T cells in tumour immunity  
Worldwide, cancer is in the top 5 leading causes of death (WHO source). Breast cancer is the 
second most common type of cancer and the fifth most common cause of cancer death. 
However, without our immune defence system in identifying and eliminating nascent 
tumour cells the incidence of cancer would be much greater. This is the concept so-called 
tumour immunology proposed by Paul Ehrlich in 1909 and further advanced as immune-
surveillance by Lewis Thomas and Frank MacFarlane Burnet.  
T cells play a crucial role in tumour immunity. With the development of 
immunohistochemical and flow cytometric techniques, immunologists have elucidated that 
the major tumour infiltrating lymphocytes (TIL) are CD3 T cells, which can be further 
stratified to CD8 cytotoxic T lymphocytes (CTL) and CD4 help cells, including Th1, Th2, and 
most recently discovered regulatory T cells (Treg).  
CTL destroy tumour cells via a triggering of apoptosis by means of cytotoxic granule 
exocytosis, such as perforin and granzyme B, and/or the Fas/FasL receptor-mediated 
pathway (1) (2) (3). The presence or absence of CTL in the tumour-draining lymph nodes 
predicts the disease-free survival in breast cancer, which is more accurate than tumour stage 
and nodal status (4). 
The role of tumour-specific CD4 T cells in the host anti-tumour response is an area of 
considerable debate (5) (6) (7). Th1 response is associated with CTL activation and is 
considered to be beneficial for anti-tumour immunity, while Th2 cells facilitate antibody 
production by B cells and polarize immunity away from a beneficially cell-mediated anti-
tumour response (8) (9). CD4 Treg are found to be accumulated in many human carcinomas 
and are known as tumour guardians. We will have a detailed look on Treg subset in chapter 
4.2. 
In the studies of human cancers including breast carcinoma, large interest and effort have 
been given to detect tumour-reactive memory T cells in the patients, since their responses 
might be required for the durable prevention of tumour recurrence and metastasis following 
the surgery. And one elemental characteristic of a T-cell response is its magnitude. In this 
regard, the frequencies of antigen-specific T cells are commonly evaluated. Breast cancer is 
characterized by high numbers of recurrences that are due to an early dissemination of 
tumour cells. A predominant organ for breast tumour dissemination and maintenance is the 
bone marrow (BM) (10). Accordantly, our group has previously observed and reported 
INTRODUCTION 
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higher frequencies of tumour-specific memory T cells in the BM than the peripheral blood 
(PB) of primary breast cancer patients (11) (12) (13).  
Another fundamental parameter for the magnitude of T-cell response is the expression of 
specific effector functions, such as interferon-γ (IFN-γ) production which is a hallmark of Th1 
lymphocytes, as well as CD8 T cells upon activation. IFN-γ secreted by CTL is critical for 
tumour elimination. IFN-γ can directly act on different tumour cells to facilitate apoptosis 
(14; 15; 16). It can also regulate angiogenesis and promote vasculature destruction leading 
to tumour necrosis (17; 18).  
 
4.2 Regulatory T cells in tumour immunity 
4.2.1 History of Treg 
Historically, Treg were initially hypothesized as suppressive T cells in early 1971 by Gershon 
and Kondo (19) (20). Five years later, a negative correlation between tumour immunity and 
regulatory T cell was first proposed by Sehon and his colleagues (21). After another five 
years, North and his colleagues evidenced the existent tumour-suppressor T cells with 
CD4+CD25+ phenotype (22; 23; 24). Thus, the study of regulatory T cells in tumour immunity 
has been established. Unfortunately, subsequent studies were hindered due to an extensive 
scepticism as well as lack of specific molecular markers and difficulties in their isolation and 
culture. The renaissance of these regulatory cells came decades later attributed to two 
major investigations: 1) in 1995, Sakaguchi and his colleagues discovered that interleukin-2 
(IL-2) receptor α-chain, CD25, could serve as a phenotypic marker for CD4+ suppressor T 
cells. Transfer of CD4 T cells that had been depleted of the CD25+ population into 
congenitally athymic mice induced autoimmune diseases while transfer of intact populations 
of CD4 T cells did not (25); 2) in 2001, the autoimmune Scurfy mice and a human immune 
dysregulation, polyendocrinopathy, enteropathy X-linked (IPEX) patient were found to have 
mutations in Foxp3 gene. Foxp3, forkhead box P3, is a member of the forkhead/winged-helix 
family of DNA transcription factor (26) (27) (28). In 2003 Foxp3 was reported as the master 
transcriptional regulator for naturally occurring Treg cells (nTreg) (29) (30). Recent studies 
have acknowledged Treg to be instrumental in the prevention of autoimmune disease, such 
as type I diabetes (31), the limitation of chronic inflammatory disease, such as inflammatory 
bowel disease (IBD) (32). However, on the down-side, Treg also appear to be a detrimental 
factor in the generation of host-versus-tumour immunity via suppression of tumour-specific 
effector T-cell responses and development of immune tolerance to neoplastic cells (33).  
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4.2.2 Origin and phenotype of Treg 
Naturally occurring CD4 Treg originate in the thymus by high-affinity interaction of T cell 
receptor (TCR) with self-peptide/MHC expressed in the thymic stromal cells. nTreg 
constitutively express high level of IL-2 receptor α-chain, CD25, and other surface markers, 
such as glucocorticoid-induced tumour necrosis factor receptor (GITR) (34) and cytotoxic T-
lymphocyte antigen 4 (CTLA-4) (35; 36). Foxp3 is a master gene, which controls nTreg 
development and function, and is currently the most reliable molecular marker for nTreg. 
Induced regulatory T cells (iTreg) are generated in the periphery. Their phenotype resembles 
nTreg. However, to distinguish the function and the particularly relative importance of these 
two Treg populations in experimental animals as well as in humans has been elusively 
difficult. In addition, naive T cells in humans readily express Foxp3 upon TCR stimulation, 
although the expression is generally much lower and more transient than nTreg (37; 38).  
 
4.2.3 Lineages of Treg 
CD4 Treg are conceptually divided into three populations. Thymus-derived nTreg are the 
classic Treg with CD4+CD25+FOXP3+ phenotype; iTreg can be further divided into two 
subsets: Tr1 and Th3 cells. CD4 Treg secreting IL-10, called Tr1 cells, are induced in vitro by 
antigenic stimulation of naive T cells in the presence of IL-10 (39). Antigen-specific TGF-β 
secreting Treg, called Th3 cells, are induced in the context of orally administered protein 
antigens (40; 41). Regarding the expression of Foxp3, at least some Th3 cells appear to be 
TGF-β-induced Foxp3+ cells, while Tr1 cells do not express Foxp3. However, the properties of 
Tr1 cells in vitro are very similar to those of nTreg. For example, upon antigenic stimulation 
they display an activated cell surface phenotype, exhibit hypoproliferation, exert cell-cell 
contact dependent suppression, and scarcely produce IL-2. Therefore, some immunologists 
do not consider Tr1 cells as a distinct lineage but rather a certain state of nTreg. Actually, in 
this classification, the cytokine and suppressive modes are not mutually exclusive and they 
often overlap (42). 
 
4.2.4 Suppression mechanisms of Treg 
To understand how Treg exert their suppressive function has its therapeutic importance via 
elucidating potential targets. From the observations to date, the various suppression 
mechanisms utilized by Treg fall into four basic “modes of action”. They are the suppressions 
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through a) inhibitory cytokines, b) cytolysis, c) metabolic disruption and d) modulation of 
dendritic cell (DC) maturation and/or function (43).  
Through inhibitory cytokines: IL-10 and TGF-β are no doubt immunological suppressors 
utilized by Treg. In vitro data showed that in a human tumour microenvironment, IL-10 is 
required for a cell-cell contact independent suppression mechanism (44). TGF-β is reported 
to be produced by Treg in order to limit anti-tumour immunity, for instance, in head and 
neck squamous-cell carcinoma (45), in follicular lymphoma (46) and in lung cancer (47). 
Whether IL-10 and TGF-β work in a synergetic way is not clear yet. However, IL-10 was found 
to be utilized by Treg alone (48) and with TGF-b (49).  
Recently, a novel inhibitory cytokine, IL-35, has been described that is constitutively secreted 
by mouse Foxp3+ nTreg but not by resting or activated effector CD4 T cells. IL-35 is a new 
member of IL-12 family and is formed by a pairing of Epstein-Barr virus-induced gene 3 
(Ebi3) and p35 (also known as IL2α). Ebi3-/- and IL12α-/- Treg had markedly reduced 
regulatory activity in vitro, failed to control homeostatic proliferation of effector T cells and 
resolved IBD in vivo. Therefore, IL-35 is required for maximal suppressive activity of Treg. 
Moreover, IL-35 is sufficient to confer a regulatory capacity on naive T cells (50). 
Through cytolysis: Besides NK cells and CTL, few circulating human CD4 T cells can express 
granzyme A and B. Tr1 cells generated from CD4 T lymphocytes by antibodies CD3/CD28 
were reported to be capable of expressing granzyme B and of killing target cells in a 
perforin-dependent, but MHC/TCR- independent, manner (51).  
Through metabolic disruption: This idea was proposed long time ago that Treg might starve 
Teff through deprivation of local IL-2 due to their bright CD25 expression (52) (53). 
Through targeting DC: By using intravital microscopy, Tang Q. and his colleagues first 
showed direct interaction between Treg and DC in vivo, and this interaction was considered 
to attenuate Teff activation by DC (54) (55). Treg can modulate DC through CTLA-4 to 
CD80/CD86 pathway. Consequently, they induce DC to express IDO, a potent enzyme 
inducing apoptosis in Teff cells (56).  
 
4.2.5 Treg in cancer  
Naturally occurring Treg constitute 5-6% of overall CD4 T cell population and bear a TCR 
repertoire for self-antigens (57). Thus, they are thought to be one likely source of tumour 
infiltrating Treg, as most of tumour-antigens are unaltered self-antigens (58). nTreg mediate 
immune suppression through cell-cell contact mechanism (59). 
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Also, iTreg have been identified in cancer patients, for instance, a human gastric cancer (60). 
These Treg induced by MHC-peptide stimulation secrete a large amount of IL-10 and/or TGF-
β, and suppress immune responses through a cytokine-dependent mechanism (61). In 
human cancers, increased numbers of Treg accumulating in several types of solid tumour 
have been observed by using initially CD4+CD25+ Treg markers and recently with or without 
a combination of the more specific marker Foxp3.  
Besides the high amount of tumour infiltrating Treg, elevated percentages of Treg among 
total T cell pool are often reported in various cancers, including breast carcinoma (62). The 
augmentation of Treg in the periphery was also reported to be correlated with a poor 
prognosis in ovarian cancer patients (63) 
How tumour-associated Treg are recruited to the tumour microenvironment is under 
intensive study. To date, the only observation of chemokine-mediated attraction was 
revealed in ovarian cancer. Treg govern CCR4 on their surface in order to be response to its 
ligand CCL22 which is secreted by tumour-associated macrophages (63).  
In addition to Treg recruitment, Treg expansion might be led by encountering tumour 
antigens at tumour sites. A third alternative would be a conversion of naive and/or effector 
cells into Treg by TGF-β and/or IL-10 cytokine secreted by tumour-associated cells, immature 
myeloid DC or immature myeloid suppressor cells etc at the tumour sites (64) (65).  
Even though it is conceivable, whether tumour antigen specific Treg exist in human cancer or 
not remains largely unknown. To date, compelling positive evidence was only shown by the 
group of Rong-Fu Wang. Two Treg colons were isolated from melanoma TIL, LAGE-1-specific 
(a homolog of testis-specific antigen NY-ESO-1) and ARTC1-specific Treg. Importantly, these 
clones retain the suppression to peptide-specific CTL function (66; 67).  
 
4.3 Immunotherapy in breast cancer  
Much has been learned about the potential of the immune system to control cancer. 
Subsequently, immunotherapy is under vigorous development. There are two major 
approaches to immunotherapy for cancer: active specific immunotherapy (cancer-vaccine) 
and passive immunotherapy (antibody therapy and T-cell adoptive transfer therapy). An 
integration of immune therapies with standard treatments for cancer represents a modern 
modality as well as a challenge.  
In order to achieve a clinically effective response, there are three requirements: a sufficient 
number of lymphocytes with avid tumour-recognition must be introduced into the tumour-
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bearing host; these lymphocytes have to successfully migrate and extravasate to the 
tumour-site; and not least, those TIL must have appropriate effector mechanisms to destroy 
cancer cells (68).  
 
4.3.1 Cancer vaccine in breast cancer  
Cancer vaccine aims to stimulate the adaptive arm of the immune system directly in vivo. It 
has a variety of modality, such as tumour-associated antigen based vaccine, DC vaccine, DNA 
vaccine etc. Apart from the vaccine construction, to define an appropriate tumour-antigen is 
essential for developing a potentially effective vaccine. So far, more than 100 peptides have 
been identified. Some are derived from proteins which are the products of unique mutations 
(tumour-specific antigen), but most of them are derived from normal proteins that are 
differentially expressed by tumour cells (tumour-associated antigen). This list is still growing 
(69) (70). Particularly in breast cancer, Table 1 lists a number of defined tumour antigens 
which have been tested as potential targets for cancer vaccine. Many tumour antigens used 
in breast-cancer immunotherapy are expressed on normal tissues but overexpressed or 
mutated on tumour cells, such as Her2/neu, Muc1, p53, CEA, hTERT and carbohydrate 
antigens. Some of these antigens are universal tumour-antigen, such as hTERT, as they are 
broadly expressed by most tumours.  
Preclinical testing of vaccines based on Her2/neu (71), Muc-1 (72) and CEA (73) in rodents 
showed tumour regression without any autoimmunity. However, it has been more than one 
decade that moving breast cancer vaccine from animal models to clinical trials only achieved 
limited or marginally clinical outcomes (74). There are two possible reasons. First, most 
immunotherapy is tested in advanced patients with progressive and refractory tumours after 
all conventional therapies have failed. Late stage tumours have already built up 
immunosuppressive environment in favour of their growth, such as suppressive factor TGF-b 
(75), soluble Fas ligand (76) or suppressive enzyme, IDO (77) (78). Under certain 
circumstances, those patients are often reported to be associated with a decrease in the 
number as well as in the function of peripheral blood lymphocytes and dendritic cells (79), 
which would dampen cancer vaccine in many means.  
Another reason is brought along with increasing understanding of regulatory T cells. The 
elevated number of functional Treg in cancer patients is believed to be a big obstacle to 
immunotherapy. More recent evidence implies that the current cancer vaccine strategy 
might provoke Treg activation and expansion. For example, one important tumour vaccine 
strategy is using engineered DC (80), namely fully matured or polarized DC. It was well 
accepted in the past that in order to obtain therapeutic efficacy fully matured DC have to be 
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carefully manipulated, since immatured and semi-matured DC were evidenced to induce 
regulatory T cells in human studies (81) (82) (83). However, more recent observations in a 
transgenic mouse model suggested matured DC can also activate and expand autologous 
antigen-specific Treg (84).  
 
Table 1. Antigens targeted in the experimental production of vaccines against breast cancer. 
Tumour Antigen Description Relevance to breast cancer Ref. 
Her2/neu  185-kD receptor belonging to the 
epidermal growth factor receptor 
family;  
 It has both extracellular and 
intracellular domains.  
 Gene is amplified or protein is 
overexpressed in 20-40% of 
patients with breast cancer.  
 Associated with poor grognosis 
(85) 
Mucin 1 (Muc-1)  Membrane-associated glycoprotein 
expressed in ductal tissues of breast, 
pancreas, airway, and 
gastrointestinal tract;  
 Involved in protection of mucous 
membranes and signal transduction 
 Overexpressed by more than 70% 
of cancers;  
 Abberrantly glycosylated in 
malignant cells  
(86) 
Mammaglobin A  10-kD glycoprotein of unknown 
function; 
 Expressed almost exclusively in 
breast epithelium 
 Overexpressed in 80% of primary 
and metastatic breast cancers 
(87) 
P53  Normal p53 contributes to DNA 
repair and, when DNA damage is 
irreparable, programmed cell death 
(apoptosis). 
 Mutated in 20% of breast cancers (88) 
Carcinoembryonic 
antigen (CEA) 
 Glycoprotein involved with cell 
adhesion;  
 Production normally restricted to 
fetal development 
 Expressed in carcinomas of the 
colon, rectum, breast, lung, 
pancreas and gastrointestinal tract 
(89) 
hTERT  The catalytic protein component of 
telomerase, which protects 
telomeric ends of chromosomes 
from degradation during successive 
rounds of cell division.  
 Continued production of 
telomerase beyond the time of 
normal cellular senescence allows 
unlimited cell divisons to occur;  
 Nearly all human ceancer cells 
express hTERT. 
(90) 
Cancer-testis 
antigens (NY-ESO-1, 
MAGE, BAGE and 
GAGE) 
 Highly immunogenic proteins 
expressed exclusively in normal 
germ cells of the testis and 
embryonic ovaries and in some 
cancers 
 mRNA expression detected in 24% 
(NY-ESO-1), 8% (MAGE), 2% (BAGE) 
and 8% (GAGE) of patients with 
breast cancer 
(91) 
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4.3.2 Passive immunotherapy in breast cancer 
Passive immunotherapy of breast cancer includes immunotherapy with antibodies or T cells. 
The most clinically effective monoclonal antibody administrated against breast cancer is 
Trastuzumab (Herpcetin) (92). However, this treatment is restricted to Her2-positive cancer 
patients. More broad usages of antibody therapy are ongoing. Lots of efforts are made to 
produce antibodies not only against known tumour antigens but also to the molecules 
produced by tumours to promote their own survival, for example, Bevacizumab (Avastin). 
Bevacizumab is a recombinant humanised monoclonal antibody developed against vascular 
endothelial growth factor (VEGF). It binds to soluble VEGF preventing receptor binding and 
inhibiting endothelial cell proliferation and vessel formation. Bevacizumab is the first anti-
angiogenetic treatment approved by the American Food and Drug Administration in the 
first-line treatment of metastatic colorectal cancer. It has shown preliminary evidence of 
efficacy for breast cancer (93).  
Of all immune cells T cells are most often affected. Leading to a prolonged deficiency of T 
cells has important clinical consequences. Accordingly, strategies to improve and recover the 
function of T cells should have a direct impact on reducing the morbidity and mortality of 
many cancers. Adoptive transfer of antigen-specific T lymphocytes is a powerful therapy, 
which has been successfully used for the treatment of virus-associated malignancies, such as 
Epstein-Barr virus-positive post transplant lymphoproliferative disease (94).  
The source of adoptively transferred T cells can be: 1) in vitro expanded CTL clones after 
several rounds of tumour antigen stimulation; 2) TCR engineered T cells, which have not yet 
been transferred into the clinical studies; and 3) short term ex vivo activated autologous T 
cells.  
The clinical trials of using CTL clones for the treatment of patients with metastatic melanoma 
were well studied in Rosenberg’s group. They used repetitive tumour-antigen stimulation for 
a relatively long term culture of CTL clones in order to achieve a sizable number of CTL for 
transfer. Also, a high amount of IL-2 was accompanied for the treatment. Even though the T-
cell clones used for therapy were highly avid and exhibited potent tumour lysis in vitro, they 
did not persist after infusion, and the clinical response was observed at average of 15% (95) 
(96).  
Regarding the possible explanations of the limited clinical outcomes, except the ones being 
mentioned above, the terminal differentiation of transferred tumour-reactive CD8 T cells 
appears to be another hindrance. The phenotype of late stage effector CD8 T cells in a 
progressive differentiation includes a loss of lymph node homing receptor CD62L; a loss of 
co-stimulatory molecules CD27 and CD28; and a loss of survival cytokine IL-7 receptor CCR7. 
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Although these phenotypes are strongly associated with effective function in vitro, they are 
evidenced to limit the survival and the effective function of the transferred T cells in vivo 
(97) (96) (98). 
Alternatively, the strategy of adoptively transferring short term (72 hr) ex vivo activated 
autologous T cells into patients with metastatic breast cancer showed 47% of biological 
response from our phase I study (99). This supports the notion that early effector CD8 T cells 
exhibit better anti-tumour effects in vivo (100).  
Besides a modulation of the status of transferred T cells, to hurdle the suppressive 
environment in hosts is becoming more and more essential for enhancing the efficacy of 
passive immunotherapy. The marked improvement of adoptive T-cell transfer in 
lymphopaneic host provided indirect evidence of the importance of Treg elimination before 
adoptive T-cell transfer (101) (102). Our previous evaluation of clinical non-responders also 
suggested that the existent of regulatory T cells have immunosuppressive impacts on both 
priming phase in the culture and proliferation phase in vivo after transfer (99). 
 
4.4 Objectives of this thesis 
This thesis is based on the context of our phase I clinical study of adoptive transfer of 
autologous bone marrow derived T cells in advanced metastatic breast cancer patients. The 
observations of T-cell unresponsiveness in 53% of study patients in this study led us to an 
investigation of Treg in their impact on type-I T-cell anti-tumour immunity. To meet this 
objective this thesis addresses five separate questions: 
 What are the frequencies of Treg in the peripheral blood and bone marrow of 
patients with breast cancer? 
 What is the extent of the immune suppression exerted by Treg in breast cancer?  
 What is the suppressive mechanism utilized by Treg in breast cancer?  
 Whether do Treg possess antigen specificity towards breast tumour?  
 How can we develop an appropriate modality of immunotherapy for breast cancer in 
order to conquer the obstacle generated by Treg? 
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5 MATERIALS AND METHODS 
5.1 Materials 
5.1.1 Clinical and healthy donor samples 
Peripheral blood and bone marrow 
of breast cancer patients 
Gynaecological Hospital, University of 
Heidelberg, Heidelberg, Germany 
Peripheral blood and bone marrow 
of Healthy donors Witzens-Harig M., Clinic of Internal 
Medicine, Department of Haematology, 
University of Heidelberg, Heidelberg, 
Germany 
Leukocyte concentrate/ buffy coat Blood donation centre, Heidelberg 
Leukapheresis Clinic of Internal Medicine, Department of 
Haematology, University of Heidelberg, 
Heidelberg, Germany 
 
5.1.2 Flow cytometric antibodies 
Specificity Species Isotype Conjugate Clone Company 
CD3 Mouse IgG2a PE-Cy5 HIT3a BD Pharmingen, D 
CD3 Mouse IgG1k PE UCHT1 BD Pharmingen, D 
CD4 Mouse IgG1 FITC RPA-T4 BD Pharmingen, D 
CD4 Mouse IgG1k PerCP-Cy5.5 SK3 BD Pharmingen, D 
CD25 Mouse IgG2b PE 4E3 Miltenyi Biotech, D 
IL-10 Rat IgG1 PE JES3-9D7 BD Pharmingen, D 
Foxp3 Rat IgG2a APC PCH101 eBioscience, USA 
Foxp3 Mouse IgG1 APC 236A/E eBioscience, USA 
CCR2 Mouse IgG2b - 48607 R&D System, D 
CCR4 Mouse  IgG1k - 1G1 BD Pharmingen, D 
CCR5 Mouse IgG2ak - 2D7 BD Pharmingen, D 
CCR6 Mouse IgG1k - 11A9 BD Pharmingen, D 
Mouse IgG/M Goat Ig FITC polyclonal BD Pharmingen, D 
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5.1.3 Flow cytometric kit and supplements 
BD Cytofix/CytopermTM solution  BD Pharmingen, Germany 
BD GolgiStopTM protein transport inhibitor BD Pharmingen, Germany 
BD Perm/WashTM solution BD Pharmingen, Germany 
Dulbecco’s phosphate buffered saline  PAA Laboratories, Cölbe, Germany 
Fixation/Permeabilisation Concentrate eBioscience, San Diego, USA 
Fixation/Permeabilisation Diluent eBioscience, San Diego, USA 
Permeabilisation Buffer  eBioscience, San Diego, USA 
Rat-Serum eBioscience, San Diego, USA 
 
5.1.4 Cell cultivation media and supplements 
DMEM PAA Laboratories, Cölbe, Germany 
Fetal Calf Serum (FCS) Biochrom, Berlin, Germany 
HEPES Biochrom, Berlin, Germany 
Human AB-Serum Sigma, Deisenhofen, Germany 
Geneticin (G418) Life Technologies, Karlsruhe, Germany 
Gentamycin Biochrom, Berlin, Germany 
Penicillin / Streptomycin  Biochrom, Berlin, Germany 
RPMI 1640 with glutamine PAA Laboratories, Cölbe, Germany 
X-VIVO 20 (serum-free) BioWhittaker, Vervier, Belgium 
Recombinant GM-CSF Essex Pharma, München, Germany 
Recombinant human IL-2 Chiron, Ratingen, Germany 
Recombinant human IL-4 PromoCell, Heidelberg, Germany 
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Recombinant human IL-7 PromoCell, Heidelberg, Germany 
Recombinant human IL-15 PromoCell, Heidelberg, Germany 
 
5.1.5 Kits, beads and supplements 
5.1.5.1 Cell isolation kits, beads and supplements 
CliniMACS CD25 Reagents Miltenyi Biotech, Bergisch Gladbach, Germany 
CliniMACS PBS/EDTA Buffer Miltenyi Biotech, Bergisch Gladbach, Germany 
mCD56 IgG1, C218 Beckman Coulter, Germany 
Dynabeads Pan Mouse IgG Invitrogen, Karlsruhe, Germany 
Dynabeads M-450 CD3 Invitrogen, Karlsruhe, Germany 
Dynabeads M-450 CD19 Invitrogen, Karlsruhe, Germany 
Dynal T cell Negative Isolation Kit Invitrogen, Karlsruhe, Germany 
IFN-γ Secretion Assay - Detection Kit (PE),  Miltenyi Biotech, Bergisch Gladbach, Germany 
human 
MACS CD4+CD25+ Regulatory T Cell Miltenyi Biotech, Bergisch Gladbach, Germany 
Isolation Kit, human 
 
5.1.5.2 ELISpot kits and supplements 
Maus-anti-Human-IFN- Mabtech, Hamburg, Germany 
Maus-anti-Human-IFN- biotin Mabtech, Hamburg, Germany 
AP Conjugate-Substrate Kit Bio-Rad, München, Germany  
Staphylococcus Enterotoxin B  Sigma Aldrich, Deisenhofen, Germany 
Streptavidin-Alkaline Phosphatase MABTECH AB, Hamburg, Germany 
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5.1.5.3 ELISA kits 
Quantikine Human IL-10 Immunoassay R&D systems, Wiesbaden, Germany 
 
5.1.5.4 Cell culture kits and beads 
Dynabeads Anti-Human-CD3/CD28  Invitrogen, Karlsruhe, Germany 
T cell Expander  
Treg Suppression Inspector Kit Miltenyi Biotech, Bergisch Gladbach, Germany 
 
5.1.6 Established cell lines 
KS24.22 Gückel B., Department of Gynaecology and 
Obstetrics, University of Tübingen, Tübingen, 
Germany 
MCF7 ATCC, # HTB-22, Rockville, USA 
U937 ATCC, # CRL-1593.2, Rockville, USA 
 
5.1.7 Polypeptides  
CEA (p569-618) DKFZ (V270), Heidelberg, Germany 
EGFR (p479-528) DKFZ (V270), Heidelberg, Germany 
Her2/neu (p351-384) DKFZ (V270), Heidelberg, Germany  
Heparanase 1 (p1-50) DKFZ (V270), Heidelberg, Germany 
Heparanase 2 (p163-212) DKFZ (V270), Heidelberg, Germany 
Human immunoglobulin (Endobulin) Baxter, Frankfurt, Germany 
hTERT (p958-1007) DKFZ (V270), Heidelberg, Germany 
Mam 1 (p4-56) DKFZ (V270), Heidelberg, Germany 
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Mam 2 (p41-92) DKFZ (V270), Heidelberg, Germany 
MAGE 3 (p271-314) DKFZ (V270), Heidelberg, Germany 
Muc-1-100 (p1-100) DKFZ (V270), Heidelberg, Germany 
Muc-1-20 (p137-157)5 DKFZ (V270), Heidelberg, Germany 
p53 (p118-167) DKFZ (V270), Heidelberg, Germany 
Survivin (p93-142) DKFZ (V270), Heidelberg, Germany 
 
5.1.8 Chemicals 
3H thymidine Amersham, Braunschweig, Germany 
Aqua ad injectabilia B Braun AG, Melsungen, Germany  
Betaplate Scint Perkin Elmer, Wellesley, USA  
Biocoll Separating Solution Biochrom, Berlin, Germany 
Endoxan 50 mg Baxter Oncology GmbH 
DMSO Merck, Darmstadt, Germany 
EDTA Biochrom, Berlin, Germany 
Ethanol Absolute Riedl-de-Haen, Seelze, Germany 
Sprüh Kleber Super Tetenal AG, Norderstedt, Germany  
Trypan Blue Serva, Heidelberg, Germany 
Tween 20 Gerbu Biotechnik, Gaiberg, Germany 
 
5.1.9 Consumables 
Cell Culture Test Plates  TPP, Trasadingen, Switzerland 
(flat bottom: 6-, 24-, 48- and 96-well; 
round-bottom: 96-well) 
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CliniMACS Tubing set Miltenyi Biotech, Bergisch Gladbach, Germany 
Combitips Eppendorf, Hamburg, Germany 
Cover Slips (24 x 50 mm) R. Langenbrinck, Teningen, Germany 
Cryotubes (1.8 ml) Corning B.V., Schipol-Rijk, Netherlands 
Disposable pipettes Renner, Darmstadt, Germany 
Disposable scalpels PfM AG, Köln, Germany 
Disposable syringes (1-50 ml) BD Pharmingen, Heidelberg, Germany 
ELISpot-plates Millipore, Eschborn, Germany 
FACS-tubes Greiner, Frickenhausen, Germany  
Parafilm American National Can Company, USA 
Petri Dishes (tissue culture-treated) Biochrom, Berlin, Germany 
Pipette tips (2, 20, 100, 200, 1000 µl) Gilson, Bad Camberg, Germany 
Printed Filtermate A (90 x 120 mm) Wallac, Turku, Finland 
Safe-Lock Reaction tubes (0.5 ml, 1 ml) Ependorf, Hamburg, Germany 
Sample bag for 1450 MicroBeta Perkin Elmer, Wellesley, USA 
Sterile-filter (0.22 µm) Millipore, Molskeim, France  
Tubes (15 ml, 50 ml) Biochrom, Berlin, Germany 
Tubes with Filter Leucosep (50 ml) Greiner, Frickenhausen, Germany 
TPP tissue culture flasks (T75) Sigma Aldrich, Deisenhofen, Germany 
 
5.1.10 Equipments 
autoMACS™ Separator Miltenyi Biotech, Bergisch Gladbach, Germany 
Biological Safety Cabinet SterilGARD Hood Baker, Stanford, USA 
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CliniMACS Plus Instrument Miltenyi Biotech, Bergisch Gladbach, Germany 
Centrifuge (Minifuge T) Heraeus, Hanau, Germany 
DOS-compatible Intel P4 computer edo GmbH, Hockenheim, Germany 
ELISA-reader Labsystems, Helsinki, Finland 
ELISpot-Microscope Axioplan 2 Imaging Zeiss, Oberkochen, Germany  
FACS Calibur Becton Dickinson, Heidelberg, Germany 
FACS Canto II Becton Dickinson, Heidelberg, Germany 
Freezer (-20°C) Liebherr, Ochsenhausen, Germany 
Freezer (-80°C) Bio Freeze Forma Scientific, USA 
Glass Pipettes Hirschmann, Eberstadt, Germany 
Glassware Schott, Mainz, Germany 
Heat sealer (1295-012) Perkin Elmer, Wellesley, USA 
Incubator Nuaire, Plymouth, USA 
Liquid Scintillation Counter  Perkin Elmer, Wellesley, USA 
(1450 MicroBeta) 
MacBook Pro Apple Macintosh, Cork, Ireland 
Magnetic Particle Concentrator  Dynal, Hamburg, Germany 
(6 x 15 ml tubes, 6 x 2 ml tubes) 
MACS MultiStand Miltenyi Biotech, Bergisch Gladbach, Germany 
Micropipettes (2-1000 µl) Gilson, Bad Camberg, Germany  
Milli-Q Water Purification Device Millipore, Eschborn, Germany 
Multichannel Pipettes (8, 12 channels) Rainin, Leiden, Netherlands  
Neubauer counting chamber (0.1 mm) Brand, Wertheim, Germany  
OctoMACSTM separator Miltenyi Biotech, Bergisch Gladbach, Germany 
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Pipetboy Brand, Wertheim, Germany 
Phase-contrast microscope Zeiss, Göttingen, Germany 
Refrigerator Liebherr, Ochsenhausen, Germany 
Roller-mixer RM5 Karl Hecht GmbH, Sondheim, Germany    
Spectrophotometer Titertek Labsystems, Helsinki, Finland 
Multiscan Plus 
Tabletop centrifuge Heraeus, Hanau, Germany 
Tomtec Harvester Mach 3 Perkin Elmer, Wellesley, USA 
Vortexer (Reax 2000) Heidolph, Schwabach, Germany 
Water bath (SW21) Julabo, Seelbach, Germany 
 
5.1.11 Softwares 
CELLQuest Pro (4.02) Becton Dickinson, Heidelberg, Germany 
FACS Diva Software Becton Dickinson, Heidelberg, Germany 
FlowJo FACScan Software (6.2) Tree Star, San Carlo, USA 
Graphpad Prism 5 GraphPad Software Inc., San Diego, USA 
KS-ELISpot Zeiss, Göttingen, Germany  
Mac OS X Apple Macintosh, Cork, Ireland 
Microsoft Windows XP Microsoft, Redmond, USA 
Microsoft Excel 2007 Microsoft, Redmond, USA 
Microsoft Word 2007 Microsoft, Redmond, USA 
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5.2 Methods 
5.2.1 Sample Collection  
Each sample was obtained upon approval by the informed participant. The protocol was 
approved by the Ethical Committee of the University of Heidelberg. Clinical bone marrow 
samples were aspirated from the anterior iliac crest immediately after surgery, while the 
participants were still anaesthetised. The bone marrow of healthy donors was obtained 
under local anaesthesia. 
Leukapheresis was obtained by the department of haematology of clinic of internal 
medicine, University of Heidelberg. This procedure is co-operated with Cytonet Heidelberg 
GmbH. 
 
5.2.2 Methods of cell cultivation 
5.2.2.1 Solutions and buffers 
Trypan Blue stain: 
Trypan Blue 1.28 g 
NaCl 8.5 g 
ddH2O (filtered sterile) ad 1 l 
NaN3 Cfinal = 1% (v/v) 
 
Freezing solution: 
Human AB-serum 800 µl 
RPMI 1640 (for T cells) or 100 µl   
X-VIVO 20 (for dendritic cells) 
DMSO 100 µl 
 
5.2.2.2 Media and supplements 
Tumour cell line medium: 
DMEM 50 ml 
FCS 10% (v/v) 
Penicillin / Streptomycin 1% (v/v) 
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TC medium, pH = 7.4: 
RPMI 1640 50 ml 
HEPES 10 mM 
Human AB-serum 10% (v/v) 
Penicillin 50 µg/ml 
Streptomycin 50 µg/ml 
Human recombinant IL-2 100 IU/ml 
Human recombinant IL-4 60 IU/ml 
(Human recombinant IL-7 20 ng/ml) 
(Human recombinant IL-15 20 ng/ml) 
 
DC medium, pH = 7.4: 
X-VIVO 20 50 ml 
GM-CSF 560 IU/ml 
Human recombinant IL-4 1000 IU/ml 
 
5.2.2.3 Cultivation of cells 
All types of cells were cultivated in sterile incubators at 37°C with a CO2-concentration of 5% 
(v/v). T cells and dendritic cells were cultivated in the above described media, whereas DC 
medium was added 2% (v/v) autologous plasma. The cell lines U937, KS24.22 and MCF7 
were cultivated in tumour cell line medium.  
 
5.2.2.4 Quantification of viable cells 
A Neubauer counting chamber was applied for the quantification of viable cells. For this 
purpose, cell suspension was diluted 1:10 or 1:100 in Trypan Blue stain and injected into the 
chamber. The average number of cells in one of large 9 counting areas was calculated under 
a microscope, whereat blue coloured cells were excluded from calculations. These cells were 
regarded to be nonviable, as Trypan Blue can only traverse the damaged plasma membrane 
of nonviable cells. The determined average cell number was multiplied with the respective 
dilution factor and the chamber factor 104 for the quantification of cells per 1 ml of 
suspension volume. 
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5.2.2.5 Passage of adherent cell lines 
When confluence was reached, adherent cells were passaged under sterile conditions. After 
the removal of cell culture medium, cells were washed with Dulbecco´s PBS and detached 
from the flask by adding an EDTA/trypsin-mixture. EDTA resolves cell-cell contacts through 
the deprivation of essential divalent cations and the protease trypsin truncates cellular 
adherence molecules that establish the attachment to the flask. The reaction was quenched 
with RPMI 1640 + 10% (v/v) FCS after 5 minutes of incubation at 37°C, as the proteolysis by 
trypsin is not restricted to adherence molecules but cytotoxic with increasing reaction time. 
The detached cells were spun down at 1400 rpm for 10 min, the pellet was resuspended in 
tumour cell line medium and finally distributed to 3 tissue culture flasks. 
 
5.2.2.6 Storage and thawing of cells 
In order to store cells for longer periods of time, these were spun down at 1400 rpm for 10 
min and resuspended in 1 ml freezing solution. The suspension was transferred to a 
cryotube and kept on ice for 30 min, to secure a slow cooling before dropping temperature 
to -80°C. The slow cooling prevents the formation of detrimental ice crystals. For thawing, 10 
ml medium was pre-heated to 37 C and added to the frozen cell suspension. This effected a 
rapid transition to the liquid phase and allowed a fast separation of cells from the freezing 
solution by spinning down (1400 rpm, 10 min) and resuspending in a new medium. The fast 
separation of cells from the freezing solution is crucial, as DMSO not only has cryo-protective 
properties but also is highly cytotoxic. 
 
5.2.3 Methods of immunobiology 
5.2.3.1 Isolation of mononuclear cells from human peripheral blood and bone marrow   
For the isolation of mononuclear cells, peripheral blood and bone marrow were subjected to 
a Ficoll gradient density centrifugation. In detail, 15 ml Biocoll solution were added to a Ficoll 
(Leucosep) tube. This was quick-spun to 1000 rpm, to make the solution pass the filter. 
Now, 15 ml RPMI 1640 were added on top of the filter and 20 ml peripheral blood were 
slowly mixed with the medium. For bone marrow, 15 ml Biocoll solution were firstly added 
to a 50 ml tube. 20 ml bone marrow were mixed with the 15 ml RPMI 1640 and very 
carefully layered on top of the 15 ml Biocoll solution. Filter-added Ficoll tubes were not used 
for the purification of mononuclear cells from bone marrow, as these regularly contained 
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solid particles which would have plugged the filter and interfered with the formation of an 
interphase. After centrifuging the prepared tubes at 2000 rpm with a disabled break for 20 
min, the formed interphase of mononuclear cells between supernatant and Ficoll-Hypaque 
was collected. Subsequently, the cells were washed with RPMI 1640 and cultured in 
cytokine-free X-VIVO 20 for 2-16 hr at 37°C. The incubation was carried out in tissue culture-
treated petri dishes, enabling the later enrichment of plastic-adherent monocytes by slowly 
washing off non-adherent cells. Dendritic cells were generated from CD14+ monocytes 
through cultivating for 5-8 days in DC medium, whereas non-adherent cells were separately 
cultivated in TC medium. 
 
5.2.3.2 Enrichment of dendritic cells 
Dendritic cells were enriched from plastic-adherent monocytes by slowly washing off non-
adherent cells and followed with 5-8 days culture in DC medium. Enriched DC were used for 
pilot clinical studies. 
 
5.2.3.3 Purification of dendritic cells 
Dendritic cells were generated from CD14+ monocytes through cultivating for 5-8 days in DC 
medium. Dendritic cells were purified via immunomagnetic Dynabeads. These are 
superparamagnetic polymer particles sized to 4.5 µm and coated with a monoclonal 
antibody. Using the affinity of the antibody for defined cell surface molecules, specific cell 
subsets can be targeted by their expression of a surface marker and therefore are selectively 
labelled with magnetic beads.  
Dendritic cells were negatively selected through the labelling of CD3+ T cells, CD19+ B cells 
and CD56+ natural killer cells with respectively coated beads and by separating the beads 
from the supernatant in the magnetic field of a magnetic particle concentrator. Previously, 
Pan Mouse IgG Dynabeads were coated with αCD56 mAb, to be applied to the cell 
suspension together with the αCD3-/αCD19-coated Dynabeads, according to the 
manufacturer´s instructions.  
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5.2.3.4 Purification of T cells 
The purification of T cells from cultivated non-adherent cells was carried out with the 
Dynal T cell Negative Isolation Kit. The procedural recommendations of the manufacturer 
were followed thoroughly. The applied kit depleted all non-T cells from the suspension by 
labelling B cells, NK cells, monocytes and erythrocytes with magnetic beads that were 
separated from the supernatant.  
 
5.2.3.5 Isolation of CD4+CD25+ T cells 
MACS buffer, pH = 7.2: 
Human AB-serum 500 µl 
Dulbecco´s PBS 47 ml 
EDTA 2 mM 
 
Regarding research grade, CD4+CD25+ T cells were isolated from previously purified T cells by 
applying the MACS CD4+CD25+ regulatory T cell Isolation Kit. The instructions of the 
manufacturer were respected apart from using MS columns for both separations and 
flushing all columns 2x with MACS buffer, to more efficiently elute labelled cells. In detail, 
CD4+ T cells first were negatively selected followed by a positive selection of CD4+CD25+ T 
cells. No cell subset was discarded, as eluted CD8+ T cells from the first separation were 
pooled with CD4+CD25- T cells in the flow-through of the second separation. The pooled 
population was denoted as Treg-depleted Tcon, whereas the isolated CD4+CD25+ T cells 
were regarded as Treg enriched. 
Regarding clinical grade, CD4+CD25+ T cells were isolated from leukapheresis by applying the 
CliniMACS CD25 Reagent. The instructions of the manufacturer were respected. In detail, 
the CliniCD25 labelling was carried out at beads to cells ratio of 1:27, and 30 min incubation 
at RT. Cells then were washed with CliniMACS PBS/EDTA Buffer 2x before running through 
a CliniMACS Plus Instrument with Program 3.1 or Program 2.1. 
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5.2.4 Analytical methods of immunobiology  
5.2.4.1 Solutions and buffers 
Flow cytometry buffer: 
Dulbecco's PBS 50 ml 
FCS 2% (v/v) 
 
ELISpot wash buffer: 
Dulbecco's PBS 1 l 
Tween 20 500 µl 
 
ELISpot substrate solution (for 100 wells): 
ddH2O 10 ml 
25x substrate buffer 400 µl 
Substrate A 100 µl 
Substrate B 100 µl 
 
5% (v/v) AB-medium: 
Human AB-serum 2.5 ml 
RPMI 1640 ad 50 ml 
 
10% (v/v) AB-medium: 
Human AB-serum 5 ml 
RPMI 1640 ad 50 ml 
 
Protein/peptide-solutions:  
lyophilisates of polypeptides were dissolved in Aqua ad injectabilia to final concentrations 
between 2 and 50 µg/µl 
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5.2.4.2 Flow cytometry  
The phenotyping of cells was conducted via flow cytometric analysis. 5 x 105 mononuclear 
cells or 105 enriched T cells were required for each experiment. In the cases that a 
combination of intracellular staining of IL-10 was applied, BD GolgiStopTM protein transport 
inhibitor was added into PBMC stimulation culture for the last 10 hr. In any cases, the flow 
cytometric assay was started with the staining of surface antigens. Cells were washed by 
spinning down (whole protocol: 5500 rpm for 1 min) and resuspending in flow cytometry 
buffer. The entire subsequent procedure was conducted on ice. After washing, cells were 
spun down, resuspended in 50 µl Endobulin (2.5 µg/µl) and cell surface Fc-receptors were 
blocked by incubating for 15 min. A following surface staining of washed cells was carried 
out, resuspending the pellet in 50 µl of 1:10 diluted primary, fluorescence dye- or biotin-
labelled antibody(ies) and incubating for 20 min. Unbound antibody was washed away and 
the pellet was resuspended in 100 µl flow cytometry buffer for later analysis. Given the 
incubation with primary un-labelled antibody(ies), the pellet was resuspended in 50 µl of 
1:10 diluted fluorescence dye-labelled secondary antibody and incubated for further 20 min, 
before preparing for analysis.  
To stain intranuclear Foxp3, a fixation and permeabilisation of cells was conducted by 
resuspending in 750 µl Fixation/Permeabilisation Buffer and incubating for 30 min. 
Afterwards, a blocking with 2% (v/v) Rat-Serum and an incubation in 50 µl 1:10 diluted 
αFoxp3 mAb was performed analogously to the surface staining, but using Permeabilisation 
Buffer instead of flow cytometry buffer for dilutions and washing steps.  
To stain intracellular IL-10, thoroughly resuspend cells were treated with 100 µl of BD 
Cytofix/CytopermTM solution for 20 min at 4°C followed by 2x wash with BD Perm/WashTM 
solution. After being thoroughly resuspended, the fixed/permeabilized cells were stained in 
50 µl of BD Perm/WashTM solution containing 1:50 diluted PE-conjugated αIL-10 antibody for 
30 min at 4°C in the dark.  
Finally, expression patterns were read out, collecting > 5 x 104 events with a FACS Calibur or 
FACS Canto II that ran CELLQuest Pro and FACS Diva Software, respectively. The acquired 
data was analysed with FlowJo FACScan Software. 
 
5.2.4.3 IFN-γ Secretion Assay 
The IFN-γ secretion assay was designed for the detection and analysis of viable IFN-γ-
secreting leukocytes, especially for the detection and isolation of antigen-specific T cells. 
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After a restimulation with specific antigen in vitro secretion of IFN-γ is induced. In this thesis, 
we applied this assay to evaluate the impact of Treg on type-I T-cell anti-tumour immunity. 
In detail, purified T cells derived from breast cancer patients were stimulated with MCF7 or 
U937 cell lysates presented by autologous DC for 16 hr in an incubator at 37°C. After coating 
all cells with IFN-γ antibody on ice for 5 min warm X-VIVO 20 were added to dilute cells to 
106 cells/ml. IFN-γ capture was then carried out in a rotating incubator for 45 min at 37°C. 
Next, the secreted and retained IFN-γ on cell surface was labelled with PE-conjugated 
secondary Ab anit-IFN-γ. Meanwhile αCD3 and αCD4 Abs were applied in order to define the 
interest population. The PE positive cells can finally be targeted by anti-PE magnetic beads, 
and isolated through a column applied in a magnetic field. 
 
5.2.4.4 IFN-γ ELISpot (enzyme-linked immunospot) assay 
The ELISpot assay was designed, in order to detect the secretion of immunological relevant 
molecules on the single cell level and to determine the frequency of secreting cells within a 
population. Thereby, it employs the sandwich ELISA technique, visualising molecules that 
have bound to an immobilised antibody followed by an automated readout. In this study, a 
short-term (40 hr) ELISpot assay was applied, to quantify activated T cells upon antigen 
encounter. Therefore, the secretion of IFN- was analysed, as this cytokine is known to be 
primarily produced and secreted by activated CD4+ and CD8+ T cells.  
Initially, the nitrocellulose membrane of a 96-well ELISpot-plate was coated with αIFN-γ 
mAb. In detail, 100 µl Dulbecco´s PBS mixed with 15 µg/ml αIFN-γ mAb were added to each 
well. The plate was vortexed gently and incubated at 37°C for 3 hr or at 4°C o/n. After 
coating, the supernatant was discarded and the plate was washed 4x with 200 µl ELISpot 
wash buffer. Subsequently, 200 µl 5% AB-medium/well were added followed by an 
incubation at 37°C for 30-45 min. This step saturated remaining membrane binding sites 
with human serum proteins to prevent the non-specific binding of secreted IFN-γ. 
Afterwards, the blocking solution was discarded, the plate was washed 3x and 100 µl X-VIVO 
20/well were added. 
Simultaneously, enriched dendritic cells from peripheral blood and bone marrow were 
pooled and pulsed with antigens. For that purpose, 104 dendritic cells/well were cultured 
o/n at 37°C in 200 µl X-VIVO 20 with 200 µg/ml antigen. The next day, 5 x 104 total T cells or 
Treg-depleted Tcon/well were distributed to the ELISpot-plate. Each T cell type was added in 
triplicate of per tested antigen. Now, antigen-pulsed dendritic cells were distributed to the 
plate in a DC:Tcon-ratio of 1:10 (5 x 103 dendritic cells/well) to a total reaction volume of 
200 µl/well. The 2x quantity of required dendritic cells had been pulsed, due to a strong loss 
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of cells during the pulsing procedure. As controls, only antigen-pulsed dendritic cells and 
only T cells were added to the plate. The T cells were activated by the superantigen SEB and 
represented the positive control. Now, T cells and antigen-pulsed dentritic cells were 
cocultured at 37°C for 40 hr.  
The secretion of IFN- by total T cells and Tcon in response to several different 
antigens/antigen-mixes was analysed. First, the reactivity against lysates from the allogenic 
tumour cell lines MCF7, KS24.22 and U937 was tested. The breast cancer cell line MCF7 is 
known to overexpress several breast cancer marker-proteins like the oestrogen receptors α 
and β. Comparably, the genetically modified breast cancer cell line KS24.22 overexpresses 
the breast cancer-associated proteins Muc-1 and Her2/neu. Further, this cell line was 
generated under GMP conditions and can therefore be used in clinical studies. In contrast, 
U937 is a promonocytic leukaemia cell line that was applied to assess the background-
reactivity against common tumour antigens and the basic reactivity against alloantigens. 
Apart from cell line antigens, dendritic cells were also pulsed with polypeptides that 
comprised single antigens from breast cancer-associated proteins. All peptides were 
designed with respect to reported epitopes in these sequences. In addition, the T cell 
response against the human immunoglobulin-mix Endobulin was determined, to assess the 
background T cell reactivity against human endogenous proteins. 
After incubating for 40 hr, the supernatant of the ELISpot-plate either was kept for further 
analysis or discarded. The plate was washed 4x with 200 µl wash buffer and each well was 
incubated with 200 µl ddH2O in order to lyse remaining cells. The plate was washed for 3 
additional times and then 100 µl Dulbecco's PBS/well with 1 µg/ml biotin-labelled IFN- 
mAb were added. Incubation at 37°C for 2 hr was succeeded by 4 washing steps and a 
further incubation at 37°C for 1.5 hr with 100 µl alkaline phosphatase-labelled 
streptavidin/well (1 µg/ml). Afterwards, the plate was washed 5x with washing buffer and 1x 
with Dulbecco´s PBS. The bound IFN- was finally visualised, applying the AP Conjugate-
Substrate Kit and incubating for 20-50 min in the dark. The colourigenic reaction was 
stopped by washing 3x with ddH2O and the membrane was dried for 72 hr in the dark. The 
quantity of IFN- spots was read out automatically with an Axioplan 2-microscope and the 
KS-ELISpot software. 
 
5.2.4.5 Suppression assay 
Two different types of suppression assay were performed in this thesis, both quantifying the 
suppression of T cell proliferation by Treg via the detection of incorporated 3H-thymidine. 
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The assays differed in form of the provided stimulus, as in one case these were polyclonally 
stimulated, whereat an additional antigen-specific stimulation of Treg via antigen-pulsed 
dendritic cells was provided in the second type.  
For the polyclonal suppression assay, 5 x 104 Tcon/well were added to a 96-well U-bottom 
plate. The Tcon were seeded without and in coculture with isolated Treg in ratios of 1:8, 1:4 
and 1:2 (Treg:Tcon). Each approach was resuspended in 10% AB-medium and delivered in 
triplicate to a volume of 200 µl/well. Next, T cells were stimulated by adding CD3/CD28 T cell 
Expander beads to each well (Tcon:beads = 1:1) and incubating at 37°C for 72 hr. 1 µCi 3H-
thymidine/well was added for the last 18 hr.  
Another polyclonal suppression assay was performed with Treg Suppression Inspector Kit 
which has been developed for the functional characterization of human Treg by in vitro 
suppression assays. The instructions of the manufacturer were respected. In detail, 
CD4+CD25+ Treg and CD4+ responder T cells (Tresp) were seeded as outlined in Table 2 in a 
total volume of 210 ul X-VIVO. In this protocol, one MACSiBead Particle per cell (bead-to-cell 
ratio of 1:1) was used for stimulation. Triplicates were carried out. Cells were stimulated in 
an incubator at 37°C and 5% CO2 for 4 days. 1 uCi 
3H-thymidine was added into each well for 
the last 16 hr.  
 
Table 2: Number of responder T cell (Tresp), regulatory T cells (Treg) and 
Treg Suppression Inspector (MACSiBeads Particles) per well.  
 
(http://www.miltenyibiotec.com/download/datasheets_en/1099/DS130-092-909.pdf) 
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For the antigen-specific suppression assay, Tcon and Treg were stimulated separately and in 
different ways. In detail, 5 x 104 Tcon/well were incubated with CD3 mAb-coupled 
magnetic beads in a ratio of 1:1 at 37°C for 18 hr. At the same time, triplicates of 2.5 x 104 
Treg/well were cocultured with control antigen- and breast cancer antigen-pulsed dendritic 
cells in a ratio of 5:1 (Treg:DC). After 18 hr, the beads were detached from the polyclonally 
stimulated Tcon by heavy pipetting and were separated from the cells with a magnetic 
particle concentrator. Subsequently, the activated Tcon were added 1:1 to the differently 
stimulated Treg and cocultured at 37°C for further 72 hr. The quantification of Tcon 
proliferation in all approaches was conducted analogously to the polyclonal suppression 
assay. In contrast to the polyclonal suppression assay that only gave information on the 
general, non-specific suppression of the isolated Treg population, this suppression assay 
determined the impact of antigen-specific activation on the extent of exerted suppression. 
No matter which suppression assays were performed, the incorporation of radioactively 
labelled thymidine by proliferating T cells was stopped through transferring the plate to a -
20°C freezer. The frozen plate was thawed at 37°C, frozen again and thawed, in order to 
promote cell lysis. This was followed by the harvesting of cells, implicating the lysis of 
residual T cells with ddH2O and the transfer of nucleic acids from the supernatant of each 
well to a filter membrane. This membrane now exhibited spots of bound nucleic acid, 
comprising different quantities of incorporated 3H-thymidine. The more proliferation had 
taken place in a well, the more 3H-thymidine had been incorporated and was now bound to 
the filter membrane. Next, the membrane was dried in a microwave at 600 W for 2 min, 
added 5-7 ml of scintillation fluid and sealed in a plastic bag. Finally, the extent of 
proliferation was read out with a liquid scintillation counter, enabling the quantification of 
Treg suppression on the proliferation of Tcon in each approach. 
 
5.2.4.6 IL-10 ELISA (enzyme-linked immunosorbent assay) 
The ELISA was developed by Engvall et al. in 1971 as an immunoassay that quantified 
antigen concentrations without the use of radioactively labelled compounds. While the 
original protocol was based on a competitive binding of the tested antigen to an antibody, 
the "sandwich ELISA" applied in this study employed the non-competitive binding of the 
antigen to an immobilised antibody and its detection with a second antigen-specific, 
enzyme-labelled antibody. The enzyme converted a transparent substrate into a coloured 
product in proportion to the amount of bound antigen. Finally, the concentration of 
coloured product could be read out with an ELISA-reader. 
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The concentration of IL-10 in the supernatants of conducted ELISpot assays was determined 
by the application of the Quantikine Human IL-10 Immunoassay Kit, following the 
instructions of the manufacturer.  
 
5.2.5 Statistical analyses 
Three statistical techniques were applied in this thesis to pertain the interpretations of data. 
They are Student´s t-test, Wilcoxon signed-rank test and Fisher’s exact test. Student´s t-test 
was performed by a paired two-tailed calculation if not indicated. A paired Student´s t-test 
was applied in a comparison in-between the data obtained from the same individual. A one-
tailed Student´s t-test was applied for determining a statistical difference between the data 
obtained against breast cancer antigens and control antigens. A Fisher’s exact test was 
performed by a two-tailed calculation when a statistical difference between percentages of 
tumour antigen-reactive patients without and with Treg depletion was analysed. Wilcoxon 
signed-rank test was performed when a distributional assumption was regardless in a 
comparison. A statistical significance was considered when a calculated p-value is not more 
than 0.05.  
RESULTS – PART I 
P a g e  |  47 
6 RESULTS 
Part I Proof of principle 
-- Role of regulatory T cells on spontaneous anti-tumour T-
cell responses in breast cancer 
6.1 Pilot clinical study of adoptive T cell transfer immunotherapy implies an 
undesired suppressive impact from regulatory T cells 
6.1.1 Study design 
Based on our previous findings that breast cancer patients often harbour anti-tumour type-I 
memory T cells (mTC) in their bone marrow (BM) but less frequently in the peripheral blood 
(PB), and that ex vivo reactivated BM mTC with specific breast tumour antigens completely 
rejected autologous tumours in xenotransplanted mice, a pilot clinical study of adoptive T 
cell transfer immunotherapy (ADI) was initiated by our group in 2003. 
This study was applied on metastasized breast cancer patients who had previously received 
standard cytostatic treatments, such as chemotherapy or hormone therapy and were in a 
palliative treatment situation. Patients with secondary malignancies, auto-immune diseases, 
renal failure or pregnancy were excluded. 
Patients whose BM contained detectable tumour-antigen (TA) reactive mTC were recruited 
for ADI. The presence as well as the frequencies of BM residing mTC were determined by a 
short-term (40h) IFN-γ ELISpot assay as a short activation period does not allow the priming 
and effector function of naïve T cells. Established breast tumour cell lines, MCF7 and 
KS24.22, served as sources of tumour antigens, whereas U937, a promonocytic leukaemia 
cell line, was used as a source of irrelevant tumour antigens. T cells were stimulated with 
autologous dendritic cells (DC) which were pre-pulsed with cell lysates. The amount of 
reactive T cells which secreted IFN-γ in experimental wells can be measured in the number 
of spots. When significantly higher numbers were exhibited in the wells with an interest 
antigen than ones with its control antigen, this patient was considered as an immunological 
responder. And the number calculated from a subtraction of the mean value of triplicates 
from test wells to that from the control wells is referred as the frequency of TA-specific T 
cells in this thesis. 
To treat the eligible patients, their BM cells were collected for an enrichment of T cells, and 
PB-derived monocytes (PBMC) were cultured for a generation of DC. The reactivation of 
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tumour-specific TC was performed by co-culturing BMTC with TA pre-pulsed DC for 72 hr. 
Then the therapeutic T cells were adoptively transferred into the patients intravenously. 
 
6.1.2 Clinical monitoring 
In total, 17 patients with metastasized breast cancer were treated. In order to monitor the 
immunological responses, blood samples were collected prior to the therapy (Day0), weekly 
during the first month after the transfer (Day7, 14, 21, Mon1) and three months after the 
transfer (Mon3). BM samples were collected one month and three months after the 
treatment (Mon1 and Mon3). IFN-γ ELISpot assay was conducted to investigate the 
frequencies of tumour-reactive PBTC and BMTC. IL-4 and IL-10 secretions and CD69 
expression on T cells in activation cultures were evaluated in assessable patients by Dr. 
Katrin Ehlert, a former PhD student of our group, who initiated this project.  
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Figure 1. Immune monitoring of adoptive T cell transfer immunotherapy (ADI) in the frequencies of tumour-Ag 
specific type-I T cells. The frequencies of MCF7 or KS 24.22 –specific type-I T cells were measured in samples of 
PB (black) or BM (blue) obtained on days indicated below X-axis. Each dot represents a frequency that was 
identified in an individual patient. The frequencies of non-responders are depicted at X-axis. The numbers of 
responders to total analysed patients are displayed in parentheses.  
 
Considering the proportions of tumour-antigen responding patients, the best clinical effect 
was observed on Day7 (Figure 1). Before the therapy there were 11.8% (two out of 17) of 
study patients containing spontaneous tumour-reactive T cells in their blood, while one 
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week after the treatment, the proportion went up to 47.1% (eight out of 17) composed with 
seven de novo responders and one responding maintainer. Two weeks after ADI, we were 
still able to detect three responders who retained the immunological responses from Day7 
and one additional de novo responder. The numbers of ADI responders were then declined 
to two, one and zero on Day21, Mon1 and Mon3, respectively. Interestingly, the 
maintenance of detected TA-specific T cells in the BM was persistent through the entire 
study time (Mon1: 77.8%, Mon3: 100%).  
Regarding the immunological non-responders, Ehlert observed that the transferred T cells of 
those patients secreted increased type-II cytokines IL-4 and IL-10, exerted reduced 
proportions of early activated CD4+ and CD8+ T cells determined by CD69 expression and 
contained higher proportions of CD25high T cells (enriched in regulatory T cells) (99). These 
findings pointed to the possibility that regulatory T cells present in bone marrow T cell 
populations of some advanced breast cancer patients might inhibit the appropriate 
restimulation of pre-existing tumour reactive memory T cells.  
Taken together, this study demonstrates a promising biological response, especially on Day7; 
and the existed immune suppression might hamper the non-responders from benefits of 
ADI. In order to enhance the clinical efficacy, conquering this immune suppression might not 
be evitable. 
 
6.2 Frequencies of Treg are significantly lower in the bone marrow than the 
peripheral blood of patients with primary breast cancer 
To further clarify our hypothesis that the present regulatory T cells impeded the occurrence 
of type-I T-cell anti-tumour immunity in immunological non-responders of the study, we 
started with quantifying the frequencies of Treg in breast cancer patients by multicolour 
flow cytometry. Despite of increasing observations showing the importance of CD8+ Treg, we 
focused in this thesis on CD4+ Treg which contribute a majority of suppressive Treg.  
We defined Treg with cell surface markers CD3, CD4, CD25 and one intra-nuclear marker 
Foxp3. As shown in Figure 2, within a CD3+CD4+ T cell gate (Figure 2B), we further specified 
Treg subpopulation according to their double expressions of CD25 and Foxp3 (Figure 2C). 
The number in the upper-right quadrant of Figure 2C was used for quantifying frequencies of 
Treg. Hereafter Treg are referred to CD4+CD25highFoxp3+ T cells.  
PB and BM samples from a total of 34 primary breast cancer patients and 10 healthy donors 
were evaluated. Results are shown in Figure 3. The mean frequency of Treg among CD4+ T 
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cells was found higher in the PB than the BM, which was counted for both healthy donors 
(PB: 4.32% ± 0.9% versus BM: 3.44% ± 1.04%) and patients (PB: 3.88% ± 1.49% versus BM: 
2.48% ± 1.25%). The difference in patients but not healthy donors displayed a statistical 
significance (p<0.001). The comparisons between patients and healthy donors showed a 
significant decrease in the mean frequency of Treg in the BM of patients (p=0.022), but a 
statistically unaltered one in the PB.   
 
A. B. C. 
   
Figure 2. Definition of CD4
+
CD25
high
Foxp3
+
 Treg. A, a lymphocyte gate was set according to the size (FSC) and 
the granularity (SSC) of all acquired cells. B, within the lymphocyte gate, CD4
+
 T cells were selected according to 
CD3 and CD4 double expression. C, CD4
+
 Treg were then quantified by CD25
high
 and Foxp3
+
 (the upper-right 
quadrant). Small numbers in the plots represent corresponding percentages.  
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Figure3. Frequencies of Treg in the peripheral blood and the bone marrow of breast cancer patients and 
healthy donors. Each symbol represents an individual. Mean±SD is depicted in blue above each mean value bar 
in respective groups. Statistical analyses between interested groups are connected with horizontal lines above 
the plot. Paired two-tailed t-test was performed for comparisons between PB and BM; unpaired two-tailed t-
test was performed for comparisons in-between MaCa and HD. n.s.: not significant. 
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6.3 Preliminary results from IFN-γ secretion assay enlightened a negative 
effect of regulatory T cells on anti-tumour type-I T-cell immunity 
Next, we set out to determine the impact of Treg on anti-tumour T-cell responses in breast 
cancer patients. To start, we established a Treg depletion protocol with MACS© CD4+CD25+ 
Regulatory T Cell Isolation Kit. This protocol was conducted as illustrated in Figure 4. In order 
to achieve equal amounts of T cells required for a comparison with and without Treg 
fractions, two thirds of purified T cells were used for an accomplishment of Treg depletion 
procedure due to an inevitable loss of cells during additional purification steps. The 
depletion of CD4+CD25+ T cells was conducted by an initial isolation of CD4+ T cells via 
negative selection (positive selection of CD8+ T cells) followed by a positive selection of 
CD25+ cells from the previously isolated CD4+ T cells. The residual CD4+CD25- cells were 
returned to the selected CD8+ T cells from the first purification step and denoted as Tcon or 
“TC-”. The un-touched T cell population is denoted as TC or “TC+”. The sufficiency of 
depletion was confirmed by flow cytometry as shown by a representative example in Figure 
4B. CD25high and Foxp3+ cells were substantially reduced in TC- fraction compared to TC+ 
one, indicating this protocol is able to provide a successful depletion of Treg. Accordingly, 
the depleted CD4+CD25+ cells were largely enriched in “Treg” fraction as observed that more 
than 60% of these cells co-expressed Foxp3 and CD25. 
IFN-γ catch assay was chosen to study the impact of Treg because of its allowance of specific 
isolation and expansion of viable T cells. First we compared the capacities of IFN-γ 
production of T cells in the presence or absence of Treg upon breast tumour antigen 
stimulation. Same amounts (4x106) of TC+ and TC- from one breast cancer patient were 
activated with MCF7 cell lysates presented by autologous DC for 16 hr. Then an IFN-γ catch 
assay was conducted. The numbers of captured cells, namely IFN-γ secreting cells were 
counted. Interestingly, 1.3-fold more cells were captured from TC- group (1x106) than from 
TC+ group (0.76x105) (Figure 5A), indicating that the present Treg have a suppressive impact 
on T-cell activation.  
To evaluate which T-cell population was inhibited by Treg, we performed multicolour flow 
cytometric analyses. At a single cell level, we detected that the suppression was exerted on 
both CD4+ and CD8+ T-cell populations by Treg. As shown in Figure 5B, upon MCF7 
stimulation the percentages of IFN-γ secreting CD4+ T cells increased from 0.39% in TC+ 
group to 2.25% in TC- group (5.8x), and the percentages of IFN-γ secreting CD8+ T cells 
increased from 0.23% in TC+ group to 2.59% in TC- group (11.7x). These data indicate that 
Treg of breast cancer patients have an inhibitory impact on both CD4+ and CD8+ T-cell 
activation in response to tumour antigens. 
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Figure 4. Schematic overview of Treg-depletion protocol. A, Purified TC are unevenly separated into two parts. 
One-third of TC containing un-touched Treg served as original TC+ population. Two thirds of TC was subjected 
to an isolation of Treg. This was achieved by a negatively selection of CD4
+ 
TC followed by a positive selection of 
CD25
+
 TC. The residual CD4
+
CD25
-
 TC were pooled together with CD8
+ 
and denoted as Tcon or TC-. B, Flow 
cytometry analyses confirm the purity of Treg-depletion. Each plot shows the population designated at the left 
side. The cells were pre-gated on CD3
+
CD4
+
 TC, and are shown by Foxp3 staining versus CD25 staining. The pink 
boxes inside the plots indicate the Treg population. These results represent 3 independent experiments.  
 
To understand whether this suppression was tumour specific, we repeated the experiment 
with an additional irrelevant tumour antigen (U937). Flow cytometric results are shown in 
Figure 5B. Similarly low percentages of IFN-γ secreting TC among CD4+ and CD8+ T cell 
populations were observed in response to both MCF7 and U937 prior to a conducted Treg 
depletion. However, a sharp difference was observed after eliminating the Treg. As 
described above, a dramatic restoration of type-I T-cell immunity was observed in response 
to MCF7, but not to U937 (CD4+, TC+ versus TC-: 0.59% versus 0.0084%; CD8+, TC+ versus TC-
: 0.2% versus 0.66%). These data suggest that Treg exert a suppression through an antigen-
specific manner in breast cancer patients. 
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Figure 5. Exemplary results show the advantage of pre-Treg-depletion for IFN-γ secretion assay. Purified bone 
marrow T cells were stimulated with breast tumour antigens derived from MCF7 cell line or control tumour 
antigens from U937. 16h later an IFN-γ catch assay was performed. A, Treg-depletion benefited the expansion 
of IFN-γ-captured cells upon post-polyclonal stimulation. IFN-γ secreting cells were captured on Day0 and were 
immediately cultured with anti-CD3 & CD28 beads at a beads:cells ratio of 1:1. The absolute counts of cells 
were followed on indicated days. B, Enhancement of MCF7-specific type-I T cell proportions in both CD4 and 
CD8 subsets are found in Treg pre-depleted group but not in non-depleted one. The percentages of IFN-γ 
secreting T cells were determined by multicolour flow cytometric analyses.  
 
Next, the impact of Treg on IFN-γ captured cells was evaluated regarding their proliferative 
ability. The captured MCF7-reactive T cells were stimulated with αCD3 and αCD28 mAb 
coated beads at beads to TC ratio of 1:1 in the cultivation with a concentration of 1x106 
TC/ml. Cell counts were followed before and after stimulation (Figure 5A). Compared to 
Day0, declines in cell counts were observed on Day3 in both TC+ and TC- originated groups, 
however, with a larger extent in TC+ group (% of decrease: TC+, 67% versus TC-, 35%); 
whilst, a vital expansion was obtained on Day6 in TC- group but not in TC+ group (compared 
to Day0: 2.7-fold and 1.3-fold increase, respectively). These findings suggest that Treg from 
breast cancer patients have a subsequent impact on polyclonal expansion of TA activated T 
cells.  
This concept was further confirmed by a post-stimulation with tumour specific antigens. In 
detail, the captured KS24.22-reactive TC from TC+ and TC- groups, as well as the cells in flow 
through fraction, namely non-captured cells, of TC- group were re-stimulated with irradiated 
KS24.22 at a ratio of TC to tumour cell 5:1. Seven days later, a vigorous clonal expansion was 
observed in the wells of the TC obtained from TC- originated group (Figure 6A middle). The 
captured TC from TC+ group were able to recognize tumour antigens since several clusters 
were formed around tumour cells at beginning, but they failed to develop clonal expansions 
(Figure 6A top). Whilst the flow through TC from TC- group did not possess the specificity 
towards KS24.22 as they were found to be separated from tumour cells through the entire 
cultivating time (Figure 6A bottom), which also suggests an efficiency of this assay.  
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Collectively, these data demonstrate that besides an inhibitory effect on T-cell activation 
Treg in breast cancer patients have a subsequent impact on clonal expansion of Teff in vitro. 
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Figure 6. Exemplary results show the impact of Treg on clonal expansion and cytolytic activity of tumour-
antigen specific T cells from IFN-γ secretion assay. The captured T cells from both TC+ and TC- groups, as well as 
flow-through T cells from TC- group were re-stimulated with irradiated KS24.22 at a ratio of 5:1. Different T-cell 
fractions are indicated in the middle panel. A, cell cultivations show clonal expansion capacity of different T-cell 
fractions observed 7 days after breast tumour antigen re-stimulation. B, 
51
Cr release assay shows cytolytic 
activities of different T-cell fractions obtained 30 days after breast tumour antigen re-stimulation. E:T indicates 
the ratio of effect cells to target cells. Bars; standard deviation of triplicates.  
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Moreover, this antigen-driven clonal expansion also implies an impact of Treg on immune 
recall. To confirm this concept, 51Cr release assay was carried out with those KS24.22 re-
stimulated cells 30 days later. KS24.22 and U937 were used as target cells. Results are shown 
in Figure 6B. A tumour-specific cytotoxicity was remarkably elicited from TC- originated 
group with high significances observed from three different ratios of effector to target cell 
(p-value50:1 =2x10
-5; p-value25:1 =1x10
-4; p-value1.25:1=2x10
-3). In a sharp contrast, none of the 
compared samples exhibited tumour-specific killing. These data evidence a long term 
suppression of Treg on Teff function, which is likely imprinted into Teff during the priming 
phase.  
On the other hand, our results demonstrate that by removing Treg from breast cancer 
patients, whose in vivo immunity was steadily established, their anti-tumour responses can 
be rescued.  
 
6.4 Spontaneous anti-tumour type-I T-cell responses are suppressed by Treg 
in breast cancer patients  
Being encouraged by the results presented above, we then enlarged the sample size in order 
to have a solid conclusion of Treg impact on spontaneous anti-tumour T-cell responses of 
breast cancer patients. The same Treg-depletion procedure was performed as described 
above. IFN-γ ELISpot assay was performed as a read-out system. T-cell responses in the 
presence or absence of Treg were evaluated against polyvalent breast tumour antigens 
derived from MCF7 and KS24.22 (Result 6.4.1), as well as against defined tumour-associated 
antigens derived from synthetic polypeptides (Result 6.4.2) 
 
6.4.1 Treg suppress type-I T-cell responses against polyvalent breast tumour 
antigens derived from MCF7 and KS24.22 cell lines. 
Taking an advantage that the cell lysates of breast tumour cell lines cover a wide spectrum 
of tumour antigens, we started this part of study with MCF7 and KS24.22 cell lysates as the 
source of breast tumour antigens; meanwhile, U937 was served as an irrelative control. 
Exemplary results of IFN-γ ELISpot are shown in Figure 7. In this patient, prior to a Treg 
depletion, TC immunity was lacking in the PB, while a weak reactivity was observed in 
response to KS24.22 but not to MCF7 in the BM. However, with a Treg deprivation, the 
breast tumour-specific T-cell immunity was unmasked dramatically in both PB and BM in 
response to both KS24.22 and MCF7 (see the p-values in the figure). 
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Figure 7. Impact of Treg on type-I T-cell responses. Primary data of an exemplary IFN-γ ELISpot assay. 
Peripheral blood (PBTC) and bone marrow (BMTC) T cells were stimulated with breast tumour antigens derived 
from KS24.22 (black columns) or MCF7 (gray columns) cell lines, and with control tumour antigens from U937 
(white columns). The frequencies of IFN-γ secreting T cells were determined by mean values of three wells per 
antigen. Without and with a performed Treg-depletion are indicated as Treg depl. – and +, respectively. 
Statistical differences were calculated by unpaired two-tailed t-test. Significant p-values are depicted above 
small lines which connect the compared groups. n.s.: not significant. 
 
In order to evaluate an overall effect of Treg-depletion in breast cancers, we analyzed the 
differences in the frequency of IFN-γ secreting T cells without and with a conducted Treg-
depletion in each studied group. Accumulative data are shown in Figure 8A (PB) and 8B 
(BM). Regarding MCF7-reactive TC the mean frequencies increased 2.6-fold in the PB 
(141.9/105 versus 371/105 TC; n=26) and 2.3-fold in the BM (167.1/105 versus 387.2/105 TC; 
n=24). Similarly, the mean frequencies of KS24.22-reactive TC augmented 2.3 and 2.6 times 
in the PB (209.9/105 versus 484.2/105; n=20) and the BM (229.2/105 versus 596.2/105; n=21), 
respectively. All these effects displayed statistical significances (see p values in the figures).  
More importantly, these effects appeared to be breast cancer specific as no significant 
differences were detected in response to the irrelevant tumour antigens (PB: 120/105 versus 
200/105, n=31; BM: 133.9/105 versus 227.6/105, n=27) in despite of a few individuals 
exhibiting higher responsiveness after applying a Treg-depletion. To confirm it, we analysed 
the tumour specific responsiveness with altogether 31 PB and 27 BM samples of primary 
breast cancer patients (Figure 8C). Without a Treg-depletion, anti-KS24.22 T-cell immunity 
was detectable in the PB but with a relatively low extent, whereas it was absent in the BM. 
MCF7-specific reactivity was not detectable, neither in the PB nor in the BM. However, the 
absent or weakly existing T cell responses were profoundly recovered by applying a Treg 
depletion (see p values in the figures).  
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Figure 8. Treg-depletion leads to a specific increase of reactive T-cell frequencies against breast tumour 
antigens. A, PBTC and B, BMTC were stimulated with MCF7 and KS24.22 and control U937 from the left to the 
right, respectively. Frequencies of reactive TC were determined by IFN-γ ELISpot analyses. Each symbol 
indicates a mean value of triplicates. Dash lines connect corresponding frequencies within individuals before 
(+) and after (-) Treg-depletion. Statistical differences were calculated with unpaired two-tailed t-test. C, Treg-
depletion has antigen specific effect in breast cancer patients. Frequencies of responding PBTC (left) and BMTC 
(right) were cumulated, and values are depicted as columns with SEM bars. KS24.22: black; MCF7: gray; U937: 
white. P-values indicate the statistic differences within the interested groups as combined by short lines. 
Unpaired one-tailed student t-test was performed. n.s.: not significant. 
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Collectively, these data substantially confirmed our previous finding that Treg existing in 
breast cancer patients suppress spontaneous anti-tumour type-I TC immunity.  
Also, these data imply that the inhibitory function of Treg requires appropriate tumour-
antigen activation. To confirm this concept, we calculated the frequencies of antigen-specific 
T cells by subtracting background ones (U937) from interested values (MCF7 or KS24.22) 
within those immunological responders, and normalized all non-responders to the value of 
0. Accumulative data are shown in Figure 9. Within PBTC, MCF7-specific frequency was 
dramatically unmarked by a Treg depletion (10x, p=0.022). Similar significance was also 
displayed regarding KS24.22-specific frequency (5x, p=0.03). Within BMTC, the influence was 
relatively less as a 3-fold and 4-fold induction in MCF7 (p=0.02) and KS24.22-specific 
frequencies were detected, respectively.  
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Figure 9. Treg-depletion unmasks anti-breast-cancer specific responses in both peripheral blood and bone 
marrow. A, the specific frequencies against breast tumour-antigens were determined by subtractions of mean 
values of U937 from KS24.22 (black columns) and from MCF7 (gray columns). The performance of Treg-
depletion was indicated as –: not conducted; +: conducted. Bars represent SEM. Unpaired two-tailed p-values 
together with increased folds are depicted above short lines which connect compared groups. 
 
Surprisingly, the frequencies of breast tumour specific T cells in the PB approached that in 
the BM after conducting a Treg-depletion. In particular, the mean frequencies of 
spontaneous KS24.22-reactive T cells between PB and BM were narrowed down from 48% to 
15%. Even better situation was observed regarding MCF7-specific responses, as the 
difference was greatly reduced from 61% to 9%. Given the evidence from our pilot study 
that the more tumour-reactive T cells which were transferred into patients, the better 
chance for them to achieve anti-tumour responses afterwards, this finding, therefore, has a 
profound meaning in improving ADI project as a large amount of T cells which contain 
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tumour-reactive ones are able to be generated from a leukaphoresis instead of limited BM 
source. Consequently, more patients would be benefited from this immunotherapy.  
Next, we evaluated the impact of Treg on the proportions of immunological responders. 
(Figure 10). Without depleting Treg from the PBTC, there was 26.1% (6 out of 23) of MCF7 
responders, and 35% (7 out of 20) of KS24.22 responders. When the Treg were eliminated 
from the samples, the proportion of MCF7 and KS24.22 responders significantly increased to 
60.9% (14 out of 23 patients, p=0.036) and 76.5% (13 out of 17 patients, p=0.020), 
respectively. In other words, Treg-depletion revealed minimally 34.8% of patients who 
naturally contained tumour-reactive mTC in their blood. 
In the BM compartment, Treg-depletion induced substantial but not significant proportions 
of responders. Without and with a Treg removal, the proportions of MCF7 responders went 
up from 31.8% (7 of 22) to 50% (10 of 20), while KS24.22 responders increased from 45.5% 
(10 of 22) to 68.4% (13 of 19). The less benefit of Treg-depletion found in the bone marrow 
of breast cancer patients might be due to the more pre-existing functional TA-specific mTC 
compared to the periphery compartment. 
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Figure 10. The beneficial effect of Treg-depletion in the proportion of tumour-antigen responding patients. The 
percentages of responding patients who exerted specific responses against breast tumour antigen (MCF7 and 
KS24.22) were compared before (white) and after (MCF7: gray; KS24.22: black) Treg-depletion. Last 4 columns 
show accumulated results of patients who responded either to MCF7 or KS24.22 (light blue and light pink: 
before Treg-depletion; blue and pink: after Treg-depletion). P-values indicate the statistical difference 
performed by Fisher’s exact test. n.s.: not significant. 
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As the spectrums of tumour-antigens carried in MCF7 and KS24.22 not only have overlaps 
but also are compensative, we pooled the results from both studies in order to evaluate a 
general impact of Treg in breast cancer. To this end, patients who responded to at least one 
of the tumour antigens (either MCF7 or KS24.22, or both) were considered as immunological 
responders. Results are shown in Figure 10 (the last 4 columns). A highly significant benefit 
of Treg elimination from PBTC (p=0.0006) was obtained; whilst a marginal significance was 
displayed in the analysis of BMTC (p=0.088). Interestingly, the percentages of breast tumour 
responders were enhanced to the same level after depleting Treg from periphery (76.7%) 
and bone marrow (76%).  
Taken all, these data demonstrate that spontaneous type-I TC immunity against polyvalent 
tumour antigens are inhibited by Treg in the patients with primary breast cancers. This 
suppression is likely triggered in an antigen-specific manner. 
 
6.4.2 Treg suppress type-I T-cell responses against tumour-associated antigens 
derived from synthetic polypeptides  
The so far presented findings are studied with polyvalent breast tumour antigens derived 
from allogeneic cell lines (MCF7 and KS24.22). It is interesting as well as important to clarify 
the impact of Treg on T-cell responsiveness against breast tumour-associated antigens 
(TAAs). To this aim, an appropriate activation for Treg which enables them to exert inhibitory 
function was considered. We elaborated 50-100mer synthetic polypeptides which flank HLA-
A*0201 binding motifs and cover several potential CD4+ epitopes. 12 well characterized HLA-
A*0201-restricted nonameric peptides were selected from four breast cancer specific 
tumour antigens and six common cancer tumour-associated antigens (Table 3). A polyvalent 
human immunoglobulin served as control antigen. IFN-γ ELISpot assay was performed as a 
readout system.  
An exemplary result obtained from PBTC of one breast cancer patient is shown in Figure 11. 
Among 12 tested polypeptides, T cell reactivities were found towards three and seven TAAs 
before and after a Treg-depletion, respectively, indicating a Treg-depletion benefit. Of note, 
in this patient, the Treg-depletion did not only favour to anti-tumour immunity, as the pre-
existing hTERT and MAGE responses were abolished after applying it. This is possibly due to 
concomitantly depriving current effector T cells through their highly expressed CD25 marker. 
Nevertheless, these data showed that the responsiveness against four TAAs was suppressed 
by the existing Treg in this assessed patient. 
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Table 3. Synthetic polypeptides designed from tumour-associated antigens HLA-A*0201-restricted nonamers.  
TAA and control abbreviation 
start position 
of nonamer in 
amino acid 
sequence 
HLA-A*0201 –
restricted-
peptide 
sequence 
Designed polypeptide 
position in amino acid 
sequence 
Heparanase HpaI 16 LLLGPLGPL 1-50 
Heparanase HpaII 183 DLIFGLNAL 163-212 
Mammaglobin Mam1 4 LMVLMLAAL 4-56 
Mammaglobin Mam2 
66 
83 
FLNQTDETL 
LIYDSSLCDL 
41-92 
Her2/neu Her2/neu 369 KIFGSLAFL 351-384 
Mucin-1 tandem repeat M20 9 STAPPAHGV 137-157 
Mucin-1 signal sequence M100 12 LLLLTVLTV 1-100 
Epidermal growth factor 
receptor 
EGFR 479 KLFGTSGQKT 479-528 
p53 p53 149 STPPPGTRV 118-167 
Melanoma asscociated 
antigen-3 
MAGE3 271 FLWGPRALV 271-314 
Human telomerase hTERT 988 YLQVNSLQTV 958-1007 
Survivin Survivin 96 LMLGEFLKL 93-142 
Carcinoembryonic Antigen CEA 571 CGIQNSVSA 569-618 
Human immunoglobulin IgG / control - - 40-89 
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Figure 11. Treg impact on type-I TC reactivity against a spectrum of tumour associated antigens (TAA). An 
exemplary result shows the IFN-γ productions of PBTC before (PBTC+) and after Treg-depletion (PBTC-) against 
12 tested polypeptides (represented in different colours) and control IgG (white) presented by autologous DC. 
Columns and bars represent mean value of triplicates and SEM. Asterisks indicate where the statistical 
significances (p<0.05) are obtained when compared to the values of control IgG. Pared two-tailed t-test was 
performed.   
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Figure 12. Impact of Treg on the frequencies of type-I T cell in response to polypeptides. Frequencies of 
polypeptide responding T cells were determined by IFN-γ ELISpot analyses. Light blue columns: without Treg-
depletion; dark blue columns: with Treg-depletion. Bars:SEM. The studied polypeptides are depicted under the 
respective columns. Control IgG (Endo) was used as irrelevant antigens shown with open columns. Asterisk 
indicates a statistical difference of p<0.05 comparing the values of indicated polypeptides and respective 
controls (*: paired two-tailed t-test; *: unpaired two-tailed t-test). A significant difference within a studied 
polypeptide is depicted with an arrow and p-value above (2-tailed paired student t-test). The experiments were 
performed with peripheral blood T cells (PB) shown in A, and with bone marrow T cells (BM) shown in B from a 
total of 41 patients.  
 
To have an overview, results from 38 PB and 26 BM samples of primary breast cancers were 
evaluated as shown in Figure 12. With PBTC, the benefits of Treg-depletion were observed in 
different extents with almost all studied polypeptides except MAGE3. In particular, the 
significant inductions were achieved against five tumour antigens: HpaI, HpaII, Mam1, Muc1-
20 and Her2/neu. Regarding the TAA-specific responsiveness, Treg-depletion elicited 
significantly higher IFN-γ productions of PBTC in response to Muc1-20, Muc1-100, EGFR and 
CEA than to control IgG (see asterisks in the figure). Of note, this approach reversed the 
significant response towards MAGE3. As we speculated above, this loss likely implies a 
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general on-going occurrence of MAGE3 Teff which were undesirably depleted through CD25 
targeting.  
In contrast to PBTC, Treg withdrawal from BMTC did not trigger any significant 
augmentations in TC immunity against TAAs, rather a significant reduction of CEA-
responsiveness. However, compared to the values of controls, TAA-specific responses 
against HpaI, Muc1-20 and Muc1-100 were significantly favoured from the Treg-depletion 
protocol (see asterisks in the figure).  
Of note, the Muc1-100-reactivities in both PBTC and BMTC were pre-established prior to a 
conducted Treg-depletion, and remained with an increasing degree after applying it.  
So far, these data indicate that Treg suppression on TAA-responsiveness exist in both PB and 
BM. And this impact is stronger and broader in the PB than the BM. 
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Figure 13. The same anti-tumour T-cell reactivity was obtained by PBTC and BMTC after a performed Treg 
depletion. A, Accumulated data of mixed polypeptides are gathered from in total 41 studied breast cancer 
patients. The mean frequencies of peripheral blood T cells (PT) and bone marrow T cells (BT) in the presence (+, 
white) and absence (-, black) of Treg are depicted as columns with SEM bars. Numbers depicted inside columns 
indicate the mean values. Numbers (n) of studied samples of each group are listed below respective columns. 
Statistical analyses were performed between the groups indicated by arrows with p-values above. n.s.: not 
significant. Numbers in parenthesis indicate increasing folds. B, Accumulated data of mixed polypeptides are 
gathered from only immunological responders. Each dot represents one individual value. Small bars inside 
groups represent median frequencies of T cells among TAA-recognizing breast cancer patients. Paired two-
tailed t-test was performed.  
 
In order to evaluate the accordance of using polypeptides with polyvalent antigens derived 
from cell line lysates, the frequencies of TAA-specific TC were accumulated from all tested 
samples from in total 41 breast cancer patients. Results are shown in Figure 13A. A highly 
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significant unmasking effect from Treg deprivation was revealed in the blood (p=0.0002). 
The mean frequencies boosted from 24 to 47 per 105 PBTC (1.96x). Although the influence in 
the bone marrow was not statistically significant, the mean frequencies of reactive BMTC 
were also increased from 36 to 47 per 105 BMTC (1.3x). Thus, in line with the results 
obtained with polyvalent breast tumour antigens, these data show that a Treg depletion is 
able to result in a replenishment of otherwise significant lower (p=0.037) spontaneous T-cell 
immunity in the PB and to a level as high as in the BM afterwards.  
In consistence with this, when a similar comparison was preformed only within 
immunological responders, a pronounced increase in the mean value of responding T cells 
was observed in the blood (p=0.006), but not in the bone marrow (Figure 13B). Besides the 
mean frequencies, the median of TAA-specific PBTC also showed a substantial increase by 
1.5-fold (PT+ versus PT-: 65/105 versus 95/105). Whilst the medians were relatively stable 
concerning BMTC (BT+ versus BT-: 75/105 versus 77/105).  
These observations demonstrate that spontaneous T-cell responses towards tumour-
associated antigens are suppressed by Treg in the blood and the bone marrow of primary 
breast cancer patients, especially in the blood. 
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Figure 14. Comparisons of spontaneous T-cell reactivity against tumour-associated antigens in patients and 
healthy donors. A, cumulative data of frequencies of TAA-recognized T cells in the blood. Paired two-tailed t-
test analyses were performed to compare the differences within breast cancer patients (MaCa) and within 
healthy donors (HD) before (+) and after (-) a performed Treg-depletion. Unpaired two-tailed t-test was 
performed to analyse the differences between breast cancer patients and healthy donors with a same 
treatment. Bars: mean±SEM. B, the same analyses as A were performed with bone marrow T cells.  
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Further, we evaluated whether this observed T-cell reactivity against designed polypeptides 
was specific to cancer patients. To this end, we conducted the same experiments with 
healthy donor (HD) derived T cells in the presence or absence of Treg. Altogether, 28 PB and 
25 BM samples of HD were measured. Accumulative results are shown in Figure 14A (PB) 
and 14B (BM). A few of HD exhibited cross responses to TAA polypeptides with some of 
them even displayed exorbitant values. However, compared to breast cancer patients, the 
mean values of frequencies regarding TAA-reactive T-cells in HD was highly significantly low 
(see p-values in the figure), which is counted for both PBTC and BMTC, and also for both 
with and without Treg presence. These observations imply a potential relevance of utilizing 
these polypeptides for diagnostics, tumour vaccine design, and predicting T-cell immune 
responsiveness in breast cancer patients. 
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Figure 15. With or without Treg presence T cells show different patterns of tumour-associated antigen 
recognition in the peripheral blood (A) and the bone marrow (B). The frequencies of TAA-specific responding T 
cells were determined by IFN-γ ELISpot assay. Data from only immunological responders are shown here. Each 
dot represents an individual test. Light blue dots showed on left side and dark blue dots showed on right side 
represent the frequencies before (+) and after (-) a performed Treg-depletion, respectively. Bars indicate 
median values. To have a relative comparison, a lowest and most reliable value was chosen (red dash box) to 
be a comparative object for the other polypeptides in each section. P-values above arrows indicate statistical 
differences calculated with unpaired two-tailed t-test. 
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Next, we were interested in defining the spectrum of T-cell TAA-responsiveness exerted by 
Treg in breast cancer patients. To this end, we analyzed frequencies of TAA-specific T cells 
only from immunological responders, and compared the mean values of accumulated data 
to the lowest one displayed among interested T-cell groups. Results are shown in Figure 15 
(A: PT, B: BT). The value of HpaI was designated as the reference for the study of PBTC 
without a conducted Treg-depletion. Compared to this, the frequencies of hTERT and 
MAGE3-specific T cells exhibited substantial elevations (p=0.013 and 0.014, respectively). 
After depleting Treg, the lowest frequency of TAA-reactive T cells was observed against p53. 
And in comparison to this, the frequencies of Muc1-20 and MAGE3-reactive T cells showed a 
significant (p=0.046) and a marginally significant (p=0.09) induction, respectively. These 
findings might have a potential clinical implication regarding peptide vaccine as different 
spectrums of TAAs should be considered according to whether a Treg depletion is 
preconditioned in breast cancer patients or not. 
In the BM, the values obtained from Mam1 tests were designated as comparative objects in 
the groups of without and with a performed Treg-depletion. Under this condition, we did 
not observe any superior antigeneic tumour antigens according to statistical analyses.  
Last, the impact of Treg on proportions of immunological responders was evaluated (Figure 
16). In general, Treg-depletion-induced enhancements were detected in response to nine 
and five out of 13 studied polypeptides in the PB and BM, respectively. The significant effect 
appeared regarding Her2/neu in the PB (p=0.03), indicating a strong inhibition of Treg to T-
cell reactivity against Her2/neu in breast cancer patients. 
In a conclusion, these data demonstrate that type-I T-cell immunity against various tumour-
associated antigens is suppressed by Treg in patients with primary breast cancer. 
 
6.5 The suppressive regulatory T cells in breast cancer patients display 
tumour antigen specificity  
So far we have shown the existence of Treg in breast cancer patients as well as their 
negative modulation capacity on anti-tumour type-I TC immunity. However, it remains 
unclear whether a tumour antigen-specific manner is utilized by Treg to exert this 
suppressive activity. Although the findings reported above have indirectly evidenced this 
conception, we are going to address this intriguing question with more direct evidence in 
this chapter.   
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Figure 16. The impact of Treg on proportions of TAA-specific responders in breast cancer patients. Anti-tumour 
reactivity in the PB (A) and the BM (B) were tested against 13 different TAAs (indicated beneath X-axis) by IFN-γ 
ELISpot assay with (light blue) and without (dark blue) Treg presence. Columns represent the percentages 
(indicated in the column) of immunological responders among all tested patients. The exact numbers of 
responding patients to total analysed ones are listed below. Statistical differences within one studied antigen 
are calculated by Fisher’s exact test. 
 
 
6.5.1 Confirmation of the suppressive capacity of Treg enriched from an 
established protocol. 
First of all, to identify the antigen specificity of Treg in breast cancer patients, a prerequisite 
is to confirm the purity of our so-called Treg, including the phenotypic and functional 
purities. In the previous report of this thesis (Figure 4B), we have shown that Treg are rather 
enriched than purified from a Treg-depletion approach as the phenotypic purity is constantly 
RESULTS – PART I 
P a g e  |  68 
around 60% of total isolated “Treg” fraction determined by co-expressions of Foxp3 and 
CD25. (Little note: to avoid confusion, even though there is a contamination with 40% of 
other CD4+ TC, the term “Treg” is still used for denoting this population.)  
However, a more important concern is whether these 60% of Treg are sufficient to exert 
suppression? To testify this, we performed a polyclonal suppression assay and Treg-adding-
back IFN-γ ELISpot assay. 
Treg are known to be hypo-proliferative and effectively suppress proliferation of Tcon upon 
a polyclonal stimulation. In this regard, we first assessed the functional purity of Treg with a 
standard proliferation assay performed as following: Tcon and Treg were co-cultured with 
titrated ratios of Tcon:Treg from 1:0, 1:1, 2:1, 4:1 to 8:1, and were polyclonally stimulated by 
αCD3 and αCD28 mAb coated magnetic beads for three days. During the last 18 hr 3H 
thymidine was provided for being incorporated into proliferating T cells. The amounts of 
incorporated radioactivity were used for quantifying the extent of proliferation.  
A representative result obtained with PBTC from a primary breast cancer patient is shown in 
Figure 17. An undetectable proliferation of Treg alone and a vigorous amplification of Tcon 
were observed upon a polyclonal stimulation as expected. The latter proliferation was 
inhibited in the presence of Treg. The intensity of inhibition was correlated to the proportion 
of Treg in the co-culture. Significant suppression of Treg was displayed at Tcon:Treg ratio of 
1:1 (p=0.004) and 2:1 (p=0.005). Even though there was no statistical difference shown at 
higher ratios (4:1 and 8:1), substantial reductions in the amplification of Tcon were 
sustained. Hence, these data demonstrate that 60% Treg isolated from a Treg-depletion 
protocol are sufficient to inhibit polyclonal proliferation of Tcon in vitro.  
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Figure 17. Treg suppress the proliferation of 
Tcon upon polyclonal stimulation. Primary data 
from PBTC of a breast cancer patient are shown 
here. White bars: Tcon only. Black bars: Tcon in 
co-culture with autologous Treg at different 
ratios as indicated. Cell cultures were 
polyclonally stimulated and incubated for 72h. 
The proliferations of Tcon were quantified by 
the values of incorporated 
3
H-thymidine. 
Statistical analyses were performed between 
co-cultures and Tcon alone. P-values are 
calculated by paired two-tailed t-test. This 
result represents 3 independent experiments. 
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Next, we evaluated the functional purity of Treg by its suppression on cytokine secretion. 
Previously, we have shown that a withdrawal of Treg can rescue type-I cytokine secretion in 
PBTC and BMTC upon tumour-antigen stimulation. In order to obtain more direct evidence, 
we utilized the same IFN-γ ELISpot assay, and compared the outcomes with TC- population 
in the absence and re-presence of autologous Treg which were added back at different 
ratios.  
An exemplary result of a primary breast cancer patient is shown in Figure 18. Without the 
presence of Treg, KS24.22-specific responsiveness was found in both PBTC (p=0.002) and 
BMTC (p=0-009). However, they were substantially abrogated by returning autologous Treg 
at TC- to Treg ratios of 2:1 and 4:1. The only restored KS24.22-specific reactivity in this 
experiment was observed in the BM (p=0.05) when Treg proportion was reduced to a ratio 
of TC:Treg 8:1.  
Accordantly, the extent of Treg suppression on T-cell responsiveness again KS24.22 was 
dramatically reduced in the co-cultivations at TC-:Treg ratio of 2:1 and 4:1, which was 
counted for both PBTC and BMTC. This inhibitory effect appeared to be Treg dose 
dependent as IFN-γ productions were gradually restored determined by mean values of 
tumour-reactive T cells and eventually statistically vanished at a ratio of 8:1 (see p-values in 
the figure). Markedly, U937 background IFN-γ secretion was not inhibited by adding back 
Treg, suggesting an antigen specificity of Treg in breast cancer patients.  
Collectively, these findings confirm the functional purity of Treg isolated from a Treg 
depletion protocol.  
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Figure 18. Added back Treg suppress autologous type-I T-cell response against breast tumour antigens. 
Columns represent the frequencies of KS24.22 (black) and U937 (white) reactive T cells with PBTC and BMTC in 
the absence of Treg (TC-) and in the presence of Treg with different ratios as indicated below X-axis. Statistical 
analyses were calculated between interested groups showed by arrows with p-values above. Paried two-tailed 
t-test was performed. n.s.: not significant. This exemplary result represents 3 independent experiments. 
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6.5.2 Treg from breast cancer patients recognize tumour-specific antigens 
6.5.2.1 Experiment design 
It is documented that Treg require TCR triggering to become functionally suppressive, but 
once activated they suppress function of Tcon blindly. According to this notion, we designed 
a novel approach for examining the existence of breast-tumour-specific Treg. As shown with 
a schematic in Figure 19, this method was modified from a T-cell proliferation assay. In 
detail, Treg were activated with breast tumour antigens presented by autologous DC for 24 
hr. Meanwhile Tcon received polyclonal stimulation from αCD3 and αCD28 mAb coated 
wells. Afterwards, pre-activated Tcon were given into Treg stimulation cultivation at a ratio 
of 1:1 for three days to allow a full exertion of suppression. The last 18h 3H thymidine was 
provided into the co-cultivations. The degree of Tcon proliferation was quantified by the 
amount of incorporated 3H thymidine. We named this experiment “Treg specificity assay”. 
 
Figure 19. Schematic of Treg specificity assay. 
Treg 
 Antigen-specific stimulation 
 DC:Treg = 1:5 
 24 hr 
Tcon 
 Polyclonal stimulation 
 [1µg/ml ] αCD3 & αCD28 mAb  
 18 hr 
 
Tcon & Treg co-culture 
 Tcon:Treg = 1:1 
 3 days 
 
3H thymidine incorporation 
 18 hr 
 
analysis 
 
6.5.2.2 Treg recognizes polyvalent tumour antigens derived from MCF7 or KS24.22 cell 
lines 
To start, we assessed the specificities of Treg towards a large spectrum of breast tumour 
antigens provided in MCF7 and KS24.22 cell line lysates. And in order to testify the reliability 
of newly designed protocol, we performed several rigid control experiments. 1) The 
proliferative extents of Treg alone with different antigen stimulations were evaluated. 2) 
RESULTS – PART I 
P a g e  |  71 
Since Treg are known to be generated according to self-antigen recognition, we also 
measured the spontaneous proliferation of Treg possibly triggered by autologous DC on 
which endogenous self-antigens were presented. 3) To further prove the genuine inhibition 
of Treg to the proliferations of Tcon, the 3H thymidine incorporations in the wells of 
activated Tcon with and without a presence of Treg were examined.  
 
A. 
0
1.0104
2.0104
3.0104
U937-DC
DC
Treg only Tcon+TregTcon only
MCF7-DC
0.03
0.02
0.02
n.s.
3
H
 T
d
R
 u
p
ta
k
e
n
 (
C
C
P
M
)
 
B.                                      PB                                                                         BM 
MCF7 U937 KS24.22
0
5.0103
1.0104
1.5104
2.0104
2.5104
0.005
3
H
 T
d
R
 u
p
ta
k
e
0.001
 
MCF7 U937 KS24.22
0
2.0103
4.0103
6.0103
8.0103
0.01 MCF7
U937
KS24.22
3
H
 T
d
R
 u
p
ta
k
e
0.001
 
Figure 20. Preliminary data show a feasibility of Treg specificity assay. A, Approach controls. Treg received 
activation with MCF7 (gray column) and U937 (white column) pulsed DC, and non-pulsed DC (shadowed 
column) for 24h. Tcon were stimulated with polyclonal αCD3 and αCD28 mAbs for 18h. Afterwards, Tcon were 
added into Treg cultivation at ratio of 1:1 for three days (Tcon+Treg). Meanwhile, two control experimental 
settings were performed. Treg only: without Tcon co-cultivation; Tcon only: pre-activated Tcon were further 
cultivated with different models of pulsed DC but without Treg presence. The amounts of T-cell proliferation 
were measured by 
3
H thymidine incorporation and shown by columns with SEM bars. Statistical analyses were 
performed between the interested groups connected by short bars with p-values above. n.s.: not significant. B, 
Primary data show that Treg from both PB and BM possess breast TA-specificity. Polyclonally stimulated Tcon 
were co-cultivated with Treg that were pre-stimulated with antigens from MCF7, KS24.22 (black column) and 
U937. 
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Exemplary results are shown in Figure 20A. First of all, the lowest proliferation levels were 
observed from Treg alone groups with no detectable differences in between different 
tumour-antigen stimulations and autologous DC stimulation, which dispelled the potentials 
of antigen-driven proliferations of Treg. Second, the highest proliferations were attested 
from polyclonal activated Tcon in the absence of Treg. And according to statistical analyses 
there were no influence of different models of antigen stimulations carried out by 
autologous DC. Third, with a co-cultivation of MCF7–activated Treg, a vital polyclonal 
proliferation of Tcon was significantly suppressed (p=0.02). And importantly, this effect was 
not observed with irrelevant tumour antigen (U937) or self antigen activated Treg. Hence, 
these data demonstrate a reliability of this newly designed protocol.  
Furthermore, regarding the co-cultivated groups, a MCF7-mediated suppression was 
observed (MCF versus U937: p=0.03; MCF7 versus self-antigen: p=0.02), suggesting an 
existence of breast tumour-specific Treg in this patient. In line with this, the data from a 
representative example suggested that breast tumour specificity of Treg can be found in 
both PB and BM (Figure 20B).  
 
Figure 21. Treg possess antigen specificity towards polyvalent tumour antigens in breast cancer patients. Treg 
specificity assay were performed with purified Treg derived from peripheral blood (A) and bone marrow (B). 
Breast tumour antigens were provided by MCF7 (gray) or KS24.22 (black) and control tumour antigens were 
from U937 (open). Each circle represents one measurement. Dash lines connect values within one patient. P-
values indicate significant differences between compared groups connected with small bars. n.s.: not 
significant. Paired one-tailed t-test was performed in A and B. In B, by excluding a strong influence from one 
patient (orange dot), the suppression on Tcon proliferation by KS24.22-stimulated Treg was significant (p-value 
showed in orange). C, Accumulated data of 26 breast cancer patients. When suppression existed in one patient 
no matter in the PB or BM and no matter elicited by MCF7 or KS24.22, the lowest value was considered in this 
analysis. P-value was calculated by unpaired two-tailed t-test.  
A.                                PB B.                              BM C.                 accumulated 
MCF-7 U937 (n=14) KS24.22
0
1.0104
2.0104
3.0104
4.0104
4.0104
8.0104
p = 0.04
n.s.
3
H
 T
d
R
 u
p
ta
k
e
 [
c
.p
.m
]
 
MCF-7 U937 (n=12) KS24.22
0
1.0104
2.0104
3.0104
4.0104
5.0104
p  = 0.005
n.s.
(0.031)
3
H
 T
d
R
 u
p
ta
k
e
 [
c
.p
.m
]
 
control MCF7 or KS24.22
0
5.0103
1.0104
1.5104
2.0104
p=0.046 n=26
3
H
 T
d
R
 u
p
ta
k
e
 [
c
.p
.m
]
 
RESULTS – PART I 
P a g e  |  73 
In an overview, results of Treg specificity assay from 14 PB and 12 BM samples of total 26 
breast cancer patients were collected as shown in Figure 21A and B. In the peripheral blood, 
Treg pre-activated with KS24.22 antigens exerted a significant (p=0.04) and homogeneous 
suppression on polyclonal proliferation of Tcon. In contrast, the existence of MCF7-
recognizing suppressive Treg is rather heterogeneous in the blood. Regarding BM samples, 
apart from one outlier patient (indicated in orange), both MCF7 and KS24.22-specific Treg 
elicited significant suppression on polyclonal proliferation of Tcon (p=0.005, p=0.031, 
respectively). By further pooling the results from different sources of breast tumour antigens 
(MCF7 or KS24.22) and different sources of Treg (PB derived Treg and BM derived Treg), we 
observed a significantly (p=0.046) lower proliferation of Tcon in the analysis with breast 
tumour-antigen stimulated Treg than that with respective control U937 stimulated ones 
(Figure 21C). Therefore, we substantiate that Treg possess polyvalent antigen specificities in 
breast cancer patients. 
 
6.5.2.3 Treg exhibit multifarious tumour antigen recognition in breast cancer patients 
Next, we sought out to define the spectrum of tumour antigens which can be recognized by 
Treg in breast cancer patients by utilizing synthetic polypeptides.  
First of all, we tested the feasibility of applying our designed Treg specificity assay with 
polypeptides. Figure 22 shows a series of testing experiments from the blood sample of one 
breast cancer patient. In A we tested the proliferative capacity of Treg upon different 
stimulation conditions, in detail, with autologous DC, with IgG pulsed DC and with αCD3 and 
αCD28 mAb. As expected, none of them triggered Treg expansion. Purified Tcon exhibited a 
vigorous proliferation in response to a polyclonal stimulation. In B, the responses of Treg 
against individual polypeptides are shown. A similarity of proliferative behaviours was 
observed including the control IgG. Thus, a hypo-proliferative characteristic of Treg upon 
stimulations with different peptides is confirmed. In C, we showed an example of Treg 
specificity assay performed with different polypeptides. Interestingly, polypeptide pre-
activated Treg suppressed the proliferations of polyclonally stimulated Tcon in different 
extents with significant effects in studied groups of Her2/neu (p=0.01) and Mam1 (p=0.06) 
(Figure 22C). Of note, Mucin-derived antigens did no alter the outcomes; whilst p53 drove a 
significant higher proliferation (p=0.008). This interesting phenomenon implies that in the 
blood of this patient there was: i) a presence of Her2/neu and Mam1-specific Treg, ii) an 
absence of Mucin-recognizing Treg and iii) a presence of p53-reactive Teff with a possibly 
concomitant absence of p53-responsive Treg. Altogether, we claim this approach can be 
applied for investigating the existence of TAA-specific Treg. 
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A. control experiment Figure 22. Preliminary data show a feasibility of 
utilizing polypeptides for Treg stimulation in 
Treg specificity assay. Columns represent the 
extents of proliferations measured by 
3
H 
thymidine incorporations. A, Control tests 
confirm hypo- and hyper- proliferative activity 
of Treg and Tcon, respectively, upon different 
stimulations. Stimuli are indicated blow each 
bar. B, The proliferation of Treg are not 
induced by TAAs or IgG. Treg were cultivated 
with different polypeptides (colourful columns) 
and IgG (control, white column) pulsed 
autologous DC. C, The suppressions on 
polyclonal proliferation of Tcon are TAA-driven. 
In this particular patient, suppressions are 
significantly elicited by Her2/neu and Mam1-
actiated Treg. P-values are shown above lines 
which connect the values of interested group 
and IgG control. Statistical differences were 
analysed by paired two-tailed t-test. 
 
0
5.0104
1.0105
1.5105
2.0105
Treg Tcon
unpuls.DC IgG-DC CD3/28 CD3/28
3
H
 T
d
R
 u
p
ta
k
e
n
 
B. Treg only 
co
nt
ro
l
M
uc
1-
10
0
M
uc
1-
20
H
er
2-
ne
u
M
am
1
p5
3
0
2.0104
4.0104
6.0104
8.0104
3
H
 T
d
R
 u
p
ta
k
e
n
 
C. Treg and Tcon co-culture 
, 
co
nt
ro
l
M
uc
1-
10
0
M
uc
1-
20
H
er
2-
ne
u
M
am
1
p5
3
0
2.0104
4.0104
6.0104
8.0104 0.060.01 0.008
3
H
 T
d
R
 u
p
ta
k
e
n
 
 
co
nt
ro
l
M
uc
1-
10
0
M
uc
1-
20
H
er
2-
ne
u
M
am
1
H
pa
I
p5
3
0
4.0104
8.0104  0.029
n=
 0.025
18 18 9 17 13 8 7
3
H
 T
d
R
 u
p
ta
k
e
n
 
Figure 23. Treg in breast cancer patients 
possess diverse antigen specificities. 
Accumulated results of Treg antigen specificity 
assay performed with 18 blood samples of 
breast cancer patients. Columns: 
3
H thymidine 
incorporation. Bars: SEM. Treg were activated 
with different TAA (black) and IgG control 
(white). P-values were calculated by paired 
two-tailed t-test. Exact numbers (n) of patients 
assessed for each TAA are indicated below.  
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A.% of inhibition 
Figure 24. Antigen specificities of Treg in breast 
cancer patients possess a diverse and 
individual repertoire. A, Five randomly picked 
measurements show a highly individual pattern 
of antigen specificity of Treg existing in breast 
cancer patients. Columns represent 
percentages of inhibited proliferation of Tcon 
analysed by comparing the values of thymidine 
incorporation between TAA groups and IgG 
control ones. n.t.: not tested. B, Accumulated 
results of inhibition percentages pooled from 
PB and BM samples of 17 breast cancer 
patients. Take the least inhibited value, 
namely, HpaI (white), a significant higher 
inhibition was observed in Mam1- stimulated 
Treg group. P-value was calculated by unpaired 
two-tailed t-test. C, Diverse proportions of 
breast cancer patients in regarding to antigen 
specificity of Treg. Columns represent the 
percentages (depicted in each column) of 
patients who contain Treg specificity towards 
indicated tumour antigens. The exact numbers 
(n) of responders to total assessed patients are 
listed in parenthesis.  
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In an overall (Figure 23) from altogether 18 blood samples of breast cancer patients, Muc1-
100 and Mam1-activated Treg were found to exert significant suppressions on Tcon 
proliferation compared to the control (p=0.025 and 0.029, respectively), suggesting a 
general existence of functional Muc1-100 and Mam1-specific Treg in the peripheral blood of 
breast cancer patients.  
To further estimate if the spectrum of antigens recognized by individual patient might be 
largely different or overlapping, we calculated the ratio of proliferation inhibition by 
analysing the thymidine incorporation values between TAA groups and IgG control groups of 
each tested antigen in every patient. Surprisingly, the pattern is highly diverse. The 
multifariousness is not only counted for various antigen recognitions, but also for their 
differently inhibitory degrees as shown in Figure 24A with five randomly picked experiments.  
Concerning the suppressive extent (Figure 24B), Mam1-recognized Treg exerted more than 
30% inhibitory activity. This was substantially exceeding to the others, especially, when 
compared to the value of HpaI-driven Treg suppression (p=0.08). Moreover, Mam1 also 
displayed as the most frequent tumour-associated antigen recognized by Treg in breast 
cancer patients (85%) (Figure 24C).  
In summary, we conclude from our data that Treg from breast cancer patients have 
preferential TAA-recognitions towards Muc1 and Mam1, and Mam1-recognized Treg trigger 
the strongest inhibitory activity. And in an individual level, the spectrum of tumour antigens 
recognized by Treg is rather broad. 
 
6.5.3 IL-10 production of Treg is driven by tumour-specific antigens in breast 
cancer patients 
Interleukin-10 (IL-10) is a major cytokine with pronounced immunomodulatory and 
immunosuppressive properties. It was reported that antigen-specific Tr1 cells were 
generated in the presence of IL-10, and, in turn, exerted suppression mostly through IL-10. 
For this reason, we tried to attest Treg specificity by analyzing an antigen-driven secretion of 
IL-10 in breast cancer patients. 
To this end, we first carried out an IL-10 ELISA assay to evaluate the IL-10 secretion during TC 
activation. The supernatants of eight IFN-γ ELISpot experiments were collected from both 
with and without Treg-present cultures. The breast tumour antigen mediated IL-10 secretion 
was determined by subtracting mean value of IL-10 concentrations of test wells from the 
control cultures. Under these conditions, we observed an abrogation of IL-10 secretion after 
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Treg-depletion (Figure 25A, p=0.0195), which implies that secretion of IL-10 possibly from 
Treg is driven by specific breast tumour antigens. 
In support of this, more direct evidence was obtained by assessing intracellular IL-10 
production of purified Treg in response to different antigen stimulations. In detail, Treg were 
stimulated with breast cancer antigens derived from MCF7 and KS24.22, and control tumour 
antigens from U937 presented by autologous DC for 20 hr. Protein secretions were blocked 
by Brefeldin A for the last 12 hr. Afterwards, an intracellular staining of IL-10 and a staining 
for defining Treg population were performed. Data were acquired by flow cytometry. The 
percentages of IL-10 positive cells among Treg were then analyzed. An exemplary result 
representing three independent experiments is shown in Figure 25B. Upon MCF7 
stimulation, the proportions of IL-10 producing Treg was four times more than that in the 
situation of U937 control (mean±SD; MCF7: 0.17±0.08%; U937: 0.04±0.03%). The difference 
is statistically significant (p=0.04). A similar effect was observed in response to KS24.22 
(0.11±0.03%) with a less (2.4 times) but also significant (p=0.03) extent. Collectively, these 
data suggest that Treg in breast cancer patients possess antigen specificity determined by IL-
10 production. 
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Figure 25. Treg possess breast tumour specificity suggested by measurements of IL-10 productions. A, 
Accumulated data of eight breast cancer patients show MCF7-dependent IL-10 secretion. The supernatants of 
ELISpot assay were collected after 40h, and measured for IL-10 concentration by ELISA assay. Each symbol 
represents a subtraction of IL-10 concentrations from the cultures stimulated with MCF7 to that with U937. 
Dash lines connect the values before (round) and after (square) a conducted Treg-depletion within one patient. 
P-value was calculated by an unpaired two-tailed t-test. B, A representative result shows percentages of IL-10 
secreting Treg among total Treg upon different tumour antigen simulations (indicated in the plot) obtained 
from blood derived Treg of one breast cancer patient. These data represent three independent experiments. 
Columns: mean values of triplicates. Bars: SEM. P-values were calculated by unpaired two-tailed t-test between 
interested groups connected by short lines.  
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6.6 Expressions of chemokine receptors on polyclonally activated Treg  
A high frequency of tumour-infiltrating Treg was reported in breast cancer, which was likely 
due to an environment of preferential recruitment created by tumour cells and tumour-
associated cells. Previous study of our group revealed an interesting phenomenon in primary 
breast cancer patients that the higher numbers of tumour infiltrating Treg was associated 
with better type-I T-cell anti-tumour responses in the BM. According to the findings in this 
thesis, Treg retained in the BM were substantially less than the PB. We also reported that 
bone marrow served as a priming site for TC immunity upon blood borne antigen presented 
on immigrated DC. Based on these findings, we proposed a hypothesis that Treg were 
actively emigrating from bone marrow after encountering the tumour antigens, and then 
progressively accumulating in the tumour mass.  
In support of this hypothesis, we analysed 13 adhesion molecules on Treg and found that the 
expressions of CCR2, CCR5 and CCR6 were higher in the BM of primary breast cancer 
patients than their counterpart PB and the BM of healthy donors, suggesting a potently 
migratory capacity of Treg obtained from the BM of breast cancer patients. In addition, CCR4 
was reported to enable Treg to migrate into ovarian tumour. Whether these observations 
were resulted from activation (possibly occurred in the BM); and the comparisons of 
activation-induced expressions between Treg and Tcon were investigated in this thesis.  
 
6.6.1 Treg from the peripheral blood of healthy donors are able to upregulate 
chemokine receptors upon a polyclonal stimulation  
First, we evaluated whether Treg were able to respond activation in term of upregualting 
interested chemokine receptors. To this end, freshly isolated monocytes from healthy 
donors were cultured in the wells pre-coated with αCD3 mAb, or in parallel with αCD3 and 
αCD28 mAb, for 16 hr. In order to design a proper dose of stimuli, we titrated mAb with 4 
different concentrations: [1µg/ml], [0.5µg/ml], [0.25µg/ml] and [0.125µg/ml]. As a readout 
system CCR2, CCR5, CCR6 expressions were performed with activated cells by flow 
cytometric assay. CD3, CD4, CD25 and Foxp3 were co-stained for specifying Treg.  
The increases in the percentages of respective CCR expressions were found on both Treg and 
T conventional cells (Tcon) upon polyclonal TCR-mediated stimulation with different extents 
as shown in Figure 26. The most significant upregulations were observed with the strongest 
stimulation setting in all tests, namely [1µg/ml]. Accordingly, this concentration was applied 
hereafter for all the experiments. Of note, the existence of co-stimulatory molecule, CD28, 
hindered CCR2, CCR5 and CCR4 expressions on Treg but not (CCR2, CCR4) or less (CCR5) on 
RESULTS – PART I 
P a g e  |  79 
Tcon. Besides, by giving a less alteration observed concerning CCR6, it was not included in 
the rest of this study.  
Nevertheless, these data demonstrate that Treg possessed the ability of upregulating certain 
chemokine receptors upon a polyclonal activation. 
 
Figure 26. Treg and Tcon derived from healthy donor respond to polyclonal stimulation. Monocytes isolated 
from healthy donor peripheral blood were cultivated in αCD3 (A) or αCD3 and αCD28 (B) mAb bounded wells 
and control wells for 16h. Ab titrations were depicted below X-axis. Flow cytometry were performed 
afterwards with multicolour staining in order to identify the CCR expression on CD4
+
 Treg and CD4
+
 Tcon 
subpopulations. The assessed chemokine receptors are indicated beside Y-axis. Black lines: Treg; gray lines: 
Tcon. Bars: SEM. 
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6.6.2 Evaluation of CCR2, CCR4 and CCR5 expression on Treg from breast cancer 
patients upon a polyclonal stimulation  
Next we sought to evaluate chemokine receptor expressions on breast cancer derived Treg 
upon polyclonal activation. A same method as described above was performed.  
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Figure 27. Upon polyclonal stimulation CCR2 were upregulated more potently on Treg from breast cancer than 
from healthy donors. A, percentage and B, MFI of CCR2 expression on MaCa PB Treg (gray bars) and BM Treg 
(black bars) without and with [1µg/ml] αCD3 mAb stimulation. C, comparison of percentage of CCR2 expression 
on HD PB Treg (white bars) to MaCa PB Treg without and with different polyclonal stimulations. Asterisks show 
p<0.05 when compared to the respectively unstimulated values. D, CCR2 induction capacity has no difference 
between Treg and Tcon. P-values were calculated with unpaired two-tailed t-test.  
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Results from CCR2 studies are shown in Figure 27. In an unstimulated groups, namely ex vivo 
situation, CCR2 expressing Treg were significantly higher in the BM than the PB (marginally, 
p=0.08) in regard to percentages and MFI (p=0.03), which is in accordance with Christopher’s 
finding.  
A given polyclonal activation allowed substantial inductions of CCR2 expressing Treg in the 
PB but not the BM in regard to proportion (p=0.03) as well as MFI (p=0.02). Perhaps the 
basal activation status in the BM dampened the effect (Figure 27A and B). When compared 
to healthy donors (Figure 27C), the response of Treg to activation in the blood was 
significantly potent in patients. A sharp reverse pattern was observed as the percentage of 
CCR2 positive PB Treg was originally found to be significant lower in patients than the 
healthy donors (p=0.01); whilst turned to be significantly higher post-activation (CD3 
stimulation, p=0.03; CD3&CD28 stimulation: p=0.01). Certain response illuminates a ready-
to-facilitate mode in breast cancer patients. 
Further, we asked whether Treg owned better induction potency than Tcon. As shown in 
Figure 27D, it was not the case. Similar inductions in percentage of CCR2 expressing cells 
were observed with both Treg and Tcon in breast cancer patients. This was also true in 
regard to MFI analyses (data not shown). 
 
Figure 28. CCR4 is preferentially harnessed by Treg upon activation. A, percentages of CCR4 expression on PB 
Treg of HD and MaCa. HD Treg:white; MaCa Treg: gray. Different culture conditions are indicated. B, 
comparison of CCR4 expression in MFI on different T cell sources. Treg: solid; Tcon: patterned. Cultivation 
conditions are as indicated. P-values were calculated with unpaired two-tailed t-test. Compared groups are 
linked with horizontal lines. 
A.  
unstimulated  CD3 1ug/ml CD3&28 1ug/ml
0
10
20
30
40
50
n.s.n.s. n.s.
HD Treg
MaCa Treg
%
 o
f 
C
C
R
4
(n=2)
 
B. 
unstimulated CD3  1ug/ml CD3&28 1ug/ml
0
1000
2000
3000
MaCa Treg
MaCa Tcon
HD Treg
HD Tcon
p=0.03
p=0.05
p=0.08
p=0.05p=0.04
n.s. n.s.
(n=2)
M
F
I
 
RESULTS – PART I 
P a g e  |  82 
Unlike CCR2, the ex vivo CCR4 expression was higher on PB Treg derived from breast cancer 
patients than that from healthy individuals (Figure 28A). This pattern was remained after 
polyclonal activations, even though both counterparts showed substantially elevated 
percentages of CCR4 expressing Treg. The lack of statistical significance was very likely due 
to the small size of patient samples (n=2). Of note, the hindered effect in healthy donors 
resulted from the presence of co-stimulatory molecules was not observed with breast 
cancer patients. 
In the ex vivo situation, Treg from both HD and breast cancer patients exhibited significant 
higher MFI of CCR4 than Tcon (Figure 28B). Upon activation, the MFI level of CCR4 
expressing Tcon kept up with that of Treg in healthy donors but remained significant lower 
in the breast cancer patients, which was counted for both given stimulation conditions. 
Interestingly, among all studied populations, Treg in breast cancer patients exhibited the 
most prevalent responsiveness to activation.  
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Figure 29, Upon polyclonal stimulation CCR5 expression is suppressed on Tcon by Treg with breast cancer. 
CCR5 expressions on different T cell sources without or with αCD3 stimulation are compared (A) in percentage 
and (B) in MFI. Treg: solid columns; Tcon: patterned columns. HD: white background; MaCa: gray background. 
Cultivation conditions are as indicated. P-values were calculated with unpaired two-tailed t-test. Compared 
groups are linked with horizontal lines. Asterisks show p<0.05 when compared to the respectively unstimulated 
values.  
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Concerning CCR5, upon stimulation, a substantial induction of CCR5 expressing Treg in 
regard to proportions and MFI were observed in both healthy individual and breast cancer 
patients (Figure 29). However, this effect did not result a preferential pattern towards Treg 
from breast cancer patients as observed with the other chemokine receptors. Further, this 
stimulation induced CCR5 expression benefited Tcon in healthy donors but not breast cancer 
patients counted for the analyses of percentage (p=0.01) and MFI (p=0.04).  
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Part II From bench to bedside 
-- Clinical exploitations of Treg manipulation in breast cancer  
The observations in Part I of this thesis demonstrate that regulatory T cells play a crucially 
negative role in breast cancer and by removing them the T-cell anti-tumour reactivity can be 
rescued, especially, in the peripheral blood. These basic findings provide a principle of 
developing an immunotherapy of breast cancer by modulating existing Treg in the patients. 
Thus, our next challenge is: how to move “from bench to bedside”?  
Immunotherapy regarding Treg depletion is currently being exploited in clinical trials, such as 
daclizumab, an αCD25 antibody; Ontak (Denileukin Diftitox), an IL-2 fusion toxin; αCD25 
microbeads (magnetic cell sorting, MACS); an αCD25 immunotoxin (IT); or metronomic 
administration of low-dose cyclophosphamide which selectively eliminates Treg, and so on. 
However, the most effective method has not yet been defined.  
In this thesis, a pre-clinical study of large-scale depletion of Treg from a leukapheresis and a 
pilot clinical study of metronomic low-dose cyclophosphamide therapy were applied on 
metastatic breast cancer patients. The outcomes are analysed and presented in Result 1.7 
and Result 1.8, respectively.  
 
6.7 Pre-clinical study of a large scale depletion of Treg from leukapheresis of 
a metastatic breast cancer patient 
6.7.1 Transferring the protocol of Treg-depletion to a clinical grade under GMP 
guideline 
Good Manufacturing Practice (GMP) is a term that is recognized worldwide for the control 
and management of manufacturing and quality control testing of foods, pharmaceutical 
products and medical devices.  
According to the European Union’s GMP, all the manufacturing and testing equipments are 
required to be qualified, and all the operational methodologies and procedures (such as 
manufacturing, cleaning, and analytical testing) utilized in the drug manufacturing process 
are required to be validated. 
In order to transfer the Treg depletion protocol to a clinical use, we did following changes 
according to the GMP guideline: 
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Agents: αCD25 microbeads from Miltenyi Biotec Company were successfully utilized in our 
bench experiments. The same Ab clone has been produced under the GMP guideline in the 
company. Also, clinical grade microbeads are available for coupling this GMP mAb, so called 
CliniCD25. Therefore, to transfer this agent to a clinical application is feasible.  
Devices: For a therapeutic aim, CliniMACS is supplied for depleting Treg with CliniCD25 by 
the company.  
Protocols: Basically the experiments are performed according to the manufacturer’s 
instruction. However, optimizations need to be carried out. For example, a sufficient but not 
exaggerated ratio of CliniCD25 microbeads to cells needs to be determined. A suitable flow 
rate needs to be selected with CliniMACS machine. 
 
6.7.2 Optimizing a CliniMACS protocol with a small-scale Treg-depletion on the 
autoMACS machine 
To evaluate this clinically potential protocol, we started with validating the efficacy of 
applying CliniCD25 microbeads regarding the effect of immune-responsiveness 
subsequently. To this end, small amounts of blood samples (40ml/patient) of primary breast 
cancer patients were operated; TC and DC were generated and purified under a research 
grade. The protocol was adapted accordingly. In detail, a beads to cells ratio of 1:27 was 
carried out as suggested for positive selection, and an incubation was performed at room 
temperature for 30min. The cell separation was running with an autoMACS machine which 
carries the same column structure as CliniMACS but for a smaller sample size. The fastest 
flow rate (40ml/min) program was chosen as it allows retaining normal to high antigen 
expressing cells on the magnetic column. 
Under these conditions, IFN-γ ELISpot assay was applied as a readout system. Results from 
one exemplary appliance are shown in Figure 30. After applying this protocol, we observed a 
significant (p=0.04) induction of IFN-γ secretion in response to KS24.22 but not to the control 
U937, which also resulted in a breast tumour specific response (p=0.004) in an otherwise 
absent situation. Most impressively, the benefit of applying this protocol was shown not 
only quantitatively but also qualitatively in an antigen specific way as illustrated in Figure 
30B that higher amounts as well as more potent IFN-γ spots were appeared in KS24.22 
stimulated wells afterwards. These data represent five independent experiments. 
Altogether, we conclude that CliniCD25 microbeads applied with the new protocol function 
as efficiently as the system with research grade. 
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Figure 30. Performed CliniCD25 enhanced type-I T cell response against breast tumour antigen. A, An 
exemplary result of IFN-γ ELISpot assay from a primary breast cancer patient. The frequencies of KS24.22 
(black) and control U937 (white) reactive PBTC were assessed without or with a CliniCD25 microbeads 
performance and depicted here by columns. Bars: SEM. Statistical differences between mean values were 
calculated with unpaired two-tailed t-test. P-values are indicated above small lines which connect compared 
groups. n.s.: not significant. B, corresponding original data show higher counts and more potent IFN-γ dots are 
observed in the well of responding to KS24.22 with a performed CliniCD25 depletion (right lower picture). 
 
The presented experiments above were performed with TC and DC purified under research 
grade. In order to adapt it to GMP, DC purification was replaced with DC enrichment from 
adherent mononuclear cells as we used in the clinical study of adoptive T cell transfer 
immunotherapy of metastatic breast cancer patients discussed in Part I of this thesis.  
Regarding the negative selection of TC, the available GMP agents are very costly. On the 
other hand, it has been reported that CD4+ Treg depletion could be conducted directly with 
peripheral blood mononuclear cells (PBMC), which subsequently resulted in an enhanced 
anti-tumour immune response determined by IFN-γ ELISpot assay. Thus, we then tested a 
feasibility of utilizing PBMC as a substituent by evaluating the purity of Treg depletion with 
flow cytometry and anti-tumour effect with IFN-γ ELISpot assay. Results shown in Figure 31 
are from one representative breast cancer patient out of eight tested ones. According to the 
phenotypic analyses, the frequencies of Treg among CD4+ TC were substantially reduced 
(before: 3.15% versus after: 0.026%), suggesting a successful Treg-depletion performance 
directly with PBMC. Further, by applying IFN-γ ELISpot assay, a breast cancer specific benefit 
was confirmed with both PBMC and BMMC samples (see p-values in the figure).  
In total, the proportions of immunological responders analysed with PBMC displayed a 
substantial increase (before: 37.5% versus after: 62.5%) after a performed CliniCD25 
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depletion (Figure 32), which was comparable to the outcome obtained previously, namely, 
with TC purified and Treg depleted under research grade (before: 38.5%  versus after: 77%).  
Collectively, these data demonstrate a feasibility of applying CliniCD25 with peripheral blood 
mononuclear cells in a small size by an autoMACS machine.  
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Figure 31. CliniCD25 depletion can be applied directly with PBMC. A, Purity of Treg-depletion directly from 
PBMC using CliniCD25 microbeads. Representative flow cytometric data show cell proportions before (upper 
row) and after (lower row) conducting a CliniCD25 depletion. Left panel: Y-axis versus X-axis shows CD4 versus 
CD3 staining. Pink squares in each plot gate CD4
+
 and CD8
+
 T cell populations at top and bottom, respectively. 
CD4
+
 T cells were further analysed in right panel with CD25 versus Foxp3 (Y-axis versus X-axis) staining. Up-right 
quadrants indicate Treg population. Small numbers in the plots depict respective percentages. B, Treg-
depletion directly from PBMC by CliniCD25 microbeads resulted in an enhancement of type-I T cell responses 
determined by IFN-γ ELISpot. Columns represent frequencies of MCF7 (black) and U937 (white) reactive TC. 
Bars: SEM. Statistical analyses were performed between interested groups connected by short lines. P-values 
were calculated with paired two-tailed t-test. n.s.: not significant.  
10
0
10
1
10
2
10
3
10
4
FL3-H
10
0
10
1
10
2
10
3
10
4
F
L
1
-H
60.6
24.8
10
0
10
1
10
2
10
3
10
4
FL4-H
10
0
10
1
10
2
10
3
10
4
F
L
2
-H
1.87 3.15
1.0693.9
10
0
10
1
10
2
10
3
10
4
FL3-H
10
0
10
1
10
2
10
3
10
4
F
L
1
-H
62.7
23.7
10
0
10
1
10
2
10
3
10
4
FL4-H
10
0
10
1
10
2
10
3
10
4
F
L
2
-H
0.59 0.026
0.9298.5
RESULTS – PART II 
P a g e  |  88 
 
In addition, we evaluated the correlation between input cell numbers and total cell recovery 
(% = output # / input #) with autoMACS machine. Interestingly, 1x107 of input cell numbers 
were minimally required in order to exceed 85% of recovery. A higher yield was associated 
with a higher input (Figure 33). This side investigation might be useful for the people who 
are dealing with this device.  
 
Figure 33. Correlation between input of cell 
numbers and recovery in percentages with 
autoMACS machine. Each symbol represents an 
independent experiment. X-axis: absolute input 
cell numbers. Y-axis: percentages of recovery 
calculated by dividing a sum of cell counts from 
depleted and flow through fractions to the cell 
counts of input. 4 symbols separated by dash 
lines at the up-right corner indicate that in order 
to reach higher than 85% recovery with 
autoMACS, at least 1x10
7
 input cells are 
required. 
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Figure 32. Comparable benefits of Treg-depletion are exhibited 
with pre-clinical procedure and research system in regard to 
percentages of immunological responders. Percentages of IFN-γ 
ELISpot positive patients are depicted with small numbers in 
representing bars. White bars: without treatment; light blue: 
Treg-depletion with research grade CD25 microbeads applied 
with purified TC; dark blue: Treg-depletion with CliniCD25 
microbeads applied with PBMC. Numbers of tested samples in 
each group are shown at the bottom in parentheses. 
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6.7.3 Adapting a large-scale Treg-depletion from a leukapheresis of one advanced 
breast cancer patient on the CliniMACS machine 
The reproducibility observed in small-scale preparations prompted us to further develop a 
CliniMACS procedure suitable for large-scale application. In this regard, leukapheresis was 
operated. One metastasized breast cancer patient was recruited, whose spontaneous TC 
anti-tumour immunity could be detected in the peripheral blood and was sustained after 
Treg-depletion with a manual protocol (Figure 35). One hour running apheresis allowed us to 
collect 4.5x109 white blood cells (WBC) from this donor.  
CliniMACS provides two possible depletion programs according to the flow rate and 
customers’ desire. Program 2.1, which utilizes a relatively low rate of 10 ml/min, is originally 
designed for purer negative selection; hereafter, we denote it as Depl. 2.1. Whilst program 
3.1 is designed for an enrichment of labelling cells due to its higher flow rate of 20 ml/min; 
we named it Enri. 3.1. These two programs were conducted in parallel in order to compare 
and to establish the protocol. To this end, WBCs were first aliquoted evenly into two bags 
according to the weights, meaning that the assumed cell numbers for each program would 
be approximately 2.25x109 (half of total numbers). Afterwards, the cell labelling procedure 
was performed as delineated in small scale system.  
The evaluations concerned cell viability, recovery and phenotypic purity. Anti-tumour 
responses of desired cell fractions were assessed by IFN-γ ELISpot assay. 
We observed that cell viabilities of all fractions were greatly above 90%. Table 4 enumerates 
cell count and its relative proportion in each fraction separated with different programs. 
Both programs showed similar yields of desired cell fractions (CD25 negative fractions) and 
not more than 7% systemic loss (waste bag).  
 
Table 4. Enumerations of cell products separated by a large-scale CliniCD25 application with CliniMACS 
 
Depl. 2.1 resulted 5-folds more cell counts in Treg containing fraction (CD25 positive 
fraction) than Enri. 3.1, implying an either insufficient Treg removal by Enri. 3.1 or an 
undesirable depletion of effector T cells by Depl. 2.1. Flow cytometric analyses ruled out the 
 cell count (x10
8
) /% of initiation 
 Initiation 
post-  
CD25 pos. fraction 
post-  
CD25 neg. fraction 
Waste bag Total Yield 
Enri. 3.1 22.5 / 100 1.1 / 5.0 18.8 / 83.6 1.6 / 7.1 21.5 / 95.6 
Depl. 2.1 22.5 / 100 5.75 / 25.6 18.4 / 81.8 1.3 / 5.6 25.4 / 112.9 
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CD25 
Foxp3 
first assumption as Treg populations determined by double expressions of CD25 and Foxp3 
were substantially reduced by both programs (Figure 34) (before: 1.74%;  Enri. 3.1: 0.09%; 
Depl. 2.1: 0.03%). However, considerable amounts of non-Treg were concomitantly removed 
observed by both programs (data not shown). Thus, further optimizations, such as beads to 
cell ratio, labelling duration are urged.   
 
Leukapheresis Enrichment 3.1 Depletion 2.1 
   
 
 
Figure 34. Flow cytometric evaluations of the purity of Treg depletion with a large scale CliniCD25 application 
with CliniMACS. Cells from leukapheresis, CD25 negative fractions from a performed Enri. 3.1 and Dep. 2.1 
were stained with αCD3, αCD4, αCD25 and αFoxp3 mAb. CD25 versus Foxp3 expressions of the cells pre-gated 
with CD4
+
 TC populations were shown here. Numbers displayed in each quadrant represent corresponding 
percentages.  
 
In addition, we compared the sub-groups of T cells in proportion in CD25 negative fractions 
generated by Enri. 3.1 and Depl. 2.1 (Table 5). Concerning the absolute cell numbers, the 
latter program resulted in less CD3+ T cells, but more CD8+ T cells in the desired fraction with 
lower Treg contamination.  
 
Table 5. Phenotypic analyses of T cells in leukapheresis products and in CD25 negative fractions generated by 
Enri. 3.1 and Depl. 2.1. 
% CD3
+
 of total CD4
+
 of CD3 CD25
+
Foxp3
+
 of CD4 CD8
+
 of CD3 
Pre- separation 80.1 66.5 1.74 30.7 
Post- CD25-neg. Fraction  
(Enri. 3.1/Depl. 2.1) 
76.6 / 71.4 57.9 / 40.6 0.09 / 0.03 40.4 / 57 
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Nevertheless, the most valuable evaluation towards different procedures is whether the 
potency of anti-tumour response is enhanced within Treg eliminated population. To clarify 
this, we compared the results of IFN-γ ELISpot assays performed with diagnosis samples and 
leukapheresis in the presence or absence of Treg manipulated by a manual protocol or by 
different CliniMACS programs (Figure 35). Observations are the following: 1) without any 
treatment (depicted as – in the figure) we observed an overall decline of TC immunity from 
the diagnosis day to the leukapheresis taken date (one month interval) in despite of a 
remaining anti-tumour significances, suggesting the spontaneous anti-tumour 
responsiveness was weakening in vivo; 2) a manually applied Treg-depletion did not 
influence the outcome in diagnosis sample but gave rise to a loss of anti-tumour reactivity in 
leukapheresis; implying Treg may not play an essential role responsible for the declining T-
cell immunity; 3) when comparing the results sourced from leukapheresis, lower frequencies 
of IFN-γ secreting T cells were detected with CliniMACS-manipulated samples, which 
evidenced directly that CliniMACS programs dampened the potencies of T-cell anti-tumour 
reactivity possibly due to excessive depletion of Teff; 4) not least, between the two 
CliniMACS programs, Enri. 3.1 exhibited better efficacy according to statistical analyses, 
suggesting that accelerating flow rate may facilitate less Teff retaining when running through 
the column. 
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Figure 35, Evaluation of the efficacy of applying a large scale Treg-depletion with CliniMACS system. IFN-γ 
ELISpot assay was carried out with one metastatic breast cancer patient at two different time points: on 
diagnosis day and 1 month later when leukapheresis was achieved and CliniMACS system was applied. The 
frequencies of IFN-γ secreting TC in response to MCF7 (gray), KS24.22 (black) and irrelevant control U937 
(white) were shown by columns. Bars: SEM. Treg depletion was performed in three different means as 
indicated. Statistical analyses were performed by unpaired two-tailed t-test. *, p<0.05; **, p<0.005.  
Altogether, the data from this preliminary experiment confirmed a feasibility of modulating 
Treg in leukapheresis of advanced breast cancer patient under a clinical-grade condition by a 
sufficient depletion of Treg, a high viability of isolated cells and a remarkable recovery of 
total cell counts. However, the protocol needs to be further optimized and the therapeutic 
potential has to be validated. 
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6.8 Pilot clinical study of metronomic cyclophosphamide treatment of 
patients with advanced breast cancer  
6.8.1 Study design  
Cyclophosphamide (CTX) when administrated with a low amount and daily (metronomic) 
was reported to have a capacity of selectively eliminating Treg and consequently enhancing 
anti-tumour immunity in refractory cancer patients. However, the sole role of metronomic 
CTX in dampening Treg regarding proportions as well as functions has not yet been 
documented in clinical trials with breast cancer patients. In this regard, we performed a pilot 
clinical study of metronomic CTX treatment with advanced breast cancer patients who were 
under progressive disease. Also being interested in a long-term efficacy of this regimen, we 
followed up Treg percentages and type-I T-cell immune responses in the blood of study 
patients for three months.  
 
Table 6. Patients Characteristics.  
Median age (range) 60.3 (47-74) 
ECOG performance status, median 1.4 
Most common sites of metastases: n= 
Liver 5 
Lung 9 
Pleura 2 
Bone 13 
Soft tissue 5 
Brain 3 
LN 3 
Prior Therapy: n= 
Surgery 13 
Chemotherapy 13 
Radiation 10 
Bisphosphonat 9 
Herceptin 3 
Tam/aromatase inhibitors 7 
(ECOG, Eastern Cooperative Oncology Group) 
 
From October 2007 to July 2008, 13 breast cancer patients with metastatic disease were 
randomly enrolled in this study. These patients had previously received surgery and standard 
cytostatic treatments such as chemotherapy, endocrine and antibody therapy (Table 6) and 
were in a palliative treatment situation. Two patients failed to go through an entire 
treatment due to their strong tumour progressions (stopped at Day14 and Day56). One 
patient resigned inclusion after 28-days treatment with a partial regression of secondary 
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tumour (glioma tumour). Data from one patient except the one from Day0 was excluded due 
to her poorly clinical condition. 
Patients received oral CTX 50mg daily for three months. Before and fortnightly during the 
treatment, percentages of CD4+CD25highFoxp3+ Treg among CD4+ T cells in the peripheral 
blood were monitored by flow cytometry and spontaneous anti-tumour T-cell responses 
were evaluated by 40hr IFN-γ ELISpot assay with breast tumour antigens (MCF7 or KS24.22) 
or irrelevant control ones (U937) presented by autologous DC. The status of tumour was 
monitored via tumour markers (CA15-3 and CEA, or MRI-Scan) in the peripheral blood. 
The treatment was well tolerated, as no severe side effects were observed, except one 
patient had anaemia (Hb 6.6 g/dl) and stopped therapy because of this. Grade I leukopenia 
was found in all treated patients. 
 
6.8.2 The frequencies of Treg were significantly reduced at early study time points  
In order to monitor Treg frequencies, flow cytometric analyses were performed with PBMC 
of enrolled patients prior and during the treatment. Treg population was specified with 
CD3+CD4+CD25highFoxp3+ as delineated in Part I of this thesis. The percentages of 
CD25highFoxp3+ Treg of overall CD4+ T cells were evaluated as shown in Figure 36.  
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Figure 36. Metronomic cyclophosphamide treatment significantly reduces Treg proportion among CD4
+
 T cells 
at early time points of this study. Percentages of Treg among CD4
+
 T cells in the blood were determined by flow 
cytometric analyses. Each dot represents one patient. Lines connect Treg frequencies measured on indicated 
days within one patient. Numbers of assessed patients are depicted below X-axis in blue. Statistical differences 
between mean values on the respective days to Day0 were analysed with paired two-tailed t-test. Significant p-
values are shown above corresponding days.  
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Prior to the treatment (Day0) the mean frequencies of Treg obtained in the blood of 
metastatic breast cancer patients were 5.1±3.0% (mean±SD), which is substantially higher 
than primary patients (3.9±1.5%; p=0.078) and healthy donors (4.3±0.9%; n.s.).  
On Day14, a dramatic decrease of Treg frequencies was observed (Day0: 5.1±3.0% versus 
Day14: 3.0±1.8%; p=0.005). This metronomic CTX induced efficacy of Treg-elimination 
sustained significance on Day28 (3.1±2.1%; p=0.02), marginal significance on Day42 
(3.2±2.0%; p=0.07), and then disappeared. These data suggest that metronomic CTX has a 
strong inhibitory impact on Treg population at early period of administration in metastatic 
breast cancer patients.  
Regarding the late stage of study a gradual replenishment of Treg in mean frequency was 
observed with a value as high as Day0 obtained on Day84 (5.2±2.2%). Whether a prolonged 
regimen will convey Treg frequency to an even higher degree is obscure. We also found that 
the individual Treg percentages of assessable patients showed a less heterogeneous on 
Day84 (ranging from 2.7% to 8.6%) than Day0 (ranging from 0.7% to 10.9%). Whether 
metronomic CTX has Treg normalizing efficacy is not clear. 
 
 
Day 0 Day 14  Fold of Decrease  
0.67 0.31 2.2 
1.93 0.93 2.1 
2.44 1.07 2.3 
4 3.75 1.1 
4.06 3.56 1.1 
4.14 2.09 2 
4.43 3.09 1.4 
4.47 3.85 1.2 
6.4 3.04 2.1 
7.08 3.5 2 
10.1 4.39 2.3 
10.9 6.93 1.6 
Table 7, Metronomic CTX is more effective to patients 
who contain abnormal Treg frequencies in the blood. 
Percentages of Treg of individual patients on Day0 and 
Day14 are listed in the left and middle column, 
respectively. The frequencies not more than 6% or less 
than 3% are shadowed in light blue. The ratio of 
reduction in Treg frequencies from Day0 to Day14 were 
calculated and listed in the right column (Fold of 
Decrease). When the ratio is more than 1.5-fold, the cell 
is shadowed in blue. 
 
It is worth mentioning that patients who contained abnormal Treg frequencies on Day0, 
either extremely high or low, were more susceptible to the treatment as evaluated by the 
ratio of Treg reduction from Day0 to Day14 (Table 7). In particular, when 1.5-fold alteration 
was set as a threshold, 100% patients whose Treg were either below 2.44% or above 6.4% of 
CD4+ TC on Day0 had an average 2.1-fold reduction in Treg frequencies on Day14. While, the 
other four out of five assessable patients whose initial Treg belong to a normal range, 
referred to healthy donor situation (4.3%), showed almost unaltered Treg proportions on 
Day14 with an average of 1.3-fold decrease.  
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6.8.3 Metronomic cyclophosphamide treatment shows a long term immune 
efficacy 
Next, we monitored the impact of metronomic CTX treatment on anti-tumour T-cell 
immunity by performing IFN-γ ELISpot assay with blood samples of enrolled patients before 
and fortnightly. Exemplary data are shown in Figure 37. A de novo spontaneous anti-tumour 
T-cell reactivity was revealed in response to both tested tumour-lysates (MCF7 versus U937: 
p=0.05; KS24.22 versus U937: p=0.001). Certain responsiveness was also detected on Day42 
and Day70 according to statistical analyses, suggesting a persistent efficacy of this 
treatment.  
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Figure 37, Exemplary patient data show type-I T cell immunity monitoring before and during the treatment. 
Frequencies of tumour reactive T cells were determined by IFN-γ ELISpot assay stimulated with breast cancer 
antigens KS24.22 (black) or MCF7 (grey) and control antigen U937 (white). Columns represent mean values of 
frequencies of IFN-γ secreting T cells from triplicate wells. Bars: SEM. Statistical analyses were performed with 
unpaired two-tailed t-test within interested groups connected by short lines. Numbers above the short lines 
indicate p-values.  
 
To overview the effect of applied regimen on anti-tumour T-cell immunity, we accumulated 
the results of IFN-g ELISpot assay from all treated patients and analysed it with Wilcoxon 
signed-rank test suggested by statisticians as it is regardless of distributional assumptions. A 
value referring to a frequency of tumour-different TC was introduced by subtracting the 
numbers of U937-reactive TC from MCF7 or KS24.22-reactive ones regardless of a detectable 
immunological response (Figure 38A). Both MCF7 and KS24.22 responsiveness displayed a 
zigzag pattern in concern of the median values (small bars) accompanied with a gradual 
progressing.  
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B. 
p-value 
(CI) 
Day 14 Day28 Day42 Day56 Day70 Day84 
MCF7 
0.25 
(-16.0,61.8)  
0.80 
(-22.7,18.2)  
0.44 
(-14.7,46.2)  
0.40 
(-20.8,114.8)  
0.03 
(7.7,92.7)  
0.48 
(-28.0,46.0)  
KS24.22 
0.78 
(-21.3,28.8)  
0.95 
(-33.5,43.7)  
0.12 
(-24.0,156.5)  
0.17 
(-6.2,174.4)  
0.04 
(0.77,3.0)  
0.46 
(-39.3,39.7)  
 
Figure 38. Day70 of the treatment display a statistical significance of anti-tumour T-cell immunity. A, 
Accumulated data of frequencies of tumour-different T cells calculated by subtracting the values of MCF7 (light 
blue dots) or KS24.22 (dark blue dots)-reactive T cells to that of U937-reactive ones. Each dot represents one 
patient. Negative results are depicted as 0 on X-axis. Short bars indicate median values of respective groups. 
Numbers (n) of assessed patients on respective days are shown below the plot. B, Statistical analyses 
performed with Wilcoxon signed-rank test. Based on the calculation in A, type-I T-cell immunities against MCF7 
or KS24.22 on each studied day were evaluated with p-value and confidential interval (CI). Individual clinical 
follow-up days indicated on the top row were compared to Day0 for each antigen. Significances are shown in 
red. C, Statistical analyses performed with student t-test. Columns represent frequencies of MCF7 (left) and 
KS24.22 (right) responsive T cells accumulated from all study patients. Significant p-values were appeared on 
Day70 calculated by paired two-tailed t-test.  
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Based on these calculations, a Wilcoxon signed-rank test was performed. Results are listed in 
Figure 38B. Interestingly, statistical significances were obtained on Day70. It was counted for 
both MCF7 (p=0.03) and KS24.22 (p=0.04) responsiveness. In line with this, a student t-test 
with frequencies of tumour antigen-specific T cells also displayed statistical significances on 
Day70 (Figure 38C) in response to either MCF7 (p=0.047) or KS24.22 (p=0.040). These 
analyses provide conclusive evidence that this regimen has a long-term efficacy of enhancing 
anti-tumour T cell immunity in metastatic breast cancer patients.  
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Figure 39. Percentages of immunological 
responders before and during metronomic 
CTX treatment. Numbers in the columns 
and columns themselves show percentages 
of responders assessed on indicated days. 
The absolute numbers of responders and 
total assessable patients are are displayed 
at the bottom with n= responder/total 
patients. The statistical analyses of each 
monitoring day comparing to Day0 were 
calculated by Fischer’s exact test, and the 
p-values are shown on the respective days.  
 
Next, we assessed the proportions of patients who exhibited spontaneous tumour-specific T-
cell responses on each clinical monitoring day. Results are shown in Figure 39. Prior to the 
treatment there were 27.3% of responders. However, it increased dramatically (p=0.086) on 
Day14 (72.7%) and persisted higher than 57% through the entire study. Statistical effects 
were observed on Day42 (p=0.03) and Day84 (p=0.02). These data support the conclusion 
above that this regimen possesses a long-term clinical efficacy.  
 
6.8.4 Clinical responses are correlated with T-cell immunity in the blood of study 
patients.  
Serum concentrations of tumour marker CA15-3 and CEA are the signs of disease activity, as 
well as magnetic resonance imaging (MRI). In this regard, we followed the development of 
tumour markers’ level in treated patients who were priory under progressive disease in 
order to evaluate the clinical efficacy of this study. Results are listed in Table 8. Promisingly, 
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there were seven out of 11 (63.6%) study patients showed stable disease after treatment, 
especially, when achieved by a sole application of metronomic CTX.  
 
Pat 
Performance of Tumour Markers (TM) Disease 
Status 
Frequencies of 
TAA-reactive TC 
(/10
5
 PT) 
TM 
Clinical monitoring Day 
0 14 28 42 56 70 84 Bef Aft Bef Aft 
1 CA15-3 48.1 - - - - - - 
PD - 0 102.33 
  CEA 1.3 - - - - - - 
2a MRI-Scan PD SD 0 40.33 
4 CA15-3 152.9 - - - 496.9 - - 
PD PD 45 18.33 
  CEA 75.7 - - - 433.0 - - 
5 CA15-3 90.8 - 69.4 - - - - 
PD SD 0 111.33 
  CEA 13.2 - 7.2 - - - - 
6 CA15-3 358.9 - 386.8 - 368.6 - 388.5 
PD SD 0 61.33 
  CEA 7.0 - 7.8 - 8.1 - 9.2 
7 CA15-3 1980.0 - 3656 - - - - 
PD PD 0 0 
  CEA 155.2 - 297.8 - - - - 
8 CA15-3 526.1 - - - - - 1547 
PD PD 0 0 
  CEA 178.4 - - - - - 185.8 
9 CA15-3 281.0 - 286.0 - 275.5 - 323.3 
PD SD 0 19.67 
  CEA 1.2 - 1.2 - 1.4 - 0.9 
10b CA15-3 239 - 1080 2480 2290 - 1760 
PD SDb 0 39.67 
  CEA 5.9 - 56.3 89.6 85.5 - 78.4 
11 CA15-3 1978.0 - - 2222.0 - 2768 - 
PD PD 0 16.67 
  CEA 47.1 - - 54.3 - 82.4 - 
12 CA15-3 503 - 576.6 - 470.3 - 558.2 
PD SD 92.67 14.00 
  CEA 19.7 - 35.5 - 28.9 - 33.9 
13 CA15-3 13.9 - - - - - 19.6 
PD SD 11.67 42.33 
  CEA 93.8 - - - - - 4.6 
 
Table 8. Correlation between clinical responses determined by tumour markers and disease status with 
frequencies of tumour-reactive T cells determined by IFN-γ ELISpot assay. TM: tumour markers. Pat: patient. 
PD: progressive disease; all the patients enrolled in this study were under PD. After initiation of this regimen, 
PD was determined by the extent of increase of TM in the blood, shown in red. SD: stable disease. Bef: before 
the treatment. Aft: the last time when the clinical monitoring performed corresponding to the wells shadowed 
in dark blue. -: performance was not done. a: Pat 2 was followed by MRI Scan. b: Pat 10 was considered as 
clinical SD determined by the observations of last two months. 
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In order to identify the effect of type-I T-cell potency to clinical responses, we compared the 
correlation of tumour status with frequencies of tumour-responding T cells (Table 8, Figure 
41). Prior to the therapy, spontaneous T-cell tumour reactivity was not found in 72.7% (eight 
out of 11) of study patients. After the therapy, 100% of patients who showed disease 
stabilization (SD) were associated with a detectable T-cell responsiveness in the blood, 
suggesting that type-I T-cell immunity is necessary to achieve a clinical benefit. While, 50% 
(two of four) of patients who underwent progressive disease were found to contain T-cell 
anti-tumour immunity, however, with relatively low frequencies (blue dots in Figure 40). By 
setting a comparative threshold according to the highest frequency of tumour-reactive T 
cells obtained among PD patients, we observed that 87.5% (seven of eight) benefit of clinical 
responses were associated with higher than 18.33 tumour-specific T cells found in per 1x105 
circulating T cells.  
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Figure 40, Correlation of clinical 
responses with frequencies of type-I T 
cells in treated patients. Each symbol 
represents one patient and scaled 
according to the frequencies of tumour-
reactive T cells assessed in the blood after 
the treatment. Open squares represent 
patients with stable disease; blue ones 
represent patients with progressive 
disease. The highest frequency of 
tumour-responding T cells of PD patients 
is indicated by a dash line with absolute 
numbers shown in a box. 
 
6.8.5 Correlation of Treg frequencies with immunological effects of study patients  
We have reported a significant reduction in Treg frequency on Day14. And interestingly, we 
also observed a considerable group of treated patients who gained enhanced anti-tumour T-
cell responses on Day14. For example, as the presented data in Figure 37, after 14 days 
therapy, this patient obtained a de novo anti-tumour response. Simultaneously, the 
frequency of circulating Treg within this patient was decreased from 4.1% on Day0 to 3.7% 
on Day14. Thus, it is interesting to elucidate whether there is a correlation between Treg 
frequency and T-cell anti-tumour reactivity with metronomic CTX dosed patients. 
Disappointingly, a significant improvement of tumour-specific IFN-γ production was not 
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found statistically on Day14 as shown by both Wilcoxon signed-rank and student t-test 
(Figure 38), which is likely due to an insufficient power of study.  
Next, a long term effect was evaluated with mean percentages of Treg among CD4+ T cells 
and mean frequencies of tumour-specific T cells (responding to either MCF7 or KS24.22) of 
all assessable patients on each clinical monitoring day. Results are shown in Figure 41. As 
discussed above, Treg frequencies (black line) displayed an early decline phase and a late 
rebound phase separating on Day42. Interestingly, a similar but reversed pattern was 
exhibited with frequencies of tumour-reactive T cells (blue line). By applying Pearson test, a 
negative correlation was found (r=-0.932, p=0.068) between Day42 and Day84.  
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Figure 41. Correlation between 
frequencies of tumour antigen 
reactive T cells and proportions of 
Treg before and during the 
treatment. Blue line: frequencies of 
responding T cells and scaled 
according to the left Y-axis. Black 
line: percentages of CD4
+
 Treg and 
scaled according to the right Y-axis. 
Negative correlation was found at 
Treg rebound phase calculated by 
Pearson test shown by r and p-
values. 
 
It is conceivable that the reduction of Treg from Day0 to Day14 allowed initial priming of Teff 
and consequently increased activated Teff in circulation as implied by the figure. The 
negative correlation at the late period of study is reminiscent of our previous finding with 
primary breast cancer patients that the presence of breast cancer specific Treg was 
associated with the absence of spontaneous T-cell immunity in the blood. However, given 
the evidence from this study that metronomic CTX treated patients obtained benefits such 
as profound anti-tumour reactivity on Day70 and significant increase in proportion of 
immunological responders on Day84, the being outnumbered Teff by Treg in the circulation 
might likely migrate to secondary lymph organs or even to the tumour site.  
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6.8.6 Replenished Treg at late study time points exhibited potent proliferative as 
well as suppressive characteristics 
The above investigations led us to a discrepancy of metronomic CTX regimen on the late 
study time points (Day56, Day70 and Day80): a increasing Treg frequencies in the circulation 
were found to be associated with a declining tumour-antigen specific T cells, and associated 
with a significant enhanced anti-tumour responsiveness observed on Day70 and a highest 
proportion of immunologic responders (87.5%) observed on Day84. To understand this 
discrepancy, a fundamental question is whether CTX altered Treg characteristics including 
proliferative and suppressive abilities at late time points of this study.  
First of all we examined the proliferative capacity of Treg by evaluating proliferation marker 
Ki67. Flow cytometric data were obtained and compared in between following groups: (a) 
study patients at late study time points (Day56: n=5, Day70: n=7 and Day80: n=7); (b) 
advanced patients who fit the same criteria of recruited patients (n=4) (note: data from this 
group are supposed to represent the proliferative status on Day0 of study patients); (c) 
primary breast cancer patients (n=7) and (d) healthy donors (n=5).  
Results measured with CD4+ Treg population are shown in Figure 42A. Regarding the median 
values, 11.9% of Treg from healthy individuals expressed Ki67, indicating a homeostatic 
proliferation. Compared to it, a slightly higher proportion (14.8%) of Ki67 expressing Treg 
were observed with primary breast cancer patients; and even higher value (22.45%) was 
found with advanced patients (Day0), suggesting a disease associated abnormal 
amplification of Treg occurring in breast cancer patients. The median values of Ki67 
expressing Treg from metronomic CTX treated patients increased gradually starting from a 
lower value than Day0 on Day56  to a value approaching to Day0 on Day84 (Day56: 16.9%; 
Day70: 19.2%; Day84: 21.0%). According to the statistical analyses, Day84 exhibited 
significant differences in comparison to healthy donors (p=0.044) and primary patients 
(marginally, p=0.07). These data indicate that a vital proliferation capacity was gained by 
Treg of study patients at later period of this study, which provides a possible explanation for 
the observed rebounded frequencies of Treg.  
In addition, the proliferative potencies of CD4+ Tcon were analysed (Figure 42B). The median 
value of Ki67 expressions obtained from the group of advanced patients displayed the 
lowest level among all tested groups (1.32%), which implied a silence of T-cell immunity in 
metastatic breast cancer patients. Interestingly, study patients contained marked inductions 
of Ki67 expressing CD4+ Tcon (Day56: 3.78%, Day70: 4.00%, Day84: 4.51%), especially, when 
compared to the group of prior to the treatment (see p-values in the figure), indicating a 
strong impact of metronomic CTX on CD4+ Tcon proliferation. It is known that proliferation 
of Tcon is associated with IL-2 secretion and Treg maintenance and expansion is dependent 
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on the presence of IL-2. Therefore, we speculate that Treg replenishment at late study time 
points is consequently facilitated by Tcon amplification. Whether CTX provoked Tcon 
proliferation from initiating time or not will be interesting to validate. Moreover, this 
observed amplification of Tcon might also explain the restoring of anti-tumour T-cell 
immunity at the late study phase. To confirm this, experiments such as tetramer staining are 
required for clarifying the antigen specificities of proliferating CD4+ Tcon.  
Another very interesting phenomenon was observed by evaluating the CD25highFoxp3+ Treg 
in CD8+ T cell population (Figure 42C). Relatively higher proportions of Ki67 expressing CD8+ 
Treg were detected with study patients (Day56: 20.4%, Day70: 12.3%, Day84: 25.2%). 
Statistical significances appeared on Day84 when compared to HD (9.92%, p=0.011), primary 
(8.85%, p=0.008) and advanced breast cancer patients (6.35%, p=0.009). Whether that CD8+ 
Treg represent an alternative suppressive mechanism induced by metronomic CTX 
treatment and whether they exerted suppression on anti-breast tumour T-cell immunity are 
not clear. Also, it has to be considered that even though the percentages of proliferating 
Treg in CD4+ and CD8+ Treg populations are comparable, CD8+ Treg represent much smaller 
proportion in total CD3+ T cells compared to CD4+ Treg (data not shown). Nevertheless, it is 
worth to be further investigated. 
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Figure 42. Percentages of Ki67 expression with CD4
+ 
Treg (A), CD4
+ 
Tcon (B) and CD8
+
Treg (C). Each symbol 
represents individual measurement. Different groups are depicted on rightmost. Small bars indicate median 
values. P-values are calculated by unpaired two-tailed student t-test and shown on short lines connecting 
compared groups. n.s.: not significant. 
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Figure 43. Suppressive capacity of Treg on CD4
+
 Tcon proliferation with study patients on Day84 and healthy 
donors. Experiments were performed according to manufacturer instruction of Miltenyi Treg suppression 
inspector kit. Tcon to Treg ratios are indicated under each column. Columns in A-D represent values of Tcon 
proliferation determined by 
3
H thymidine incorporation. Bars; SEM. A and B show different Treg characters 
after from two exemplary patients on Day84. C and D, Accumulative data show Treg suppressive capacity with 
4 study patients on Day84 and 2 healthy donors. E, Treg in 84 days treated patients exert not altered 
suppressive capacity compared to healthy donors. Each column represents a inhibitory percentage of Tcon 
proliferation calculated as: (Tcon alone – Tcon:Treg) /Tcon alone x100%. White columns: study patients on 
Day84. Grey columns: healthy donors. Bars: SEM. 
 
Next, we studied suppressive function of Treg isolated from four study patients on Day84 
with standard Treg suppression assay. Surprisingly, we observed two completely opposite 
patterns (Figure 43A and B). Pattern A representing three of four patients showed that Treg 
sustained suppressive potency but concomitantly gained proliferative capacity. Pattern B 
obtained from the other one patient showed that Treg retained hypoproliferative 
characteristic but lost inhibitory ability simultaneously (note: this patient died one month 
after stopping dosing metronomic CTX). Then, we compared the accumulated data of study 
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patients (Figure 43C) to that of healthy donors (Figure 43D). Treg from both sources 
displayed similar hypoproliferation in response to a polyclonal stimulation and a similarly 
suppressive capacity on activated Tcon amplification. These findings were further confirmed 
by analyzing the extent of suppressed Tcon proliferation in the presence of Treg. Results are 
shown in Figure 43E. There were no statistical differences found in between study patients 
and HD. Collectively, these data demonstrate that rebounded Treg in study patients possess 
a suppressive potency. But whether it is tumour antigen specific and whether it is 
responsible for the observed declining tumour-reactive T cells at that phase are not clear. 
We assume that Treg antigen specificity assay may provide an answer.  
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7 DISCUSSION 
The major aim of this thesis was to characterize the extent of regulatory T cell–mediated 
immune suppression in breast cancer and to explore the possibilities for its potential 
therapeutic modulation. Based on initial results obtained from a pilot clinical study of 
adoptive T cell transfer in advanced metastatic breast cancer patients, the subsequent 
observations of this project led us to the following major conclusions: 1) in primary breast 
cancer patients the peripheral blood contained significantly higher frequencies of Treg than 
the bone marrow, which may explain at least partially the improved functional potential of 
bone marrow-derived memory T cells, 2) removal of Treg evoked effective T cell tumour 
immunity in the peripheral blood, 3) Treg existing in breast cancer patients exhibited 
specificity for breast tumour-associated antigens and 4) using metronomic 
cyclophosphamide treatment to selectively deplete Treg in vivo was associated with clinical 
response in 64% of metastatic breast cancer patients.   
 
Breast cancer is the most frequent form of cancer in women. Immunotherapy which utilizes 
the patient’s own immune system to eradicate tumour cells offers a variety of advantages 
over conventional therapies, such as low toxicity, high specificity, and a continuous anti-
tumour effect attributable to immunologic memory (103). 
Current immunotherapy target tumour cells by tumour-associated antigen (TAA) -specific 
cytotoxic T lymphocytes (CTL) generated through dendritic cell (DC) vaccinations, in vivo 
expansion of TAA-specific CD8+ CTL clones or adoptive transfer of TCR-transduced T cells. To 
date, adoptive T cell transfer is performed after an extensive in vitro expansion of CTL (104). 
One major obstacle of this procedure is a poor persistence of transferred T cells in the 
patients which is most likely due to an activation induced early T cell apoptosis resulting 
from a state of “terminal differentiation” (105; 106; 107; 108; 109), namely loss of the 
homing receptor CD62L (110), co-stimulatory molecules CD28 and CD27 (111) and an 
increase of pro-apoptotic molecules BID and CD95L (100; 112). In addition, this procedure 
does not encompass CD4+ T helper cells which may provide a hitherto unsuspected 
important support during CD8+ T cell survival, activation, effector function and memory 
formation (113; 114; 115; 116; 117; 118; 119; 120).  
The adoptive T cell transfer study evaluated in this thesis was designed to overcome the 
caveat of T-cell exhaustion and lack of CD4+ T-cell help by a short term (72h) reactivation of 
the complex repertoire in the bone marrow (BM) of tumour-antigen reactive CD8+ and CD4+ 
memory T cells. We also carried out a pre-selection of TAA-reactive patients, and used whole 
tumour cell lysate as a source of tumour antigens. In this pilot study 17 advanced breast 
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cancer patients including two containing tumour-reactive T cells in their blood before 
therapy were treated with breast tumour-antigen stimulated autologous BMTC. One week 
after initiation eight patients (47.1%) showed tumour-reactive T cells in the peripheral blood 
(immunological responders) (Figure 1).  
The presence of tumour-reactive T cells in the blood of our patients mainly seven to 14 days 
after activation and their subsequent decrease (Figure 1) might be explained by circulating 
TAA-reactive T cells having re-entered lymphatic organs or immigrated into peripheral sites, 
as also suggested by the observation of CA15-3 reduction in two patients (99). In 
xenotransplant models of breast cancer (121; 122) and in murine melanoma (106) tumour-
infiltration and –rejection by transferred tumour-reactive memory T cells were similarly 
observed after 7-10 days.  
Alternatively, the transferred T cells might have been functionally inhibited by immune 
suppressive mechanisms, e.g. by regulatory T cells (Treg). Early studies by Robert North 
demonstrated that during tumour progression the initial development of concomitant 
immunity was followed, but finally subverted by the establishment of CD4+ T-cell-mediated 
immune suppression (123).  
We also cannot exclude the possibility that the transferred T cells might have undergone 
programmed cell death. The loss of T cells within the first two weeks after transfer had been 
described in clinical studies using repetitively stimulated and excessively expanded T cell 
lines (124; 125; 96). Similar observations were reported by other clinical trials in which TAA-
specific T cells could be detected for only 14 days even with the additional infusions of IL-2 
(126; 127). Since the T cells we used were not excessively stimulated, we assume that the 
latter hypothesis is less likely.  
Regarding the possible causes which impeded the occurrence of T cell-mediated anti-tumour 
immunity in the other patients (non-responders), we observed that transferred T cells of 
these patients secreted increased type-II cytokines IL-4 and IL-10, exerted reduced 
proportions of early activated T cells determined by CD69 expression and contained higher 
proportions of CD25high T cells (enriched in Treg) (99). These findings pointed to the 
possibility that regulatory T cells present in bone marrow T cell populations of some 
advanced breast cancer patients might inhibit the appropriate restimulation of pre-existing 
tumour reactive memory T cells. In support of this hypothesis, previous clinical study 
showed that cytostatic, non-myeloablation preconditioned adoptive T cell transfer improved 
the clinical outcome in up to 50% of the patients most likely due to the pre-elimination of 
(chemotherapy-sensitive) Treg (128; 129). In murine models it was shown that the depletion 
of Treg enhanced spontaneous tumour immune protection and elicited concomitant 
immunity in tumour-bearing mice (130; 131). Accordingly, in our study we could show that 
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the depletion of Treg from BM T cell populations resulted in a significantly reduced secretion 
of IL-10 upon T cell stimulation with tumour antigens (Figure 25).  
Direct evidence for the inhibitory role of regulatory T cells in breast tumour specific T-cell 
responses was firstly obtained by an IFN-γ catch assay (Figure 5 and Figure 6). The removal 
of Treg by MACS© CD4+CD25+ Regulatory T Cell Isolation Kit led to an increased secretion of 
IFN-γ by 5.8 times in CD4+ TC and by 11.7 times in CD8+ TC, in response to tumour-specific 
antigens. It also facilitated polyclonal proliferation of captured T cells to the double amount. 
In a long term impact, effector functions upon tumour-specific-antigen recall such as IFN-γ 
production and cytolytic activity persisted in T cells captured from an initially Treg-depleted 
group but not in T cells from a non-depleted group. These observations suggested that in 
breast cancer patients Treg exerted a negative effect on CD4+ and CD8+ T-cell activation, 
clone expansion, type-I T-cell effector function and CTL cytotoxicity.  
This impact of Treg on anti-tumour immunity appeared to be superior in breast cancer 
patients’ blood than in their bone marrow as implied by the following two observations. The 
previous study from our group suggested that tumour-reactive T cells were more frequently 
harboured in breast cancer patient BM (bone marrow) than in PB (peripheral blood) (121). In 
this pilot clinical study we now observed that the proportion of tumour responsiveness in 
the BM was persistent through the entire study (Diagnosis day: 100%; Mon 1: 78%; Mon 3: 
100%), whereas that in the PB declined (Figure 1). We are aware that Treg might not be the 
only reason for this scenario. However, assuming they were, the less inhibitory environment 
in the BM than the PB might be due to either more suppressive Treg or higher counts of Treg 
circulating in the PB. The former assumption was ruled out by a suppression assay which 
showed that the proliferation of T conventional cells (Tcon) was suppressed in a comparable 
way by Treg from both PB and BM (data not shown). Similar inhibitory capacities of IFN-γ 
production was also observed with both PB and BM derived Treg by re-adding Treg to IFN-γ 
ELISpot experiments (Figure 18).  
Indeed, the results from flow cytometric analyses strongly favoured the latter explanation, 
as in primary breast cancer patients the frequencies of Treg among the total CD4+ T cell 
count were significantly (p<0.001) lower in the bone marrow (2.5±1.3%) than in the 
peripheral blood (3.9±1.5%) (Figure 3). A significant (p=0.022) reduction of Treg frequencies 
in breast cancer patient BM was further observed compared to healthy donor BM 
(3.4±1.0%). Thus, we provided here at least a partial explanation of the improved functional 
potential of bone marrow-residing memory T cells in breast cancer patients.  
Naturally occurring Treg represent 5-10% of total CD4+ T cells in the periphery of normal 
mice and humans (42). In malignant cancer patients, including breast cancer patients, Treg 
proportions are elevated in the circulating blood (132). Compared to those findings, the 
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frequencies of Treg in PB reported here are relatively low. In contrast of the knowledge on 
Treg in blood, very little is known about BM residing Treg regarding their numbers and 
immunosuppressive functions, neither with cancer patients nor with healthy donors. The 
limited reports to date are divergent. For example, Atanackovic D. and his colleagues could 
show that there were no differences between newly diagnosed myeloma patients and 
healthy donors in the percentages of Treg in both BM and PB (133). However, Zou Weiping 
and his co-workers claimed there were more than 25% phenotypic Treg in both normal 
human and murine bone marrows (134).  
All those discrepancies could be due to the heterogeneity of recruited patients, various 
tumour entireties, or different stages of cancer. For example, Her2/neu positive patients 
were reported to contain higher Treg in the tumour site than Her2/neu negative ones. In 
patients with later stages of ovarian cancer, Treg preferentially accumulated in tumours but 
rarely entered draining lymph nodes (135). Similarly, we observed in this thesis that 
percentages of Treg were higher in the blood of advanced breast cancer patients (5.1±3.0%) 
than of primary cancer patients (3.9±1.5%) and healthy donors (4.3±0.9%).  
More likely, the discrepancies resulted from different Treg markers used for specifying this 
population. To date, many markers associated with Treg have been identified, but some of 
them are also activation markers and are not specific for Treg cells. For example, the 
expression of CD25 on T cells has been a useful marker for Treg (25), but it is also known to 
be associated with activated CD4+ T cells. Caution is advised when using CD25 for quantifying 
bone morrow-residing Treg as it is also unspecifically expressed on a large number of 
conventional CD4+ and CD8+ T cells in the bone marrow (133). Fontenot’s group reported 
that CD25 was not necessarily obligatory for Foxp3+ T cells which acted as immune 
suppressors (136). On the other hand, these observations were possibly due to the loose 
gates of CD25 expression for specifying Treg as suggested by Clare Baecher-Allan et al that 
only the highest level of CD25 expressing CD4+ T cells, approximately representing 2-3% of 
total CD4+ T cells, in vitro exhibited the properties that were identical to the CD4+CD25+ 
regulatory T cells initially characterized in mice (137). Besides, there was a direct functional 
link between the presence of CD25+ Treg and CD8+ T cell mediated tumour protection shown 
by adoptive transfer of tumour-specific CTL with or without Treg isolated by CD25 targeting 
(138; 139).  
Even better marker for Treg than CD25high is Foxp3 at least in murine models because of its 
essential and sufficient role in mouse Treg development and function (140; 29). However, 
human Treg are less exclusively related to Foxp3 protein. For instance, the typical 
hypoproliferation of murine Treg following a T cell receptor (TCR)–mediated stimulation was 
altered in the human situation due to a slightly higher IL-2 production by the second isoform 
of the human Foxp3 protein which lacks exon2 (141). Human Foxp3 could be induced from 
DISCUSSION 
P a g e  |  109 
naïve or conventional T cells upon both polyclonal and antigen-specific activation (142), 
which did not occur in murine experiments (57; 30). Therefore, to ensure a relatively more 
reliable investigation we defined Treg by double expressions of Foxp3 and CD25high among 
CD4+ T cell population. 
According our study, the BM of primary breast cancer patients contained significantly lower 
frequencies of Treg than the PB. The reason for this could be a lack of migratory capacity of 
Treg towards BM or a reduced retention of BM for circulating Treg. But none of these 
hypotheses were possibly true as, firstly, it had been reported that upregulated CXCR4 
expression on activated Treg enabled them to migrate to the bone marrow through its 
ligand CXCL12 elaborated by bone marrow stromal cells (134). The blockade of CXCR4 in vivo 
abrogated the otherwise occurring migration of activated CD4+CD25+ T cells to the BM (134). 
Therefore, it was unlikely that Treg would lack BM migratory capacity. Secondly, the clinical 
study of post-allogeneic stem cell transplantation of patients with multiple myeloma showed 
an exuberant regeneration of Treg inside the BM, suggesting that the BM is capable of 
providing an environment for retaining Treg as well as for fostering their expansion (133).  
Thus, we proposed the third hypothesis that Treg in breast cancer patients actively 
emigrated from BM after encountering tumour antigens there, and were subsequently 
recruited to the tumour site. Several lines of evidence from our group as well as from others 
led us to formulate this hypothesis: i) BM was known to be able to serve as a site for naïve 
TAA-specific T-cell priming upon blood borne antigens presented on immigrated DC and as a 
preferred site for homeostatic proliferation of memory CD8+ T cells (143; 144; 145; 11). 
These findings illustrate a possibility for Treg to encounter tumour antigens in the BM. Also, 
it is conceivable that immune suppressors such as Treg might actively leave BM because of 
the type-I T cell favoured environment. ii) Treg are known to modulate immune responses 
through selective migration and progressive accumulation at sites where regulation is 
required (146; 147). Thus, the emigrated Treg from BM were likely recruited to the tumour 
site where they could promote tumour growth. In support of this, our previous experiments 
showed that the percentages of Treg among breast tumour infiltrating lymphocytes was 
inversely correlated with the outcomes of IFN-γ ELISpot assay performed with BMTC 
(Michael Hillier, unpublished data, 2007). iii) The recruitment of Treg is most likely triggered 
by chemokine-chemokine receptor interactions which are also responsible for other T-cell 
trafficking. In healthy individuals, CCR4 expressing Treg in the periphery had been reported 
to represent a major subset of circulating CD4+ T cells responding to CCL22, one of its two 
ligands (CCL17 being the other one) (148). A study of 104 ovarian cancer patients showed 
that Treg were constantly recruited to the tumour site via CCR4-CCL22 attraction (135). With 
our preliminary data, the expressions of chemokine receptors CCR2, CCR5 and CCR6 on Treg 
were found to be significantly higher in breast cancer patients’ BM than in their PB 
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(Christopher Schnappauf unpublished 2008). This distinct pattern between BM and PB was 
not observed in healthy donors (Christopher Schnappauf unpublished 2008). Accordantly, 
the levels of the ligands for those chemokine receptors (CCL2, CCL5 and CCL20, respectively) 
were frequently reported to be elevated in mammary tumour cells or tumour associated 
cells (149; 150). 
In order to testify this hypothesis, we needed to prove whether Treg could be activated by 
tumour antigens, and could consequently upregulate breast cancer profiled chemokine 
receptors in response to the tumour recruitment. In this study, following a polyclonal TCR-
mediated activation the elevated proportions of CCR2, CCR5, CCR6 and CCR4 expressing Treg 
were able to be detected in a stimuli dose-dependent manner (Result 1.6). Regarding CCR2 
and CCR4 expressions upon activation, higher responsiveness was obtained with Treg 
derived from breast cancer patients than those from healthy donors. The upregulation of 
CCR4 was predominant on activated Treg in breast cancer patients compared to Tcon, which 
is in line with others’ findings in ovarian cancer as described above. Further definitive 
experiments are planned, such as applying breast tumour specific antigens instead of 
polyclonal antibodies for stimulation and confirming chemokine receptors responsible for 
Treg emigration from BM with a chemotaxis assay.  
CCR2 and CCR5 are also expressed on other T cells which enable them to migrate to the 
tumour site (151; 152). However, this T-cell tumour infiltration may be beneficial or 
detrimental for tumour survival. For instance, CCL2 induced Th2 polarization which 
mediated humoral immunity and consequently suppressed anti-tumour activities (153). CCL5 
was associated with a recruitment of CD8+ T cells which presumably had cytotoxic activity 
against tumour (154). CCR5 was predominantly expressed on Th1-polarized T cells (155; 
156), suggesting an anti-tumour potential. In this study, we observed an elevated expression 
of CCR2 but a suppressed one of CCR5 on Tcon in breast cancer patients compared to 
healthy donors. We deducted that that was due to different strategies of immune 
suppression exerted by activated Treg. Since CCL2-responding CD4+ T cells would likely be 
polarized to Th2 cells or even be converted to Treg once inside tumour microenvironment 
(157), the control of CCR2 expression on Tcon seems not necessary; whilst CCR5 expressing 
Th1 cells are able to facilitate CTL function inside tumour, the control of CCR5 expression on 
Tcon might be inhibited by activated Treg. This inhibition could have possibly resulted from 
in vitro activated Treg, or be due to an inert responsiveness of Tcon due to long term 
suppression by Treg in vivo. Although further definitive experiments are required, these 
findings at least indicated an interesting immune suppressive capacity of Treg in breast 
cancer patients.  
Next we set out to understand the extent of Treg-mediated immune suppression in breast 
cancer patients by comparing type-I T-cell tumour immunity with and without Treg 
DISCUSSION 
P a g e  |  111 
presence. In a study of 31 PB and 27 BM breast cancer samples, the removal of Treg 
uncovered 2.3 to 2.6 folds of T-cell responsiveness towards polyvalent breast tumour 
antigens with statistical significances (Figure 8A&B). Importantly, the same effect was not 
found with irrelevant controls (Figure 8A&B).  
Further study with defined tumour associated antigens (TAA) confirmed Treg-depletion-
mediated improvements in type-I T-cell anti-tumour immunity with statistical significances 
observed in response to HpaI, HpaII, Mam1, Muc1-20 and Her2/neu in the blood of 38 
breast cancer patients (Figure 12A). In contrast to blood, in the bone marrow of 26 breast 
cancer patients the statistical significance was not achieved despite substantial inductions of 
TAA-reactivity observed in ten out of 13 groups (Figure 12B). This reduced effectiveness is 
likely due to pre-existing higher frequencies of functional memory T cells in the bone 
marrow than in the blood, making the beneficial impact of Treg depletion less obvious.  
We are also aware of the disparity of Treg-depletion-mediated benefits exhibited by BMTC 
in response to polyvalent tumour antigens and to selected TAAs. The observed better 
outcomes displayed in the former situation implied the involvement of other TAAs than 
those chosen for this study in breast tumour immunity.  
Regarding the frequencies of breast tumour-specific T cells, a dramatic unmasking-effect 
attributed to Treg-depletion was mutually supported by the evaluations of T-cell 
responsiveness towards polyvalent tumour antigens and mixed TAAs. The frequencies MCF7 
and KS24.22-specific T cells were augmented by 5 and 10 times, respectively, in the 
peripheral blood, and by 3 and 4 times, respectively, in the bone marrow (Figure 9). 
Accumulative data of overall 13 studied TAAs revealed a highly significant (p=0.0002) 
induction (1.96-fold) in the frequencies of TAA-specific T cells in the blood and a 1.31-fold 
increase in the bone marrow (Figure 13). 
It is worth mentioning that these findings are nicely in accordance with our acquired flow 
cytometric data. The higher spontaneous T-cell responses pre-existing in the BM, as well as 
the feebler Treg-depletion-induced benefits are well correlated with the lower Treg 
frequencies found in the BM. Whereas the relatively higher Treg pool circulating in the blood 
probably accounts for the stronger immune suppression.  
The benefit of Treg-depletion in breast cancer patients could also be confirmed by the 
induction in proportions of immunological responders. About 35% patients obtained de novo 
tumour reactivity in their blood after Treg-depletion, which was accompanied by a highly 
significant impact (p=0.0006) (Figure 10). In particular, MCF7 and KS24.22 responders went 
up from 26.1% to 60.9% and from 35% to 65%, respectively. A similar effect was observed 
with an induction of Her2/neu responders analysed in the blood (from 13% to 45% p=0.03) 
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(Figure 16). As Her2/neu is known as one of the most prevalent breast tumour associated 
antigens, it is conceivable that the suppression of Her2/neu-reactivity is strongly modulated 
by breast tumour in vivo possibly through Treg as shown here.  
On the whole, our data strongly demonstrated a profound immune suppression of Treg on 
spontaneous anti-tumour type-I T-cell responsiveness in breast cancer patients which was in 
accordance with a plethora of recent in vitro as well as in vivo studies with different other 
tumour entities that drew comparable conclusions (158; 159; 160; 161).  
Our data also suggested that the tumour-tolerance could be broken by applying a CD25-
mediated Treg-depletion in breast cancer patients, which implicates a clinical application. 
The possible downside of CD25 administration for Treg elimination in vivo would be an 
undesired onset of autoimmunity as reported in the murine model (162). However, 
according to the results of this study, it would be unlikely as the unspecific secretion of IFN-γ 
against irrelevant controls did not alter before and after applying CD25 mAb (Figure 8 and 
Figure 12), suggesting a specific effect of this approach. Similarly, the mean frequencies of 
TAA-reactive T cells in healthy donors were substantially lower than those in breast cancer 
patients (p<0.0001) (Figure 14) in both PB and BM whether Treg were depleted or not. 
Another possible disadvantage of applying this approach would be a concurrent loss of 
CD25+ Teff as discovered in both animal and human investigations (163; 164). In this study 
the type-I T-cell responsiveness towards MAGE3 was reversed possibly due to this reason 
(Figure 11 and Figure 12). To avoid it, further optimization has been tried out, such as 
reducing the amounts of α-CD25 Ab, adjusting the ratio of Ab to targets, or shortening the 
incubation time of Ab with cells. 
This pilot clinical study of adoptive T cell transfer immunotherapy (ADI) in metastatic breast 
cancer patients clearly demonstrated that at least 7x103 tumour-reactive T cells were 
needed in order to achieve an immunological response (99). However, with a limited BM 
source of not more than 100 ml per patient this becomes a challenge. In this thesis, CD25-
mediated Treg-depletion restored the prior absent T-cell anti-tumour immunity especially in 
the peripheral blood of breast cancer patients, and importantly to a corresponding extent as 
in its counterpart bone marrow (Figure 9 and Figure 13). The profound meaning of this was 
instead of BM we could use leukapheresis which provides substantially larger counts of 
lymphocytes including tumour-reactive T cells for the potential improvements of ADI. 
Based on this thought, as well as being prompted by the another report (165), we set about 
a larger-scale depletion of CD25+ regulatory T cells by CliniMACS CD25 microbeads from a 
bone marrow metastatic patient leukapheresis. This pioneer exploitation proved the 
possibility of modulating Treg under clinical-grade condition by a sufficient depletion of Treg 
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(Figure 34), a high viability of isolated cells and a remarkable recovery of total cell counts 
(Table 4). However, the potential therapeutic use of this protocol was not convincing, as the 
T-cell tumour responses were not as potent as shown in the applied manual depletion 
protocol determined by an IFN-γ ELISpot assay (Figure 35), indicating a possible undesired 
loss of T effector cells by this approach. In fact, our flow cytometric data acquired from cells 
in the depleted fractions displayed a considerable loss of CD25inter T cells (data not shown). 
Another possible reason for this lesser responsiveness might be that tumour-specific T cells 
derived from an advanced breast cancer patient were more susceptible to a longer 
manipulation (CliniMACS: 12 hr) than a short one (manual depletion: 2 hr). Nonetheless, 
further optimization is required.  
Currently, many other cancer immunotherapy approaches dealing with Treg elimination are 
under intensive investigations with in pre-/clinical trials. Also concerning CD25 as a Treg 
target, most studies in cancer patients used immunotoxin denileukin diftitox (Ontak), a 
fusion protein between IL-2 and diphtheria toxin. To date in vivo anti-tumour efficacy of 
Ontak displayed discrepant results, which were very likely due to different administrated 
amounts or schedules as well as different types of tumour (166; 167; 168; 169). In addition 
to targeting CD25, an agonistic antibody which is specific to CTLA-4 is under pre-/clinical 
investigations. CTLA-4 has long been thought to control the Treg activity (170), but not until 
recently Sakaguchi’s group reported its superior role on suppressive ability of Treg with a 
conditional knockout system (171). The clinical responses of administrating CTLA-4-specific 
antibodies showed concomitant tumour regressions and severe but manageable 
autoimmune diseases (172; 173; 174). In contrast, a completely disappointing clinical result 
showing no detectable effects on decreasing numbers of suppressive Treg after CTLA-4 
administration was reported by Rosenberg’s group (175). Other immunologists suggested 
that the observed anti-tumour efficacy by applying CTLA-4-specific antibodies was a 
synergistic regulation rather than a direct suppression on Treg (176). Thus, the application of 
CTLA-4 in modulating Treg requires further critical investigations.  
Alternatively, cyclophosphamide (CTX) emerged to be an effective drug of depleting Treg in 
vivo. Cyclophosphamide belongs to a group of cytotoxic alkylating nitrogen mustard 
compounds that mediates DNA crosslinking. Because of its selective cytotoxicity on 
lymphocytes without being myeloablative, high-dose CTX treatment was initially developed 
as a preconditioning regimen for allogeneic bone marrow transplantation to prevent graft-
versus-host disease. Later, high-dose CTX treatment without bone marrow transplantation 
was used to treat severe autoimmune disorders for which multiple therapies were 
ineffective (177; 178). In contrast to such high-dose applications of CTX, with the primary 
aim of dampening ongoing immune responses in autoimmune patients, administration of 
low-dose CTX could, paradoxically, augment anti-tumour immune responses in a number of 
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murine tumour models (179; 180; 181) and in patients with metastatic melanoma (182; 183; 
184). A simultaneous enhancement of CTL response as well as antibody production was 
accompanied by tumour control. In elderly breast cancer patients, uninterrupted daily low 
dosing CTX therapy, referred to as metronomic therapy, indicated an antiangiogenic effect 
as without concomitant CTX treatment, letrozole alone led to a relatively higher Ki67 and 
VEGF expression on the residual tumour histology (185). The correlation between CTX 
administration and Treg was initially suggested in 1974 reporting that a CTX regimen-
induced anti-tumour efficacy was associated with a removal of T lymphocyte suppressors 
(186; 102), but the first evidence specifying CD4+CD25+ Treg was recently documented by 
Ghiringhelli F. et al in mice (187) as well as in late stage cancer patients (188).  
Regarding breast cancer immunotherapy, a combined regimen with metronomic CTX was 
reported to have a prolonged clinical benefit and a relevance to the Her2/neu expressing 
level by Colleoni M.’s group (189; 190). However, its own effect on Treg alterations in their 
counts and function after administration was not stated. And a long term effect of 
metronomic CTX on type-I T-cell immunity has not yet been evaluated. To address these 
issues, we applied a small pilot study of metronomic cyclophosphamide (50 mg daily) 
treatment with 13 multi-metastatic breast cancer patients, and followed up Treg counts in 
circulation by flow cytometry and type-I blood T-cell responses by IFN-γ ELISpot assay every 
two weeks for three months.  
This regimen was well tolerated. Severe side effects was not observed in any of the patients 
except one who suffered from anaemia (Hb 6.6 g/dl) and was withdrawn from the therapy 
because of this.  
In this study, we reported that low-dose CTX treatment was correlated with declines of Treg 
counts up to 42 days after initiation with significant decreases observed on Day14 (p=0.005) 
and Day28 (p=0.02) (Figure 36). Conversely, the numbers of other lymphocytes were 
preserved (data not shown), suggesting a selective depletion of Treg in vivo by this strategy, 
which is in line with Ghiringhelli F.’s finding (188). The rapid and effective elimination of Treg 
observed on Day14 also implicated a preconditioning potential of low dose CTX for adoptive 
T cell transfer or DC vaccine immunotherapy.  
According to the extents of declining Treg between Day0 and Day14, we were able to 
subgroup patients into a CTX susceptible and a non-susceptible type (Table 7). The patients 
belonging to the CTX susceptible group contained either higher (6.4% to 10.9%) or lower 
(0.67% to 2.4%) Treg frequencies on Day0 than healthy donors (average 4.3%). A possible 
interpretation is that Treg in those abnormal proportions were under vigorous self-renewal, 
which allowed them to be perfect targets for CTX (191; 192). Further investigation of the 
proliferative status of Treg on Day0 might be helpful to clarify this assumption. 
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This 3-months-follow-up study on Treg frequency allowed us to detect a gradual 
replenishment of the Treg pool in the late period of this treatment on an average level. By 
the last clinical monitoring day, the average of Treg percentages of all assessable patients 
rebounded back to the starting level (Day0: 5.1%, Day84: 5.2%) (Figure 36). Whether an 
extended administration will take the Treg frequency to an ever-growing rate was uncertain. 
It may be implied by the results of Ki67 expression assay in which we observed accordantly 
climbing percentages of under-proliferating CD4+ Treg (Figure 42A). Whether there were 
other factors contributing to the replenishment of the Treg pool remains unclear. 
Meanwhile, a markedly proliferative potency of CD4+ Tcon was obtained in a late study 
phase compared to Day0 (Day56, p=0.016; Day70, p=0.03; Day84, p=0.026) (Figure 42B). IL-2 
secretion is known to be associated with T cell proliferation, and Treg maintenance and 
expansion crucially depend on the presence of IL-2 (193). Thus, the Treg replenishment was 
likely facilitated by Tcon amplification in the late phase of this study.  
We also monitored the immunological responses in the blood of treated patients by 
performing IFN-γ ELISpot assay. Our results demonstrated that this regimen had a long-term 
clinical benefit as a significant enhancement in frequencies of tumour-reactive T cells were 
obtained on Day70, which was confirmed by two different statistical analyses (Wilcoxon 
signed-rank test, Figure 38B and student t-test, Figure 38C). The presumed T-cell immunity 
augmentation on Day14 did not appear in a statistically significant way possibly due to an 
insufficient power of study.  
In addition, a persistent clinical efficacy was shown by the percentages of immunological 
responders. Starting with a dramatic induction on Day14 (Day0: 27.3%; Day14: 72.7%), the 
percentages of immunological responders sustained above 57% through the entire course of 
the study, and ended with 87.5% on Day84 showing a statistical significance (Figure 39).  
Most importantly, of 11 patients assessable for tumour markers or MRI-Scan, we observed 
seven patients with a stabilization of the disease (SD) (64%), and four with a progression of 
the disease (PD) (36%) after the treatment. Moreover, this clinical response was well 
correlated with T-cell anti-tumour reactivity, as augmentations of tumour-reactive T cells in 
frequencies associated with 85.7% of SD patients (six out of seven); whilst all PD patients 
failed to reach 183 tumour-reactive T cells per 106 T cells in their blood (Table 8, Figure 40).  
The isolated Treg from patients’ blood in the late period of this study were found to possess 
suppressive ability on the polyclonal proliferation of CD4+ Tcon (Figure 43E). This together 
with the observation of potent type-I T-cell responsiveness at this period suggested that 
replenished Treg changed their Ag-recognition; therefore the maintained suppressive 
capacity could not affect tumour-antigen specific response. To prove it, definitive 
experiments such as our designed Treg-specificity assay are warranted.  
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It is worth mentioning that Ki67 expression was significantly elevated on the 
CD25highFoxp3+CD8+ T cell population three months after initiating metronomic CTX. 
CD25highFoxp3+ CD8+ Treg have recently been detected at the tumour sites of different 
cancer patients (194; 195; 196; 197). However, in contrast to CD4+ Treg, less is known about 
CD25highFoxp3+ CD8+ Treg and their detrimental effects on immunotherapy. Unlike CD4+ Treg 
which were naturally generated in the thymus and can be detected in the periphery, CD8+ 
Treg cells were not detectable in the peripheral blood mononucleocytes (PBMC) of healthy 
donors or cancer patients, suggesting that CD8+ Treg cells were antigen induced (194). Thus, 
our data might indicate an alternative Treg subset existing and an additional suppressive 
mechanism occurring in advanced breast cancer patients. Further experiments are required 
to clarify how metronomic CTX modulates CD8+ Treg and what the impact of CD8+ Treg on 
type-I T-cell immunity is. 
These data suggest that this simple protocol described here is worth being tested along with 
specific immunotherapy aimed at enhancing T cell function in patients bearing advanced 
breast cancer. 
 
In this study, we were also interested in antigen specificity of Treg in breast cancer patients. 
In contrast to the ever increasing evidence of the presence of CD4+CD25+ Treg in tumour-
bearing hosts, very little is known about their tumour-antigen specificity. CD4+ Treg are 
important in modulating self-tolerance as well as homeostasis following productive 
immunity; therefore, generation and maintenance of Treg have long been thought to require 
the presence of targeting antigens or tissues (198; 199). Treg were reported to display TCR 
repertoire as broad and as diverse as the other mature αβ-T cells with the tendency to focus 
on self-antigens (200; 201). Therefore, it is possible that Treg are specific for at least one 
subgroup of TAAs. Tumour-specific Treg could also be induced de novo as evidenced in HA-
TCR transgenic mice with Rag2-/- background that did not obtain any natural Treg but 
developed into Treg when presented with HA-peptide under subimmunogenic conditions 
(202). Other origins of TAA-specific Treg were proposed such as a conversion from naïve or 
antigen-experienced CD4+ T cells in the suppressive cytokine milieu at tumour sites (142; 
203; 204). Thus, it is reasonable to assume that tumour evasion is mediated by tumour-
antigen specific regulatory T cells. Several lines of observation in this thesis supported this 
concept: The removal of Treg specifically abrogated MCF7-mediated IL-10 secretion in an 
activation culture (Figure 25A). Giving isolated autologous Treg back into the ELISpot culture, 
the IFN-γ secretion was blocked in response to breast tumour derived antigens but not in the 
controls (Figure 18). And more directly, breast tumour antigen stimulated Treg produced 
significantly excessive intracellular IL-10 (Figure 25B).  
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Our knowledge of tumour-antigen specific Treg comes mainly from studies with antigen-
specific TCR transgenic murine models (205; 206; 207; 208). Regarding human cancer 
specific Treg, Rong-Fu Wang and his co-workers contributed to the identification of two 
melanoma-infiltrating Treg, LAGE1 and ARTC1 -Treg (209; 66), which in association with 
CD25, GITR and Foxp3 expressions, suppressed the proliferation of naïve CD4+ T cells and 
inhibited IL-2 secretion of CD4+ effector T cells upon activation with tumour-specific ligands. 
Defining a tumour Treg clone certainly has a profound meaning in immunotherapy, but the 
immunologic methods they used, such as limiting dilution assay and single cell cultivation, 
are very time and effort–consuming, which limited their applications for a large screening 
aim in clinical exploitation such as diagnosis or prognosis. MHC-II tetramer technique could 
fill this request, but it is not the most economical approach. Thus, a need for cost and time -
efficacy immunological method for detecting tumour-specific Treg is urged. 
To date, human tumour specific Treg, either induced de novo or isolated from TILs, required 
cognate antigens for activation. Once activated, they were capable of suppressing responses 
in an antigen-nonspecific manner. Treg were well characterized to suppress the proliferation 
and cytokine production of TCR-stimulated conventional CD4+ T cells (210; 211). Based on 
this knowledge, we proposed to identify TAA-specific Treg by measuring their inhibition 
capacity on proliferation of polyclonally activated Tcon after tumour-antigen stimulation 
(Figure 19). In detail, the protocol was designed as follows: purified Treg were activated with 
breast tumour or control antigens presented on autologous DC for 24 hr. Meanwhile Tcon 
received a polyclonal stimulation from αCD3 and αCD28 mAb coated wells. Afterwards, the 
pre-activated Tcon were given into the stimulated Treg’ culture at a 1:1 ratio for 3 days to 
allow a full suppression exertion. The degree of Tcon proliferation was quantified by the 
amount of incorporated 3H thymidine. 
To ascertain the reliability of this novel approach, a set of rigid controls was primarily carried 
out with breast cancer patient samples. First, we compared the extents of Treg proliferations 
upon different stimuli: antigen pulsed DC (Figure 20A, Figure 22B), non-pulsed DC (Figure 
20A, Figure 22A) and TCR-mediated polyclonal stimulation (Figure 22A). The 
hypoproliferations were observed from all tests, and importantly at a non-distinguishable 
level, which dispelled the potential or possibly uneven contributions from Treg itself in this 
approach. Second, the potently proliferative ability of Tcon in response to a polyclonal TCR-
mediated activation was ensured (Figure 22A). Last, the degrees of Tcon proliferation with 
different manipulated DC were compared. Ag-pulsed DC induced a slightly higher 
proliferation of Tcon than non-pulsed DC, but not in a statistically significant way (Figure 
20A). Collectively, we demonstrate this newly designed approach is reliable for examining 
Treg specificity.  
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Accumulative data from 14 PB and 12 BM samples of breast cancer patients showed that the 
proliferations of activated Tcon were significantly suppressed in the co-culture with MCF7- 
or KS24.22-stimulated Treg compared to the co-culture with control U937-stimulated Treg 
(Figure 21C), suggesting the immune suppression was mediated in a tumour-antigen specific 
manner.  
Next, we used defined tumour-associated antigens for Treg activation. Surprisingly, the 
spectrum of TAAs recognized by Treg was highly diverse in breast cancer patients (Figure 
24), which was reminiscent of our previous finding that the T-cell repertoire of breast TAA-
recognition was greatly individual (212). Hence, we postulated that breast tumour might 
actively govern Treg according to its TAA expression status as well as to the ongoing anti-
tumour T-cell responsiveness in order to dampen immune surveillance.  
Despite of the multifarious pattern in individuals, an overall analysis of 18 blood samples 
revealed that Muc1-100 and Mam1 were prevalently recognized by Treg (Figure 23), which 
mutually support our IFN-γ ELISpot results that depletion of Treg significantly induced 
Mam1-responsiveness and Muc1-100 specific reactivity (Figure 12A). Moreover, Mam1 
mediated Treg suppression (30%) was substantially exceeding the other tested TAAs and 
existed in more than 85% patients (Figure 24C). Mam1 is a polypeptide derived from 
Mammaglobin A which is an antigen expressed exclusively on breast epithelia (213), and 
overexpressed in 80% of primary and metastatic breast cancer patients (87). Capable of 
inducing a specific CD8+ T cell response in breast cancer patients further endowed 
Mammaglobin A a very attractive target for immune involvement (214; 215; 216; 217; 218). 
Currently, a clinical phase I trial of Mammaglobin A vaccination based on full-length DNA is 
carrying out with stage IV breast cancer patients in Peter S. Goedegebuure’s group (219). 
However, our results warned that manipulation of Mammaglobin A has to be deliberated 
carefully in order not to evoke suppressive function of Treg in breast cancer patients. 
In contrast to Mam1, Her2/neu specific Treg exerted only 13% inhibition of Tcon 
proliferation which was the second lowest among all tested TAAs. It is interesting as only 
Her2/neu-responders significantly benefited from Treg-depletion approach determined by 
IFN-γ production (Figure 16A) as described above. This superficial discrepancy may implicate 
different modes of suppressive preference exerted by Her2/neu specific Treg on Teff: 
inhibiting cytokine production or clonal expansion. It is possibly related to the tumour stage 
as it is known that nature Treg suppressed the priming of naïve T cells in lymph nodes (220; 
221), whereas in the later tumour stage Treg were found to be lacking in the tumour 
draining lymph nodes but accumulating at tumour site to suppress function of Teff (135). 
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